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ABSTRACT 
 
Aeruginosins are a family of marine natural products containing mostly non-proteogenic amino 
acids. These compounds contain a common 2-carboxy-6-hydroxy-octaindole (Choi) rigid 
bicyclic structure. Many aeruginosins are inhibitors for enzymes involved in the blood 
coagulation cascade, such as thrombin and Factor VIIa. In order to understand the structure 
activity relationship (SAR) of the aeruginosins and to discover novel anticoagulants with 
potentially improved inhibitory and pharmacokinetic properties, in the first part of my thesis I 
have discussed, synthesis of a series of novel analogs of aeruginosin 298-A, in which the Choi 
will be replaced with L-proline and  oxygenated Choi analogs, and the Argol is replaced with 
various other functionalities. The preparation of oxygenated Choi analogs starting from glucose 
using a new method has been discussed. 
 
In the second part of my dissertation, I have discussed the design, synthesis and self–assembly of 
glucosamine based hydro and organogelators. Carbohydrate-based low molecular weight gelators 
are an interesting class of molecules with many potential applications. A series of amides and 
ureas were prepared from the protected D-glucosamine from the corresponding acid chloride and 
isocyanates. The self-assembling properties of these compounds were studied in several solvents, 
including water and aqueous solutions. Most of these compounds were found to be efficient low 
molecular weight hydrogelators (LMHGs) for aqueous solutions. The preparation and 
characterization of these compounds will be elaborated. 
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Chapter 1 
Introduction
 
1.1. Overview: 
 
In this chapter, the background information related to aeruginosins and thrombin inhibitors will 
be discussed in the first part, this is adapted from paper: Cardiovasc. Hematol. Agents Med. 
Chem.  2009, 7, 147-165 by Wang, G. and Goyal, N. The second part composes a brief 
introduction of self-assembling of glucosamine derivatives will be introduced in the second part.  
 
Part I.  Aeruginosin analogs and other rigid bicyclic compounds as antithrombotic  
 
1.2 Introduction to Blood Coagulation  
 
Blood coagulation is a complex process of ordered events which involves both cellular (i.e., 
blood platelets and leukocytes) and proteinaceous components (i.e., the coagulation factors, 
serine proteases and cofactors).
1
 (coagulation pathway). The several important enzymes involved 
in blood coagulation cascades include thrombin (factor IIa), factor Xa and factor VIIa. Most of 
these coagulation factors are trypsin like serine proteases and they catalyze the coagulation 
cascade at different stages.  
The basic events in blood coagulation involve a primary hemostasis i.e. platelet aggregation to 
form a primary platelet plug, followed by secondary hemostasis which is activation of plasma 
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coagulation factors generating fibrin which intertwines and reinforces the aggregated platelets 
resulting in a strong fibrin clot.
2-5
 The two pathways responsible for the biochemical coagulation 
cascade leading to the generation of fibrin are (i) an intrinsic contact activation system and (ii) an 
extrinsic tissue factor system (Figure 1.1). Both pathways involve a stepwise activation of 
proteases, and they converge upon generation of active thrombin which is responsible for the 
final cleavage of fibrinogen to fibrin. The positive-feedback mechanisms along both pathways 
accelerate the coagulation process.  
However in recent years, the extrinsic system triggered by tissue factor has been considered as 
the major pathway to thrombinogenesis.
5
 
 
1.3 Problems associated with blood coagulation 
Under normal physiological conditions the coagulation system is balanced by an anticoagulation 
system and a fibrinolysis system.
6,7
 The imbalance between these mechanisms results in blood 
clotting or bleeding depending on which system dominates. A pathogenic imbalance in favor of 
the coagulation system may lead to thrombosis. In this process, a clot forms in the blood vessels 
and affects the circulation of blood. Thrombosis can become a serious condition if the clot 
migrates to the heart or to the lungs which can trigger life threatening diseases like myocardial 
infarction, pulmonary embolism (PE), deep vein thrombosis (DVT), and thromboembolic stroke. 
Thrombosis and related complications are major causes of fatal cardiovascular and 
cerebrovascular disease throughout the world.
8
 The risk of thrombosis related disorders increases 
with age, obesity, surgery etc. and these are the leading causes of death in developed countries 
and are now having increasing incidences in developing countries as well.
9
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Even though men and women can have clotting disorders, these conditions pose added 
difficulties for women because of their relationship to reproductive issues. Women with these 
disorders can develop serious complications during pregnancy leading to miscarriage. 
Pregnancy, oral contraceptives and post-menopausal hormone replacement therapy are all 
triggering events for DVT in women with thrombosis. Thrombosis may manifest itself as the 
formation or presence of a blood clot in a blood vessel or one of the cavities in the heart. In fact, 
emboli (clots or plugs brought by the blood from another blood vessel and forced into a smaller 
vessel so as to obstruct the circulation) from deep vein clots are a leading cause of death in 
hospitalized patients. Annually, 200,000 to 300,000 patients develop this form of clot for the first 
time during a hospitalization. Nearly 40% of these patients suffer from a complication known as 
pulmonary embolism (a clot that travels to the lung and obstructs a significant amount of blood 
flow to the organ). This complication is fatal in 30% of the cases.  
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Intrinsic contact
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Extrinsic tissue
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FXI FXIa
FIX
FX
FII
FIXa
FXa
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cross-linked fibrin (clot)
FXIIa
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Figure 1.1. Schematic overview of blood coagulation cascade
7  
 
Recent research shows that these disorders contribute significantly to morbidity and mortality in 
the United States. Each year, more than 600,000 Americans die from abnormal blood clots. 
Genetic thrombosis is an inherited abnormality that leads to an increased risk of thrombosis 
throughout a person's life. These may be protein C deficiency, protein S deficiency, anti-
thrombin deficiency and prothrombin mutations. Acquired thrombosis refers to a group of 
disorders that an individual is not born with, but may develop throughout his or her life due to 
another circumstance such as illness. An example of acquired thrombophilia is the development 
of a lupus anticoagulant or antiphospholipid antibody syndrome. 
 
1.4. Factors in the coagulation pathway and their inhibitors  
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Thrombin (factor IIa) is a key trypsin-like multifunctional serine protease
10 
of the blood 
coagulation cascade and is also the most potent activator of platelet aggregation. The important 
blood coagulation factors like thrombin, factor Xa and factor VIIa all belong to the trypsin 
family of serine proteases and they have active sites similar to trypsin. Thrombin cleaves 
fibrinogen to fibrin which further forms insoluble fibrin polymer clots. Factor Xa is the first 
member of coagulation factors in the final common coagulation pathway. It acts by cleaving 
prothrombin (factor II) into thrombin (factor IIa), and requires factor Va as a cofactor.  
 
Thrombosis disorders can be prevented or controlled by the proper use of an anticoagulant. The 
research for developing effective anticoagulants has intensified during the past few decades, 
since there are not many drugs available in treating or preventing thrombotic diseases. 
 
The two major drugs against thrombosis are heparin and warfarin which were introduced more 
than 50 years ago. Heparin or low molecular weight heparins are useful anticoagulants in acute 
conditions. However, the requirement of intravenous injection limits their application. The 
widespread use of heparin resulted in the occurrence of Heparin Induced Thrombocytopenia 
(HIT), a severe immune response caused by heparin-dependent antibodies. Warfarin (coumadin) 
is used as an oral drug in the chronic setting. However, the delayed onset of action, potential 
drug-drug interactions and the need for constant monitoring make this drug problematic. Despite 
these problems, they are still the major drugs for treating thrombosis disorders. The development 
of a new effective and safe drug to treat thrombosis disorder is very challenging but very 
important. Several of these anticoagulants compounds are in different stages of clinical trials. 
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Factor VIIa and tissue factor (TF) complex activates factor IX and factor X upon blood vessel 
damage, initiating the extrinsic pathway leading to activiated factor Xa. Therefore factor VIIa/TF 
has been considered as a promising target for anticogulants. Many efforts have been devoted to 
finding effective factor Xa inhibitors as anticoagulants.
11
 Some reports also suggest that factor 
VIIa/TF inhibitors prevent thrombosis with a lower bleeding risks than other types of 
inhibitors.
12
   
 
Currently only a few Direct Thrombin Inhibitors (DTIs) are approved for clinical use or are in 
the advanced stage of clinical trials.
13
 These include the small molecule thrombin inhibitors, 
Argatroban,
 
Ximelagatran, Dabigatran, and several peptide thrombin inhibitors, lepirudin, 
desirudin and bivalirudin. Lepirudin and desirudin are the recombinant analogs of hirudin (65 
amino acids), a naturally occurring polypeptide isolated from medicinal leeches, Hirudo 
medicinalis.
14
  
 
Hirudin, binds to thrombin in a bivalent fashion through interactions at both the active site and 
the remote “fibrinogen-binding exosite”.15 Bivalirudin is a synthetic polypeptide (20 amino 
acids) analog of hirudin.
16
 Recombinant hirudins and the shorter peptide analog bivalirudin are 
approved by FDA for the treatment of thrombosis associated with HIT, and they are under 
investigations for other applications in treating thrombosis disorders.
17
 These hirudin analogs are 
highly efficient direct bivalent thrombin inhibitors, i.e. they bind to both the active site (catalytic 
site) and the exosite (fibrinogen binding site) of thrombin. Argatroban 1 (Figure 1.2) is a 
synthetic small molecule thrombin inhibitor and has been recently approved for use as an 
anticoagulant for treating prophylaxis, HIT and associated thrombotic complications.
18 
These 
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thrombin inhibitors are developed in response to the urgent need for an alternative anticoagulants 
other than heparin. However, they also need to be administered through IV injection. Exanta 3 
(ximelagatran) which is the prodrug of melagatran 2, the only orally available drug for treating 
thrombosis disorders, was approved for limited uses in Europe, but the liver toxicity found from 
recent clinical trial led to the overall withdrawal of this compound from the market.
19 
  
 
It has been a challenge to achieve selectivity among these enzymes in searching for new 
anticoagulants. Recently, it is hypothesized that dual inhibitors of these enzymes may be more 
effective antithrombotic agents since they inhibit two targets in the blood coagulation cascade.
20
  
Accordingly, there is a trend in developing dual inhibitors for factor Xa and thrombin, factor Xa 
and factor VIIa, thrombin and factor VIIa. Of the currently oral anticoagulants, the two agents 
that are in the most advanced stage are Dabigatran etexilate 4 (BIBR 1048)
21
 and Rivaroxaban 5 
(BAY59-7939).
22   
N
COOH
O
HN
NH2
N
H
S
NH
NH
RO
H
N
N
N
H
O
O
NR'
NH2
O
2. Melagatran: R = H, R' = H
3. Ximelagatran: R = Et, R' = OH
O O
1. Argatroban
N
N
N
H
O
NO
NH2
N
OO
O
4. Dabigatran etexilate
N
O
H
N
O
SNO
O
O
Cl
5. Rivaroxaban  
 
Figure 1.2. Structures of several anticoagulants.  
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Dabigatran etexilate 4 (BIBR 1048), the prodrug of dabigatran, is an orally available directly 
reversible nonpeptidic small molecule thrombin inhibitor. It is currently in phase III clinical trial 
for the treatment and prevention of secondary venous thromboembolism and other conditions.
17
 
Rivaroxaban 5 (BAY 59-7939) is an oral anticoagulant currently undergoing phase IIb clinical 
trials for treating DVT and PE and other thromboembolic complications. It is a factor Xa 
inhibitor, and it may replace warfarin for a number of indications.
23 
 
1.5. Aeruginosins: A class of naturally occurring serine protease inhibitors 
 
In recent years, a new class of marine natural products, the aeroginosins were isolated from 
cyanobacterial blooms (6-13) which have long been a source of biologically interesting 
secondary metabolites y the isolation of aeruginosin 298A, a class of serine protease inhibitors 
(2) from cyanobacterium Microcystis aeruginosa.
26 
20 more compounds structurally and 
pharmacologically related to aeruginosin 298A have been isolated and identified so far and many 
of them are potent thrombin inhibitors.
27
 Few of them are shown in Figure 1.3. These mark the 
introduction of a new class of peptidic serine protease inhibitors to the chemistry community.  
 
 - 9 - 
 
HN
N
OH
HO
O
O
O NH H
N NH2
OH NH
HO
6. Aeruginosin 298-A
D-Hpla
D-Leu Choi
Argol
HN
N
HO
O
O
O N
H
HO
N
NH
NH2
12. Oscillarin
7. Aeruginosin 89-A (2S)
8. Aeruginosin 89-B (2R)
1 2
argininalHN
N
HO
HO3SO
O
O
O NH H
N NH2
O NH
HO
Cl
H
N
H
N
OH
HO
O
O O NH2
HO
9. Aeruginosin EI 461
HN
N
OH
HO3SO
O
O
O NH
HO
HO
N
OH NH
NH2
10. Aeruginosin 102 A L-Argal
11.Aeruginosin 102 B D-Argal
HN
N
HO
O
O
O
NH
HO
HN
NH
NH2
HO
13. Microcin SF608
 
 
Figure 1.3. Structures of some aeruginosins (6-13) and 3 different Choi core structures (28-30). 
 
Some of these have been gathered from geographically distinct locations and from sources 
having an unclear relationship to the Microcystis waterbloom and are small molecules/ small 
linear peptides containing natural or unnatural amino acids or their derivatives found to be serine 
protease inhibitors. Approximately 16 compounds in this family share a common new bicyclic 
amino acid core structure 2-carboxy-6-hydroxyoctahydroindole (Choi). Most of the known 
aeruginosins have been evaluated for inhibitory activity against thrombin by X-ray crystal 
structures of thrombin complexed with aeruginosin 298A (1A2C).
28 
 
 
1.6. Pharmacophore and Clinical application of direct thrombin inhibitors 
 
The central role of thrombin in the blood coagulation cascade has made it an attractive target for 
the development of antithrombotic drugs. Several X-ray crystal structures of the enzyme in 
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complex with different inhibitors have been solved, providing important information about 
enzyme–inhibitor interactions. Currently, many efforts have been devoted to searching for better 
anticoagulant therapies. Special attention has been focused on small molecules that can function 
as direct thrombin inhibitors and exploit their potential of regulating hemostasis and 
thrombosis.
29-31 
 
Despite much research devoted to finding thrombosis inhibitors that could treat or prevent blood 
clotting disorders, an orally active, safe and effective anticoagulant is still elusive. Thrombin 
consists of two polypeptide chains: A(36 residues) and B (259 residues) linked by disulfide 
bridges.
10 
The compounds belonging to the aeruginosin family inhibit the S1, S2, and the d-S3 
subsites (Figure 1.4) of the thrombin active site. The S1 subsite, also known as the specificity 
pocket, is characterized by an aspartic acid residue (Asp189) in the bottom of the pocket. This 
Asp189 is able to recognize and engage in ionic interactions with inhibitors containing basic P1 
side chains. An alanine residue (Ala190) of the S1 pocket of thrombin distinguishes it from 
trypsin, which has a serine in this position.
32 
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Figure 1.4.(a). Correlation of active site thrombin with ppack 
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Figure 1.4.(b). Correlation of active site thrombin with aeruginosin 
 
The S1 subsite is also in close proximity to the Ser195-His57-Asp102 catalytic triad and the 
oxyanion hole i.e. the backbone amide NH groups of Ser195 and Gly193. The S2 subsite, or the 
proximal P pocket, is a hydrophobic pocket primarily created in the Tyr60A-Pro60B-Pro60C-
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Trp60D thrombin insertion loop by Tyr60A and Trp60D.
33,34
 The S4 pocket or the D-pocket has 
been redefined as the distal S3 (d-S3) subsite based on the binding of d-phenylalanine in the X-
ray crystal structure of the prototypical synthetic thrombin inhibitor d-Phe-Pro-Arg chloromethyl 
ketone (PPACK, Figure 1.4).
35 
 
In general, the design of synthetic thrombin inhibitors has been based on the D-Phe-Pro-Arg 
sequence of PPACK, originally developed based on the cleavage sites of thrombin‟s natural 
substrates such as fibrinogen.
36
 The binding mode of aeruginosin 298-A resembles closely to that 
of D-Phe-Pro-Arg chloromethyl ketone 4a and other serine protease inhibitors. Initially, the 
structure of aeruginosin 298A (6a) was elucidated through 2D NMR studies and the peptide was 
found to contain four subunits: hydroxyphenyllactic acid (Hpla), leucine, a Choi core, and a 
reduced arginine (Argol). Close inspection of NOE correlations from the Choi amide of 
aeruginosin EI461 revealed an axial hydrogen atom (H-6) at C6 and a cis-fused perhydroindole.  
 
The fact that H-6 showed an NOE correlation to the ring-junction hydrogens (H-3a and H-7a) 
suggested a Choi configuration unique among the aeruginosins.  In their initial report, Murakami 
and co-workers
 26 
assigned an l-configuration to the leucine amide subunit in aeruginosin 298A 
based on degradation and derivatization of the acid hydrolyzate. Later, in 1998 Tulinsky and co-
workers
42
 published an X-ray crystallographic structure of a ternary complex of 1 bound to a 
hirugen–thrombin complex at 2.1 Å resolution providing an absolute stereochemical 
configuration. The Hpla subunit was proposed to display a d-configuration and the leucine an l 
configuration. The stereogenic centers in the substituted Choi
26 
amino acid were designated as 
2S, 3aS, 6R, 7aS, and the absolute stereo-chemistry as l-Choi, while the Argol subunit was found 
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to also have an l-configuration.  
 
The crystal structure of the ternary complex revealed some unexpected interactions between 1 
and the binding pocket of thrombin. l-Leu was found to occupy the hydro-phobic d-
enantiomorphic S3 subsite, despite its proposed l-stereochemical configuration. In addition, the 
Hpla residue was found to interact with the S3 subsite, which was expected to accommodate the 
l-leucine residue. These key observations cast some doubt on the stereochemical assignments 
initially made for aeruginosin 298A. The issue would not be resolved until the proposed structure 
(6a) was revised through total synthesis by the groups of Bonjoch
42,43
 and Wipf
44
 independently 
in 2000. This sequence is closely mimicked by the general structure of the Aeruginosins (Figure 
1.5): a hydrophobic d-amino acid, a constrained bicyclic l-proline (Choi and OHChoi), and a 
basic arginine-mimetic subunit. The d-S3 subsite formed by the side chains of Leu99, Ile174, 
and Trp215 is also hydrophobic but larger than S2.  
 
In addition to theaforementioned regions, hydrogen bonding to at least one of the Ser214-
Trp215-Gly216 residues opposite the d-S3 subsite has been found to be important for inhibitory 
activity. Aeruginosin 298-A
 
(6) inhibits thrombin (IC50 = 0.5 M) and trypsin (IC50 = 1.7 M), 
(but does not significantly affect papain, chymotrypsin and plasmin
37
 and contains sequence D-
Hpla-D-Leu-L-Choi-L-Argol. 
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Figure 1.5. Generalized structure of the aeruginosins. 
 
Aeruginosin 298-A binds to the active site of thrombin in a non-covalent fashion forming an 
antiparallel strand with thrombin. The P1 residue argininol fits into the  binding site of thrombin. 
The guanidine of argininol forms a double hydrogen bond with Asp 189 of thrombin. The D-Leu 
and D-Hpla bind to the S3 subsite. The 5-membered ring of the Choi residue occupies the 
hydrophobic S2 binding site, while its 6-membered ring projects out and loosely interacts with 
Try60 and Tyr60 from thrombin. The X-ray crystal structure of thrombin complex with 
aeruginosin 298-A is shown in Figure 1.6a (PDB code 1A2C).
28
  
 
Various aeruginosins exhibit varying degrees of inhibitory activity against serine proteases, and 
their activity profile can be explained by a high degree of pharmacophoric and structural 
homology within the family. Nearly all of the aeruginosins are composed of four subunits: an N-
terminal hydroxy or acidic group, a bulky hydrophobic amino acid, a 2-carboxyperhydroindole 
core, and a C-terminal guanidine-containing group (Figure 1.6). This array of structural and 
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functional features is responsible for their affinity to the catalytic binding pocket of trypsin, 
thrombin, and other serine proteases involved in the blood coagulation cascade. 
 
 
 
Figure 1.6. (a) The structure of aeruginosin 298-A (b) The conformation of Aeruginosin-298A 
in complex with thrombin.
28 
 
1.7. Role of Aeruginosins as DTI 
 
As a result of their structural novelty and biological activity, the aeruginosins have also garnered 
considerable attention from synthetic organic chemists. Derivatives of the 2-
carboxyperhydroindole core structure have received the most attention with respect to 
conceptually diverse synthetic approaches. To date, the total syntheses of seven aeruginosins 
have been completed; four of which involve revisions to the originally proposed structures. 
Initially the aeruginosins were classified as natural products produced by the cyanobacterium 
Microcystis aeruginosa incorporated with Choi, however in the years following the isolation of 
the thrombin and trypsin inhibitor aeruginosin 298A (6a),
26 
linear peptides containing the core 
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bicyclic subunit having similar biological activities and structural features were isolated from the 
fresh-water cyanobacteria of the family Oscillatoria and from marine sponges of the family 
Dysideidae containing the distinctive cis-fused 2-carboxy-perhydroindole core structure, and 
many of the exhibited in vitro inhibitory activity against serine proteases.
38-41
 
 
From the results of the enzyme assays listed in Table 1.1 it is evident that depending on the 
target enzyme different structural features are important. A basic P1 end group appears to be a 
prerequisite for achieving high potency against the trypsin-like serine proteases. One explanation 
for the lack in activity against chymotrypsin and elastase might be the substrate preferences of 
these enzymes, which favor peptides with bulky hydrophobic or small neutral P1 side chains, 
respectively. Consequently, a replacement of the basic P1 subunit in the aeruginosins by a 
hydrophobic group might result in a shift in inhibitory activity towards other enzymes. The main 
role of the octahydroindole core subunit seems to be to direct different parts of the tetrapeptide 
into specific regions in space conferring the bioactive conformation. Fine-tuning of the 
octahydroindole substituents has been further suggested to attain selectivity between different 
enzymes.
45,46 
 
Small changes in the nature of the P3 substituent on the amino acid residue appear to have a 
strong influence on the affinity for the coagulation factors. A striking example is the remarkable 
effect of the chlorine atom in chlorodysinosin A compared to the hydrogen-substituted dysinosin 
A (Table 1). As mentioned above, it was reported that the presence of a sugar residue on the 
octahydroindole core 
46
 as in dysinosin B had an influence on the selectivity between FVIIa and 
thrombin. This sugar moiety also resulted in a slight increase in affinity for FVIIa. Moreover, 
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they found that an N-terminal P4 sulfate group seems to contribute to both thrombin and FVIIa 
binding (cf. dysinosin D with dysinosins A–C, Table 1.1). In accordance with this observation, 
oscillarin, which lacks a P4 sulfate, exhibits a weak activity against FVIIa (IC50 = 3.9 mm). Since 
oscillarin still shows a high activity against thrombin, a P4 sulfate group might be more 
important for inhibition of FVIIa. Chlorodysinosin A exhibits the highest inhibitory activity 
against FVIIa among all the aeruginosins (IC50 = 0.039 mm, Table 1.1).
47
  
 
The large difference in activity between chlorodysinosin A and dysinosin A indicates a positive 
effect of the P3 chlorine atom upon binding to FVIIa, similar to that observed upon the binding 
to thrombin. The precise importance of the N-terminal sulfate group for different biological 
activities needs to be further elucidated. Beside the search for better activities and selectivities 
against target serine proteases
48
, other structural and pharmacological aspects should be 
addressed to render this intriguing class of natural products more “druggable”.49 The prospects of 
achieving such a daunting task are nevertheless promising, especially since the natural products 
and the totally synthetic thrombin inhibitors share the same binding sites.
50,29a,30,34,51,52,53
 As such, 
they should be amenable to a segment-coupling protocol in a structure-based organic synthesis 
paradigm
27a
 to produce potent hybrid analogues with favorable pharmacological properties. 
Attention has been directed towards other coagulation cascade factors besides thrombin (FIIa). 
Although no X-ray crystal structure of the aeruginosins in complex with factor VIIa is available, 
the high homology of the active site with that found in thrombin suggests a similar binding 
mode.
54,55
  
 
For aeruginosin 205 structure assignment, there are some dispute of the originally proposed 
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structures.
37 
Bonjoch et al argued that the structures should be revised to place the chlorine as a 
substituent on the D-Leucine residue not on the octahydroindole core structure.
56-57
 These are 
shown in Figure 1.7. This revision is supported by some later work by Hanessian based on 
observed biological activities of synthetic analogs containing D-chloro leucine unit.
58 
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Figure 1.7. The proposed and revised tentative structures of aeruginosin 205. 
 
However, the correct structure assignments of aeruginosin 205 still remain to be further 
confirmed by total synthesis. Two other glycosylated compounds, termed aeruginoside 126A and 
126B with a sugar moiety attached to the octahydroindole core have been identified recently.
59   
 
Other aeruginosins contain a different amino acid residue at the Argol position, aeruginosin 89 
contains a N-4-amino-5-oxo-pentyl-guanidine (argininal or Argal) at the P1 position. The 
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aldehyde functional group of the Argal is important for the biological activity for aeruginosin 89 
(7, 8).
19 
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The Argal group exists as an equilibrium of the open chain form and a 6-membered ring cyclic 
hemiaminal as shown in the structures of aeruginosin 102 (9-10). Aeruginosin 89-B 8 is very 
selective towards thrombin (IC50 = 0.05 g/mL) but it‟s IC50 to trypsin is 6.6 g/mL and it also 
doesn‟t inhibit papain, chymotrypsin and elastase.  
 
The stereoisomer 89-A 7 is a very potent thrombin inhibitor with 0.03 g/mL activity, however 
it‟s not very selective towards thrombin. It also inhibits trypsin at 0.4 g/mL and plasmin at 0.02 
g/mL. Aeruginosin 102-A and B (9, 10) have the sequence of D-Hpla sulfate, D-Tyr, Choi, and 
Argal. Aeruginosin 102-A inhibits thrombin and trypsin at 0.04 g/mL and 0.2 g/mL 
respectively whereas aeruginosin102-B inhibits thrombin and trypsin at 0.1 g/mL and 1.1 
g/mL respectively. The aeruginosins without an arginine like basic unit, such as 298B and 
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EI461 donot inhibit either thrombin or trypsin. Recently several new peptides banyasin A, 
banyaside A and banyaside B were isolated and their structures have been reported.
60
  
 
Although the unique new structure in banyaside represent perhaps a new class of serine protease 
inhibitors, their structure similarity with dysininosin is evident here.  Banyaside A inhibit trypsin 
at 1.48ug/mL, and thrombin at 0.39ug/mL, IC50.  However, it seems a little challenging to 
synthesize the unusual azabicyclonanonane moiety (Abn).  
 
1.8. Inhibition of Trypsin 
 
Trypsin is a digestive enzyme frequently employed as a marker for inhibition of trypsin-like 
serine proteases. Inhibition of trypsin might also by itself be of interest for the treatment of 
pancreatic disorders, such as pancreatitis.
61 
In general, the binding of aeruginosin 98B to trypsin 
is similar to that shown for the aeruginosins in complex with thrombin and closely resembles that 
of a d-Phe-Pro-Arg tripeptide.
62
 The most striking feature of the structure of aeruginosin 98B 
cocrystallized in complex with trypsin
45
 was the lack of interactions between aeruginosin 98B 
and the trypsin catalytic triad (Ser195-His57-Asp102), indicating a new possible mode of serine 
protease inhibition. The basic P1 agamatine side chain is buried in the S1 specificity pocket, 
forming two strong hydrogen bonds to the side-chain carboxylate of Asp189. The Choi moiety is 
situated in the S2 subsite with the 6-O-sulfate group reaching out into solution. It was speculated 
that the Choi sulfate group might be the primary determinant for selectivity for trypsin over 
thrombin.
74 
The P3 d-alloIle side chain is located in the Trp215 aryl-binding site and makes van 
der Waals interactions with Trp215 and Leu99. The phenol hydroxy group utilizes a water 
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molecule in the P4 position, also observed in crystal structures of uncomplexed trypsin
63 
as a 
bridge to interact with Cys220 and Ser146. Most of the aeruginosins have been assessed for 
trypsin inhibitory activity (Table 1.1). Not surprisingly, the structure-activity relationships 
(SARs) for trypsin are similar to those for the trypsin-like serine protease thrombin. To date, the 
most potent natural aeruginosins are chlorodysinosin A and oscillarin, both demonstrating IC50 
values against trypsin of 0.037 mm (0.025 and 0.024 mgmL
-1
, respectively, Table 1.1).  
 
In accordance with the substrate preference of trypsin, a basic P1 end group appears to be critical 
for inhibition. Aeruginosin 298B, which lacks a basic P1 group, is inactive against trypsin (IC50 
> 100 mgmL₃
1
, Table 1.1).
64 
Moreover, the bulky P1 ethyl hemiaminal of  aeruginosin103A to be 
responsible for its low trypsin inhibitory potency (IC50=51.0 mgmL
-1
, Table 1.1).
65
 Fukuta and 
co-workers
66
 suggested that the difference in trypsin potency between aeruginosin 298A and 
102A might be due to the P4 sulfate group found in the more potent 102A (IC50 = 1.0 and 0.2 
mgmL
-1
, respectively, Table 1.1). 
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The summary of the inhibition data against several enzymes is shown in Table 1.1.  
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Table 1.1. Summary of aeruginosins and their inhibition activities against thrombin and other 
enzymes. IC50 in g/mL unless otherwise noted.  
IC50 (g/mL) Trypsin Thrombin Factor VIIa  
Aeruginosin 98-A 0.6 7.0  
Aeruginosin 98-B 0.6 10.0  
Aeruginosin 98-C 3.9 3.3  
Aeruginosin 101 3.0 3.2  
Aeruginosin 298-A 1.0 0.3  
Aeruginosin 298-B >100 >100  
Aeruginosin 89-A 0.4 0.03  
Aeruginosin 89-B 6.6 0.05  
Aeruginosin 102-A 0.2 0.04  
Aeruginosin 102-B 1.0 0.1  
Aeruginosin 205-A 0.07 1.5  
Aeruginosin 205-B 0.07 0.17  
Microcon SF 608 0.5 ug/mL   
Oscillarin   28nM 3.9uM 
Dysinosin A   0.452M Ki   
46 nM  
0.108M Ki 
326 nM 
Dysinosin B  0.170 0.090M Ki 
Dysinosin C  0.550 0.124M Ki 
Dysinosin D  >5.1M Ki 1.320M Ki 
Chlorodysinosin 37nM 5.7 nM 39 nM 
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Although aeruginosins and related compounds exhibit promising biological activity, they haven‟t 
been used as lead compounds and developed into useful therapeutic agents. One obstacle for 
aeruginosins to be used as thrombin inhibitors is their lack of selectivity among the trypsin like 
enzymes. The selectivity for thrombin over trypsin is not very high for most of the members. 
Another obstacle is the complexity of their structures. There are also confusions about the 
absolute stereochemistry assignment in the literature. The various natural products don‟t seem to 
have a clear trend of structure activity correlations. 
 
1.9. Syntheses of Aeruginosins 298A and 298B (The P2 Choi core structures and the 
preparations.) 
 
Several core structures for the P2 group from the structures of the natural products aeruginosins, 
are shown in Figure 1.8, the most common core being structure 23. The Choi in EI461 24 has the 
different stereochemistry and dysinosins contain the dihydroxylated octahydroindole 25. The 
Choi core structure is crucial for their anti-thrombotic activity. Several total syntheses towards 
the natural products have been reported because of the interesting structure and biologically 
activities of these compounds and several methods have been developed for the synthesis of Choi 
or its analogs.
27, 42-44, 47,68-78
  
The majority of strategies involve the use of amino acids as starting materials. The absolute 
configuration of Aeroginosins obtained from the crystal structure served as the basis for two total 
syntheses reported. An efficient syntheses of the (2S,3aS,6R,7aS)-6-hydroxyoctahydroindole-2-
carboxylic acid (l-Choi) motif starting from l-Tyr(OMe)-OH (26) was found in many of the 
aeruginosins
76
 and were featured in the first total synthesis of aeruginosins 298A
42  
and 298B.
43
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Figure1.8. The structures of the Choi P2 units present in aeruginosins  
 
The azabicyclic core subunit was obtained in two steps by Birch reduction of O-methyl-L-
tyrosine 26 followed by acidic cleavage of the enol ether and Michael-type addition of the 
pendant amine nucleophile (Scheme 1.1) by Bojoch et al.
75
 
 
The resulting secondary amine was treated directly with BnBr to afford a mixture of isomers 28 
and 29. Thermodynamic equilibration of this mixture in the presence of MeOH/aq. 8 N HCl 
provided the more stable isomer 29 in 44% overall yield from 26. For the purpose of completing 
the synthesis of aeruginosins 298A and 298B, intermediate 29 was converted into 31. A variety 
of ketone-reduction conditions were examined in an effort to secure the desired 6R 
stereochemistry of the alcohol. Optimal selectivity in favor of the 6R isomer (8:1) was achieved 
by reduction with LS-Selectride. 
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Scheme 1.1. Synthesis of aeruginosin 298A by Bonjoch et al. (a) Li, NH3, THF/tBuOH, -78 °C; 
(b) MeOH, 3N HCl, 35 °C; (c) BnBr, NaHCO3, EtOH, 70 °C; (d) MeOH, 8N HCl, 65 °C; (e) H2, 
Pd(OH)2, Boc2O, EtOAc; (f) LS-Selectride, THF, -78°C; (g) TFA, CH2Cl2, 0 ⁰C; (h) Boc-d-Leu, 
BOP, NMM, CH2Cl2 ; (i) TFA, CH2Cl2, 0 °C; (j) (O-Bn,O-Ac)-d-Hpla, BOP, NMM, CH2Cl2 ; 
(k) 0.1N LiOH/THF; (l) l-Arg(NO2)-OMe, BOP, NMM, DMF; (m) LiBH4, THF; (n) H2, Pd/C, 
EtOAc/ MeOH, 6N HCl, 1 atm; (o) 0.1N LiOH/THF; (p) NH4OH, PyBOP; (q) H2, Pd/C. 
 
With the protected l-Choi derivative 31 in hand, aeruginosin 298A was assembled using standard 
peptide-coupling techniques. Thus, Boc removal was followed by BOP-mediated coupling with 
Boc-d-Leu-OH to give dipeptide 32 in 73% yield. 
 
A tyrosine-oxidation rearrangement route toward the key Choi bicyclic hydroindole, which is 
present in the aeruginosins as well as other alkaloidal natural products (Scheme 1.2) was 
developed by Wipf et al.
44
 Treatment of N-Cbz-l-Tyr-OH (35) with PhI(OAc)2 followed by 
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exposure to methanol/ NaHCO3 afforded cyclic product 36 with a diastereoselectivity of d.r. > 
98:2. Access to the desired stereochemistry at the ring-junction carbons was possible by the 
thermodynamic equilibration of benzoylated derivative 37 to give the more stable isomer 38; this 
proceeded by ring-opening to the cyclohexadienone followed by Michael-type closure. 
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Scheme 1.2. Synthesis of l- Choi derivative 42 for synthesis of aeruginosin 298A by Wipf et al. 
a) PhI(OAc)2, NaHCO3, MeOH; b) Bz2O, DMAP,pyridine, CH2Cl2 ; c) NaHCO3, DMSO, 90 °C; 
d) Zn dust, AcOH/THF, 65°C; e) H2, 5% PtO2, 10% AcOH/EtOH, 0°C; f) L-Selectride, THF, -
78 °C; g) TBSOTf, ImH, CH2Cl2; h) H2, Pd/C, EtOH, then AllocCl, pyridine; i) LiOH, 
THF/H2O, 40 °C. 
 
After recycling of recovered 37, the resulting 1.6:1 mixture of products was then separated to 
give 38 in 78% yield. Using activated Zn dust or SmI2, reductive displacement of the benzoate 
ester gave the β,γ-unsaturated ketone 39, which was hydrogenated to give cis-fused azabicyclic 
ketone 40. Reduction of the ketone function with L-Selectride afforded a 3.8:1 mixture of 
products having exo and endo hydroxy groups. Choi derivative 42 was afforded by protection of 
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the major product 41 as TBS ether, followed by exchange of the Cbz protecting group for Alloc, 
and cleavage of the methyl ester. 
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Scheme 1.3. Synthesis of aeruginosin 298A by Wipf et al. synthesis of amide 46. a) AllocCl, aq. 
NaOH; b) CbzCl, aq. NaOH, THF; c) IBCF, NMM, DMF, -20 °C, then NaBH4 ; d) TBSOTf, 
ImH, CH2Cl2 ; e) CbzCl, DMAP, K2CO3, DMF; f) Bu3SnH, [Pd(Ph3)4], AcOH, THF; g) 42, 
FDPP, DIEA, CH2Cl2; h) Bu3SnH, [Pd(PPh3)4], AcOH, THF. 
 
Following this, the argol fragment was prepared from l-Arg-OH 43 by sequential protection of 
the α-amine and guanidine groups and then reduction to the primary alcohol 44 (Scheme 1.3). 
Protecting-group manipulation gave 45 in 22% overall yield from arginine. The Choi-Argol 
fragment was obtained by pentafluorophenyl ester-mediated coupling of amine 45 to acid 42 in 
69% yield. Removal of the Alloc group gave subunit 46. 
 
In Scheme 1.4, the synthesis of the appropriately protected Hpla-Leu fragment and final 
assembly of aeruginosin 298A is depicted.  
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Scheme 1.4. Synthesis of aeruginosin 298A by Wipf et al. completion of the synthesis. a) 
t
BuLi, 
CuBr·SMe2, THF, -78 °C to -45 °C then (R)-benzylglycidol, BF3·Et2O, -45 °C to -20 °C; b) 
TBSOTf, ImH, CH2Cl2 ; c) H2, Pd/C, EtOAc; d) DMP, CH2Cl2 ; e) NaClO2, NaH2PO4, 2-methyl-
2-butene, 
t
BuOH/H2O; f) l-Leu-OBn, DEPC, DIEA, CH2Cl2 ; g) H2, Pd/C, EtOH; h) 46, DEPBT, 
DIEA, CH2Cl2 ; i) aq. HF; j) H2, Pd/C, EtOH. 
 
The Hpla subunit was prepared by reaction of (R)-benzylglycidol with an aryl cuprate. Protection 
of the alcohol as the TBS ether was followed by hydrogenolysis of the benzyl ether and 
oxidation of the resulting alcohol to carboxylic acid 49. Coupling to d-Leu-OBn, and ester 
cleavage by hydrogenolysis gave 50. Then, fragments 50 and 46 were joined in the presence of 
DEPBT
44,77-78  
to give intermediate 51 in 59% yield. Removal of the silyl and Cbz protecting 
groups afforded aeruginosin 298A 6a. 
Application of catalytic asymmetric phase-transfer alkylation reactions was recently devised for 
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the synthesis of the l-Choi subunit by (Scheme 1.5)
66,72a 
by Shibasaki et al.  
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Scheme 1.5. Synthesis of l-Choi derivative 56 for synthesis of aeruginosin 298A by Shibasaki et 
al. a) CsOH·H2O, toluene/CH2Cl2 (7:3), -70 °C; b) 4N HCl, MeOH; c) BnBr, NaHCO3, EtOH; 
d) conc. HCl; e) H2, Pd/ C, Boc2O; f) LS-Selectride, THF, -78 °C; g) aq. LiOH/MeOH. 
 
For the synthesis of the Choi core of aeruginosin 298A, the enolate of 52 was alkylated with 
bromide 53 in the presence of 10 mol% 54 as a catalyst to give 55 in 80% yield and 88% ee. A 
point to consider is the fact that the enolate of glycine derivative 52 was previously shown to 
react with a variety of electrophiles to give α-amino acids of high enantiomeric purity.81 Ketal 
deprotection and subsequent intramolecular Michael-type addition then afforded bicyclic ketones 
28 and 29, which were converted to 56 following the method previously described by Bonjoch 
and co-workers.
43
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Scheme 1.6. Synthesis of fragment 62 for synthesis of aeruginosin 298A by Shibasaki et al. a) 
CsOH·H2O, toluene/CH2Cl2 (7:3); b) HCl; c) Boc2O, TEA; d) 9-BBN, then H2O2 ; e) DEAD, 
PPh3, di-Cbz-guanidine; f) p-TsOH; g) 56, EDCI, HOBt; h) TIPSOTf, DIEA; i) ZnBr2. 
 
In Scheme 1.6, a synthesis of the l-Argol subunit utilizing asymmetric phase-transfer alkylation 
methodology is shown. Thus the allylglycine precursor 58 was obtained in excellent yield and 
enantioselectivity. Functional-group manipulation led to alcohol 59, which was further 
transformed into guanidine intermediate 60. Peptide coupling with 56 gave protected l-Choi-
Argal fragment 61 in 72% yield. Boc removal then afforded compound 62. 
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Scheme 1.7. Completion of the synthesis of aeruginosin 298A by Shibasaki et al. a) La-(S)-
BINOL-PPh3=O (10 mol%), TBHP, MS 4Å, THF; b) d-4,5-dehydroleucine-O
t
Bu, THF; c) H2, 
Pd/C; d) TIPSOTf, DIEA; e) TMSOTf; f) 62, HATU, DIEA, CH2Cl2 ; g) LiBH4, THF; h) 
HF·py; i) H2, Pd/C. 
 
The Hpla subunit was prepared by asymmetric epoxidation of imidazolide 63 (Scheme 1.7).
79 
Acid hydrolysis of 60 in methanol promoted deprotection of the imine and acetal, 
transesterification. Migration of the C-C double bond to the corresponding enone, which 
underwent Michael addition and benzylation to the bicyclic ketones 62, 63 in 2:1 ratio, led to the 
desired product 63. The undesired isomer can be isomerized to 63 by treating it with HCl in 
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methanol. Exchange of protecting group on nitrogen and stereoselective reduction lead to the 
protected Choi 64.  
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Scheme 1.8. Synthesis of Choi starting from L-glutamic acid 
 
The resulting peroxyester 64 could then be coupled by simple mixing with d-4,5-dehydroleucine-
OtBu to give amide 65. Reduction of the double bond by catalytic hydrogenation, protection of 
the alcohol, and cleavage of the t-butyl ester then gave the Hpla-Leu fragment 66. After 
extensive optimization, the final condensation reaction was performed in the presence of HATU 
to give 67 in 54% yields with minimal racemization of the Leu amide subunit (< 5%). Finally, 
removal of the methyl ester and further deprotection afforded aeruginosin 298A. Although the 
Argol and Leu subunits of the natural product are easily accessible from readily available chiral 
starting materials, Shibasaki‟s phase-transfer alkylation methodology proved particularly useful 
for the synthesis of analogues of aeruginosin 298A featuring unnatural amino acid residues.
66 
 
Another method for the formation of the Choi is using L-glutamic acid derivative as the starting 
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material. Hanessian et al have synthesized the Choi in aeruginosin 298-A (and dysinosin) by 
using L-glutamic acid as the starting material. As shown in Scheme 1.8, the protected glutamic 
acid 68 was alkylated with 3-butenol triflate to form the intermediate 69. The removal of Boc 
protecting group followed by cyclization and protection of the amide again with Boc lead to the 
5-membered ring lactam 70.  
 
Partial reduction of 70 followed by protection afforded the N-Boc carbinolamine acetate 71, 
which then with SnBr4 underwent cyclization reaction to afford the 6-bromo-ocathydroindole 
analog 72, displacing the bromo with acetate group leading to the protected octahydroindole 73. 
To prepare the dihydroxyl perhydroindole, intermediate 74 was used which was prepared by a 
similar method as shown in Scheme 1.6. 
  
Allylation of 74 via N-acyl imiinium ion chemistry afforded the product 75 in a 5.5/1 syn/anti 
ratio and the syn isomer can be converted to the desired final product via olefin metathesis and 
epoxidation of the alkene followed by acidic hydrolysis. (Scheme 1.9) 
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Scheme 1.9. Synthesis of Choi 
 
1.10. Aeruginosin analogs 
  
To date, limited efforts have been made to prepare analogues of the aeruginosin natural 
products.
58,66, 80-84
 Selected examples are depicted in Figure 1.9. Mainly aeruginosins 298A and 
98B have been explored as starting points for the synthesis of new synthetic aeruginosin-like 
serine protease inhibitors. In one of these studies, a trypsin activator rather than inhibitor was 
surprisingly identified. Radau and co-workers
80-82
 used l-proline as a core structure instead of the 
synthetically more demanding Choi. More recently, analogues possessing selective, albeit weak 
inhibition against thrombin versus trypsin (79 and 80, Scheme 1.10) and the screening of 
aeruginosin 298A analogues against trypsin
58,84
 have been reported. Both of these studies 
supported the importance of the chemical structure of the basic P1 subunit for inhibitory activity. 
Manipulations in the P3 and P4 regions had a lower impact on the trypsin inhibition.  
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Analogue 84 prepared by Shibasaki and co-workers
 66 
showed anti-trypsin activity comparable to 
that of the lead compound aeruginosin 298A. Furthermore, Takahashi and co-workers
102
 found 
the potent inhibitor 82, which is 300 times more active than aeruginosin 298A. Hanessian and 
co-workers
58
 recently reported on truncated analogues of the aeruginosins with nonnatural 
benzamidine in the P1 position and including sulfamides, exemplified by compound 83 Figure 
1.9. However, only modest activities against trypsin, thrombin, and other coagulation factors 
were obtained. A more thorough investigation of the SARs against thrombin was subsequently 
carried out focusing on the “chlorine effect” in chlorodysinosin A and probing the importance of 
all four aeruginosin subunits. The nonnatural benzamidine was found most favorable in the P1 
position, while the size and shape of the P2 Choi core was proven less important. The beneficial 
“chlorine effect” in the P3 position was confirmed, and similar effects were obtained with other 
β-branched P3 side chains, such as the β-cyclohexyl 85 and isoleucine 86 analogues, which 
showed inhibitory activities against thrombin at IC50 = 0.002 mgmL
-1
. An N-terminal d-HPla 
was superior to simpler motifs, and the terminal sulfate group of chloriodysinosin A was shown 
to have only a small impact on the thrombin inhibition. To the best of our knowledge analogue 
84, lacking the 6-hydroxy group but with a benzamidine P1 unit, is the most active in vitro 
thrombin inhibitor reported to date (IC50 = 0.0010 mgmL
-1
, Figure 1.9).  
 
Our group has also developed novel synthesis to synthesize bicyclic core structure starting from 
sugar and then incorporated them to synthesize aeruginosin 298-A. 
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Figure 1.9.  Examples of aeruginosin analogues.  
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Recently a combinatorial library of the compounds with varying amino acids on P1 and P3-P4 
positions, keeping P2 the same as in aeruginosin 298-A
83,85
 have prepared and the evaluated their 
activities against trypsin.  
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The structures 87a-87x are synthesized by solid phase method and trypsin inhibition activities 
are shown in Table 1.2. The study showed that compound D-Hpla-D-Leu-L-Choi-Agma 87g, is 
the most active one against trypsin and it inhibits trypsin at 0.043g/mL. This is in the same 
range as the sulfated Agma containing Aeruginosins 205 A and B.  
 
Table 1.2.  The structures of compounds synthesized and their inhibition activities against 
trypsin. 
Compound 
No. 
 Compound Structure  Components purity IC50 (g/mL) 
87a D-Hpla-D-Leu-L-Choi-L-Argol  A1, B1, C, D1 92 14 (1)c , (6)d 
87b L- Hpla -D-Leu-L-Choi-L-Argol  A2, B1, C, D1 91 7.9 
87c D- Hpla -D-Leu-L-Choi-L-Argal A1, B1, C, D2 92 3.4 
87d L- Hpla -D-Leu-L-Choi-L-Argal  A2, B1, C, D2 90 3.4 
87e D- Hpla -D-Leu-L-Choi-L-Arg-OH  A1, B1, C, D3 84 0.48 
87f L- Hpla -D-Leu-L-Choi-L-Arg-OH  A2, B1, C, D3 81 3 
87g D- Hpla -D-Leu-L-Choi-Agma  A1, B1, C, D4 93 0.043 
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Compound 
No. 
 Compound Structure  Components purity IC50 (g/mL) 
87h L-Hpla-D-Leu-L-Choi-Agma  A2, B1, C, D4 90 0.09 
87i D- Hpla -D-Tyr-L-Choi-L-Argol  A1, B2, C, D1 89 6.8 (28)d 
87j L- Hpla -D-Tyr-L-Choi-L-Argol  A2, B2, C, D1 89 100 
87k D- Hpla -D-Tyr -L-Choi-L-Argal  A1, B2, C, D2 89 4.8 
87l L- Hpla -D- Tyr -L-Choi-L-Argal  A2, B2, C, D2 91 4.6 
87m 
D- Hpla -D- Tyr –L-Choi-L-Arg-
OH  A1, B2, C, D3 87 0.78 (8.7)d 
87n 
L- Hpla -D- Tyr –L-Choi-L-Arg-
OH  A2, B2, C, D3 87 6.5 
87o D- Hpla -D- Tyr -L-Choi-Agma  A1, B2, C, D4 88 0.11 
87p L- Hpla -D- Tyr -L-Choi-L- Agma   A2, B2, C, D4 90 0.3 
87q D- Hpla -L-Phe-L-Choi-L-Argol    A1, B3, C, D1 94 >150 
87r L- Hpla -L-Phe-L-Choi-L-Argol   A2, B3, C, D1 93 1.1 
87s D- Hpla -L-Phe-L-Choi-L-Argal    A1, B3, C, D2 85 4 
87t L- Hpla -L-Phe-L-Choi-L-Argal     A2, B3, C, D2 95 4.6 
87u D- Hpla -L-Phe-L-Choi-L-Arg-OH   A1, B3, C, D3 82 >150 
87v L- Hpla -L-Phe-L-Choi-L-Arg-OH   A2, B2, C, D3 74 >150 
87w D -Hpla -L-Phe-L-Choi-Agma   A1, B3, C, D4 95 8.7 
87x L- Hpla -L-Phe-L-Choi-Agma   A2, B3, C, D4 96 11 (0.5)f 
 
Hanessian et al
  
also prepared quite a few analogs of the aeruginosins with varying P1, P2 and P3 
units and evaluated their inhibitory activities against thrombin. The general structure for their 
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library compounds is 83. Several sites can be modified as indicated, R
1
, R
2
, R
3
, R
4
. The results 
are shown in Table 1.3.   
 
Again, the P1 unit is important for potent inhibition activities. Among the three P1 groups tested 
here, the 4-amidinobenzyl group (compounds 88g) gave the best activity. The 1-amidino-δ3-
pyrroline 88h, 88i also gave reasonably good activity, while agamatine variants 88d, 88e are the 
least potent among the groups of compounds tested. 
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The bicyclic P2 subunit generally is considered to maintain the molecule in a favorable 
conformation in binding to the active site. The authors reported that the 6-hydroxy group doesn‟t 
influence the inhibition activity against thrombin. The compound without the 6-hydroxyl group 
gave slightly improved activities comparing to the ones with 6-hydroxy group.  
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Proline has been used often as a P2 subunit in many thrombin inhibitors, here the proline variant 
at P2 also showed considerable inhibition. Compound 89 inhibits thrombin at 11nM while 
compound 90 in which the Choi is replaced by a L-pro inhibits thrombin at 7nM. To study the 
effect of the P3 position, compounds with different R
5
 substituent were synthesized and the 
results are shown in Table 1.3. From this Table, we can see that the P3 position seems to tolerate 
quite a few different functionalities. The 3-R chloro substituent showed improved activities. 
Isoleucine and cyclohexyl group also give good activities. The observed “chlorine effect” was 
considered being routed from a better fit in the active binding site.   
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Table 1.3. The inhibition activities of library compounds with general structure 88 (R
2
 = H) 
towards thrombin and trypsin. 
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The authors also studied several different substituents at the P4 position. Phenyllactic acid as 
appeared in oscillarin was chosen to be the main group and it also gave the best inhibition 
compared to other tested groups as shown in Table 1.4.   
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Table 1.4. The inhibition activities towards thrombin for compounds with general structure 91.  
 
Compound  91a 91b 91c 91d 91e 91f 
R
5
 O
OH
 
H O
 
O
OH  
O
 
O
O
 
IC50 µM  0.0033 0.101 0.786 0.053 0.334 0.171 
 
While these aeruginosin analogs have shown better inhibitory activity comparing to the natural 
product, they are also quite potent inhibitors towards trypsin. Recently several analogs have been 
obtained by varying the different attachments. From these studies and other known systems, 
perhaps one can find better selective thrombin inhibitors by modifying the P1  groups. The 
further studies in this area will help elucidating these compounds and lead to more advanced 
drug leads as useful anticoagulants.  
 
1.11. Other compounds with rigid P2 units  
 
There are several other thrombin inhibitors containing a rigid P2 unit. The function of these rigid 
amino acids is to maintain the conformation of the overall molecule in a favorable form. Several 
of these compounds have appeared in recent reviews
5
, including those containing bicyclic 
thioazalactams such as in 92-95. These compounds contain a 7-thiaindolizidinone as the core 
structure, where the 6,5-fused bicyclic core occupies the S2 pocket
86
. 
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Compound 92 inhibits thrombin and trypsin with Ki values of 0.145 μM and 5.10 μM, 
respectively. Compound 93 has stereochemistry opposite to 92 at the P3 binding site, but it 
inhibits thrombin and trypsin with Ki of 0.111 μM and 7.90 μM, respectively. The 
stereochemistry at the C-6 seems to have no influence on inhibitor potency
87
. 
 
Compound 94 contains a different P1 group than 82. It inhibits thrombin with an IC50 of 16.4 
nM, and trypsin withan IC50 of 11.6 nM.
88
 It seems that the additional formyl group reduced 
selectivity towards trypsin. From a series of compounds containing different P3 and P1 
substituent, it was found that the optimal compound is 95, with a phenyl propyl group at P3 
position and a thiazolyl substituent at the P1 side chain inhibiting thrombin with Ki = 2 nM. 
Other bicyclic P3-P2 peptide compounds 96-98 showed promising activities against thrombin 
with Ki values in the nanomolar range, 96 (Ki = 7 nM), 97 (Ki = 10 nM) and 98 (Ki = 1.2nM) 
89-
91
. Some of them are found to be promising intravenous antithrombotic agents, but not orally 
available. Compound 96 contains a fused piperazinone system which was designed to include the 
P2-P3 unit together. This compound has also showed high in vivo efficacy. Compound 99 was 
found to be very potent towards thrombin with Ki = 0.11 nM; however, 95 and 99 are not very 
selective towards thrombin
92-93
. Selectivity can be improved by introducing more sterically 
demanding cyclic amino acids in the P1 position. 
 
For example, inhibitors 100 and 101 retained activities towards thrombin in the low nanomolar 
range but their Ki values towards trypsin are more than 10 μM.
94-95
 Other similar bicyclic 
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systems used in thrombin inhibitor design are shown in compounds 102-104, which contain an 
indolizidinone motif. 
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Compound 102 inhibits thrombin with Ki = 9nM and is about 20 fold selective over trypsin.
86
 
Compounds 103 and 104 are highly potent thrombin inhibitors, (103, Ki = 0.65 nM; 104, Ki = 
0.85 nM)
96
. They also showed some oral bioavailability, but further development of these 
compounds was stopped because of their high trypsin inhibitions with Ki values which were less 
than 1 nM. After incorporating a bulky cyclic group at the P1 position, selectivity can be 
improved. Compounds 105-107 contain a bicyclic β-strand mimetic.  
 
 - 45 - 
 
The triazolopyridazine unit was synthesized by a hetero Diels-Alder reaction between a diene 
and the 1,2,4 triazilinedione.
96-98
 These compounds are potent thrombin inhibitors, with Ki values 
of 23 pM for 105, 11 nM for 106, and 16 pM for 107. They also showed some selectivity 
towards trypsin with Ki >40nM. The conformational constrained bicyclic pyridine 108 (Ki = 0.24 
nM to thrombin)
99
 had shown improved pharmacokinetics comparing to those of piperazinone 
107. The pyridinone systems 109 and 110 are synthesized to provide rigid conformational 
stability to the molecules; however, no thrombin inhibition data were reported for these two 
compounds.
100-101
  
 
Other compounds with rigid fused ring systems include the carbohydrate derivatives 111-113.
 
The dianhydrohexitol- based benzamidines 111-113 inhibit factor VIIa and factor Xa. In these 
compounds, the amidine substituent position is important to the binding affinities. Compound 
113 inhibits factor Xa with IC50 at 150 nM and factor VIIa at 100 nM. In contrast, the IC50 values 
of isomer 112 against Xa and VIIa are 3 µM and 6 µM, respectively. 
102-103
  
 
Several other compounds containing rigid structures were also prepared and had been shown to 
be active against blood coagulation factors, especially factor Xa. These include tetracyclic 
tetrahydroquinoline
104
 114, compounds with bicyclic pyrazinones and pyridinones
105
 116a-b, 
and compounds with a bicyclic dihydropyrazolopyridinone scaffold 116a-b. Compound 116a is 
a potent factor Xa inhibitor with Ki = 0.03nM.
106
 The analog 116b inhibits factor Xa with Ki = 
0.18 nM, and it showed good enzyme selectivity and bioavailability.
106
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Based on the natural product 117, isolated from extracts of Lantana camara, which inhibits 
thrombin with IC50 of 4 nM, a fused indane lactone containing compound 118 was synthesized 
and found to be a potent thrombin inhibitor 
107.
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However, the lactone showed limited plasma stability. Thus structure optimization led to the 
trans-fused indane lactam 107 and 108, which inhibited thrombin with IC50 =0.05 µM and 0.016 
µM, respectively. Compound 108 showed improved stability compared to the lactone analog, but 
it was not developed further due to insufficient potency in APTT assays.
108
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The X-ray crystal structure of 107 covalently bound to thrombin indicated that the amidine side 
chain occupies the S1 binding pocket, while the diethylcarboxamide substituent on the pendant 
phenyl ring occupies the lipopholic S3 pocket in the acylated enzyme complex. The indane core 
does not interact with the S2 pocket, but there is a hydrogen-bonding interaction between the 
carboxamide carbonyl oxygen and the hydroxyl of tyrosine 60A. The hydrogen bonding 
compensated for the fact that the indane core has poor interaction with the S2 site 
108
. 
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1.12. Conclusions 
 
Despite the intense efforts in search of effective anticoagulants to replace the existing therapies 
using heparins or warfarins, a small molecule drug that is effective, safe and orally available is 
still elusive. Direct inhibitors of blood coagulation factors such as thrombin or factor Xa have 
occurring serine protease inhibitors. These compounds share a common rigid bicyclic amino acid 
at the P2 pocket. A few compounds in the aeruginosin family, such as oscillarin and 
chlorodysinosin, exhibited high potency against thrombin and factor VIIa. Several synthetic 
aeruginosin analogs have also been prepared and evaluated, and many of them showed promising 
activities against thrombin.  
 
Despite the progress with these novel systems, further structure optimizations are necessary in 
order to achieve the desired selectivity and potency among the serine proteases. Other 
compounds containing conformationally rigid P2 core structures have also been studied. 
Although several of them have shown great promises as thrombin inhibitors, much more effort is 
needed to understand the SAR and to further test these compounds in vivo, in order to discover 
new structure motifs as potential anticoagulants. Rigid molecular structures play an important 
role in maintaining molecular conformation. Aeruginosins and other compounds with a rigid, 
fused bicycle in their structures are potentially useful lead compounds for further SAR studies in 
order to find effective antithrombotic agents. 
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1.13 Part II: Introduction to self-assembly of D-glucosamine 
derivatives 
 
 
The word “gel” comes from Latin word “gelatus”, which means to immobilize or to freeze.109 
While this definition is very broad, a more accurate definition given by the esteemed Nobel 
laureate P. J. Flory defined a gel as “a colloidal dispersion with a continuous structure over 
macroscopic dimensions, which is permanent on the analytical time scale, and which is solidlike 
in its rheological behavior”.110 The colloidal dispersion causes an increase in the viscosity in the 
liquid medium by forming a matrix which entraps the liquid. In doing so, the system attains a 
semisolid consistency, lying somewhere between the liquid and solid state.  
 
In recent years, low molecular weight gelators (LMWGs) have gained great attention because of 
their potential applications as advanced soft materials. LMWGs are small molecules that can 
self-assemble and form 3-dimensional network which allows the immobilization of solvents.
111-
114 
Based on the solvent system they are divided into two categories. Low molecular weight 
hydro gelator (LMHGs) and low molecular weight organo gelator (LMOGs). The resulting gels 
are usually called supramolecular gels or physical gels to differentiate from polymer gels.
 
 
The self assembly process depends on a variety of different forces and on the solvents being 
used. For aprotic, organic solvents, hydrogen bonding is often the most important force for 
guiding the self assembly process, though π-stacking interactions of aromatic rings, metal 
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coordination, and electrostatic interactions can also play a significant role.
113 
For water, and to a 
lesser extent, polar protic organic solvents, hydrogen bonding and electrostatic interactions are 
not as significant, due to the ability of the solvent to participate in these types of interactions; 
hydrophobic forces (and other Van der Waals forces) and π-π stacking are the major contributors 
to self assembly of LMWGs in water.
114
 Regardless of the nature of the solvent, a delicate 
balance between hydrophobicity and hydrophilicity of the gelator molecules must be maintained 
for gelation to occur; if the gelator molecule is too soluble, complete solvation will occur instead 
of self-assembly, while extreme solvophobicity can lead to exclusion of the solvent, causing 
precipitation or recrystallization. 
 
The preparation of organogels or hydrogels using LMOGs is pretty straightforward. In general, a 
certain amount of a LMOG is placed in a vial containing the testing solvent. Then it is heated 
above the sol-gel temperature (Tgel) to dissolve the compound. Gels are formed when the 
solution is cooled below the Tgel.
115
  
 
The resulting solidification or increase of the viscosity of the solvent(s) is caused by the 
formation of a fibrous network, which is created by the noncovalent inter and intramolecular 
forces. The minimum gelation concentration (MGC) is obtained through serial dilution and 
heating until a stable gel is no longer formed. 
 
LMWGs have gained considerable amount of interest due to their implications in supramolecular 
chemistry, and their potential applications as advanced soft materials in biomedical and materials 
research.  For instance, organogelators have been more and more explored as optical electronic 
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devices and found applications in semiconductors and photovoltaic cells.
 
They have also been 
explored as sequester agent for oil spill and chemical spill cleanup.
 
 As for supramolecular 
hydrogels, they are being explored more and more for biomedical applications, such as matrix 
for cell growth, enzyme assays, drug delivery, and tissue engineering.
 
 The supramolecular gels 
are reversible and can be engineered to be stimuli-responsive. These provide the basic steps 
towards their use in biomedical research.
116-118 
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Chapter 2 
Preparation of L-proline based aeruginosin 298-A analogs: 
Optimization of the P1-moiety 
 
2.1. Abstract 
 
Aeruginosin are a family of naturally occurring oligopeptides that share a common bicyclic 
amino acid core structure. Many compounds in the family are inhibitors of serine proteases, such 
as thrombin and trypsin. Thrombin is an important enzyme in the blood coagulation cascade, and 
is a promising target for anticoagulant drug development. In order to understand the structure–
activity relationship (SAR) and to find selective thrombin inhibitors, we synthesized a series of 
aeruginosin 298-A analogs, in which the P2 bicyclic amino acid was replaced by a L-proline 
residue. The structure optimization was focused on modification of the P1 position. In choosing 
the P1 group, an effort was made to avoid using the highly basic guanidine groups present in 
nearly all naturally occurring aeruginosins. The synthesis and enzyme assays of these 
aeruginosin analogs against thrombin and trypsin are reported. We found that several compounds 
with neutral P1 groups exhibit excellent selectivity over trypsin and good potency against 
thrombin. The SAR data of the P1 groups obtained here can be used in preparing other thrombin 
inhibitors with better selectivity against trypsin. 
This chapter is adapted from paper:  Wang, G.; Goyal, N.; Hopkinson, B. Bioorg. Med. 
Chem. Lett. 2009, 19, 3798-3803. 
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2.2. Introduction 
Blood coagulation disorders can lead to serious diseases, including deep vein thrombosis and 
pulmonary embolism. The two main drugs currently used to treat such disorders are heparin and 
warfarin, however both suffer certain limitations like narrow therapeutic windows, severe side 
effects, and/or the need for parenteral administration. Intensive efforts have been made to 
develop new anticoagulants relying on direct inhibition of coagulation enzymes. There have been 
intense efforts over the past few decades to develop safer and more effective anticoagulants.
1–5 
Since thrombin is an important enzyme in the blood coagulation cascade, it has become an 
attractive target in the development of new antithrombotic drugs. Direct inhibition of thrombin 
has led to the development of several effective anticoagulants, such as argatroban and hirudin.
6,7
 
However, the discovery of new, orally available, safe drugs to treat thromboembolism is still 
very challenging.
8,9 
 
In the early 1990s Murakami and co-workers reported the isolation and characterization of the 
novel protease inhibitory peptides microginin and micropeptins A and B from Microcystis 
aeruginosa. This was soon followed by the isolation of Aeruginosin 298A from the same 
cyanobacterial source. The 20 member of natural product aeruginosin family have shown a lot of 
biological activity against serine protease inhibitor.
10-18
  
 
Thus, the knowledge that several of the aeruginosins exhibit high inhibitory potency against 
blood coagulation factors have made them attractive small-molecule targets in the search for new 
anticoagulants. Some structures (1-8) related to aeruginosins are shown in Figure 2.1. 
Aeruginosins typically contain tetrapeptid p-hydroxylphenyllactic acid (Hpla), Leucine, 2-
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carboxy-6-hydroxyotahydroinhole (Choi), argininol (Argol) or arigninal (Argal) or agamatine 
(Agma) through peptidic linkages. 
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Figure 2.1. Structures of Aeruginosin class compounds. 
 
These molecules are divided into three parts. P1 (S1), P2 (S2) and P3 (S3) subunits which are 
corresponds to the hydroxylphenyllactic acid (Hpla), Leucine, (P1), 2-carboxy-6- 
hydroxyotahydroinhole (Choi) (P2), and arigninal (Argal) at P3.  The most important regions of 
the thrombin active site for inhibition by compounds belonging to the aeruginosin family are the 
S1, S2, and the d-S3 subsites. The S1 subsite, also known as the specificity pocket, is 
characterized by an aspartic acid residue (Asp189) in the bottom of the pocket, which is able to 
recognize and engage in ionic interactions with inhibitors containing basic P1 side chains. An 
alanine residue in position 190 of the S1 pocket of thrombin distinguishes it from trypsin, which 
has a serine in this position. The S1 subsite is also in close proximity to the oxyanion hole (the 
backbone amide NH groups of Ser195 and Gly193) and the Ser195-His57- Asp102 catalytic 
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triad. The S2 subsite, or the proximal P pocket, is a hydrophobic pocket primarily created by 
Tyr60A and Trp60D in the Tyr60A-Pro60B-Pro60C-Trp60D thrombin insertion loop. 
 
 
 
Figure 2.2 Schematic illustration of the thrombin active site bound to the Aeruginosins. 
 
Although many aeruginosins exhibit promising biological activities, their structures need to be 
optimized to obtain useful therapeutic agents. One challenge is to obtain selectivity among the 
different serine proteases; other problems may include their peptide like structures and structural 
complexity. In recent years, there has been growing interest in synthesizing analogs of 
aeruginosins. 
10, 11, 19-23
 
 
L-Proline has been a commonly used P2 group in thrombin inhibitor designs including orally 
active thrombin inhibitors 
24-26
 and aeruginosin analogs.
27
 Along with the seminal works reported 
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by Hanessian‟s group and several other research teams, a significant amount of knowledge has 
been obtained regarding the SAR of the aeruginosin families. Among the various modified 
aeruginosin analogs, many showed improved potency compared to their original natural 
products; however, many of these compounds are also potent inhibitors for trypsin. The blood 
coagulation factors, such as thrombin and factors Xa and VIIa, are all trypsin-like enzymes 
which share similar active sites and can thus bind similar compounds. Therefore, it is important 
to find molecules that can exhibit selectivity for thrombin and/or other blood coagulation factors 
over trypsin in order to avoid possible side effects. In the recent years many groups have made 
an attempt to synthesize a better antithrombin using small molecules. Few research groups have 
also incorporated proline for peptide synthesis. Taking that into account we designed our 
molecules based on aeruginosin and Proline and then performed our synthesis. The P1 moiety 
has also been changed by different polar and non-polar moiety. 
 
Keeping the crystal structure binding in mind and to study more structure activity relationship 
(SAR) our group has synthesized various aeruginosin analogs, where the Choi core structure has 
been replaced with a different bicyclic oxygenated core structure derived from different sugars.  
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Figure 2.3. Bicyclic oxygenated core structures. 
 
Many different synthetic routes were followed to synthesize these bicyclic unnatural amino 
acids. And then there biological studies were performed for few molecules and rest of the 
compound biological studies is underway. 
 
 
2.3. Results and Discussion 
 
We first designed and synthesized Aeruginosin analogs by replacing P2 moiety by Proline and 
with other functionalities at P1. Figure 2.4 depicts the retro synthetic approach we applied for the 
synthesis of tetrapeptide to HPLA, dipeptide and the Argal group.  
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Figure 2.4. Reterosynthetic approach for synthesis of Aeruginosin 
 
The aeruginosins have also garnered considerable attention from synthetic organic chemists as a 
result of their structural novelty and biological activity. Although these compounds are 
composed of similar subunits, isolation of new members has often been attended by the 
discovery of previously unknown amino acids and arginine-mimetic subunits as constituents. 
Derivatives of the 2-carboxyperhydroindole core structure have received the most attention with 
respect to conceptually diverse synthetic approaches.  
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Scheme 2.1. Synthesis of D-HPLA 
 
As shown in the Scheme 2.1, for the Preparation of D-HPLA the amino group of Tyrosine ester 
17 was protected with Boc and the hydroxyl group was protected using benzyl. Then Boc group 
was removed using TFA in DCM and ester was hydrolysed using NaOH in THF: Water: MeOH. 
And then amino group was replaced by –OAc using isoamyl nitrite in NaOAc and AcOH.  
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Scheme 2.2. Synthesis of dipeptide and tripeptide 
 
The L-proline was converted to the ester 23, and it was coupled with N-Boc-D-Leucine to give 
the dipeptide 24. The Boc was removed to give the amine 25, which was coupled with the 
protected form of D-Hpla 22 to afford the tripeptide 26. The ester groups were hydrolyzed to 
form the free acid 27, which is ready to couple with various P1 groups. Scheme 2.3 depicts one 
example of the coupling reaction to prepare the teterapeptide. The diamine 28 was treated with 
N-Boc protected thiomethyl pseudourea to give the intermediate 29. 
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Scheme 2.3. Synthesis of P1 group 
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Compound 29 was coupled with the tripeptide 27 using typical coupling reagents such as EDCI, 
HOBt, HATU and PyBOP depending on the amine used. Compound 31 was then converted to 
the - 70 -ertapeptide 32 after removal of benzyl and Boc protecting groups.  
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Scheme 2.4. Synthesis of Tetrapeptide 
 
In case of the compounds where we wanted a benzyl group at P1 position we first removed the 
benzyl group of HPLA at P3 position. Followed by this, the tripeptide was coupled with the 
benzylated amine group to synthesize tetrapeptides. 
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Scheme 2.5. Synthesis of Tetrapeptide with benzyl moieties at P1 position  
 
To synthesize all these tetrapeptides, different coupling reagents were used. Here is the table for 
all the coupling reagents used and the respective percentage yields for the compounds. 
 
Table 2.1: Structure of various P1 units to form final tertapeptide and the yields for the coupling 
reaction at the last step 
Compound 
Number 
    P1 group  R = 
Coupling-reagent 
used 
(%) yield 
 
34 
N
H
N
H
NH
NH2
 
EDCI 77 
35 
N
H
NH
NH2
H
N
 
 
EDCI 72 
36 
N
H
NH
NH2N
H  
EDCI 78 
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Compound 
Number 
    P1 group  R = 
Coupling-reagent 
used 
(%) yield 
 
37 
N
H
NH
NH2
H
N
OH  
 
PyBOP 80 
38 
N
H
HN
NH
NH2
 
 
HATU 68 
39 
N
H
N
H
NH
NH2
 
 
EDCI 74 
 
40 
N
HN
NH
NH2
 
 
HATU 58 
41 
N
NH
NH
NH2 
 
EDCI 74 
42 
NH
NH
 
 
EDCI 82 
43 
NN
H N
 
 
EDCI 79 
 - 73 - 
 
Compound 
Number 
    P1 group  R = 
Coupling-reagent 
used 
(%) yield 
 
44 CN
NH  
EDCI 85 
45 
NO2
NH  
 
EDCI 75 
46 N
NH  
EDCI 82 
47 NH
Cl
Cl  
 
EDCI 89 
Several compounds with the general structure of 32 are synthesized. The structures of P1 groups 
used are shown in Table 2.1.  
Table 2.2: Structure of various P1 units and the inhibitory values against Thrombin and 
Trypsin
27
 
Compound 
Number 
    P1 group  R = 
 
IC50 (g/mL) 
Thrombin 
 
IC50 (g/mL) 
Trypsin  
 
34 N
H
N
H
NH
NH2
 
 
0.092 
 
12.5 
35 N
H
NH
NH2
H
N
 
 
1.5 
 
6.1 
36 N
H
NH
NH2N
H  
 
0.62 
 
103 
 - 74 - 
 
Compound 
Number 
    P1 group  R = 
 
IC50 (g/mL) 
Thrombin 
 
IC50 (g/mL) 
Trypsin  
 
37 
N
H
NH
NH2
H
N
OH  
 
  
3.0 
 
14 
38 
N
H
HN
NH
NH2
 
 
  
0.50 
 
No inhibition  
39 
N
H
N
H
NH
NH2
 
 
  
0.43 
 
150 
 
40 
N
HN
NH
NH2
 
 
  
0.57 
 
 
No inhibition 
41 
N
NH
NH
NH2 
 
  
3.5 
 
55 
42 
NH
NH
 
 
  
0.65 
 
No inhibition 
43 
NN
H N
 
 
  
0.084 
 
 
No inhibition 
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Compound 
Number 
    P1 group  R = 
 
IC50 (g/mL) 
Thrombin 
 
IC50 (g/mL) 
Trypsin  
 
44 
CN
NH  
  
0.20  
 
210 
45 
NO2
NH  
 
  
0.28 
 
210 
46 
N
NH  
  
0.43 
 
140 
47 NH
Cl
Cl  
 
  
0.41 
 
14.2 
 
In Table 2.2 we also carried out the enzyme assays of these compounds. The 50% inhibition 
concentrations are shown in Table 2.2 as well. Commercial thrombin inhibitor PPACK and 
trypsin inhibitor purchased from Calibiochem and Sigma were used as the standards. 
 
From the enzyme assay results, we can see that the P1 specificity group is important to the 
thrombin inhibition. For the compounds with guanidine groups (34–41), reasonable inhibition 
activity toward thrombin was typically exhibited. Compound 34 is the most potent among the 
three simplest compounds 34– 36, which have similar structures but different chain lengths of 
the P1 group. Compound 36, with a 5-methylene linker, showed the best selectivity to thrombin 
over trypsin. Compound 37 has the same structure as aeruginosin 298-A, except that the Choi is 
replaced with L-proline; it seems to have maintained similar activities toward both enzymes. 
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Compounds 38-39 contain the phenyl guanidine group, which does not seem to inhibit trypsin 
well, but has good activity toward thrombin. Compounds 42–44 have a piperidinyl group; 42, 
with the secondary amine, showed good selectivity to thrombin. Without the amidine group from 
44, compound 45 showed good activity to thrombin and no inhibition to trypsin. Several 
compounds without highly basic groups at the P1 positions gave good inhibition activity against 
thrombin while also maintaining good selectivity over trypsin. For example, compounds 
with C-4-piperidinyl-methyl (42), propyl imidazole (43), cyanobenzyl (44), nitrobenzyl (45), and 
C-4-pyridinyl-methyl (46) do not contain the highly basic guanidine group. These compounds 
exhibited reasonably good thrombin inhibition activities, and they did not inhibit trypsin at 
concentrations below 100 µg/mL. Compound 46 showed about 1000-fold selectivity for 
thrombin over trypsin. Several others exhibited even better selectivity toward thrombin. 
Compound 47 has a neutral 2,5-dichlorobenzyl P1 group, and it showed good activity against 
thrombin but is not as selective toward trypsin, with only about 35-fold selectivity. Several of the 
compounds showed diminished potency to thrombin binding, while compounds 36 and 43–47 
showed better or comparable potencies to that of aeruginosin 298-A. 
 
 2.4. Conclusion 
 
In conclusion, we have synthesized a series of aeruginosin 298- A analogs in which the Choi is 
replaced with L-proline and the P1 Argol is replaced with various functionalities. We did not 
change P3 moiety and used D-HPLA and D-Leucine for this position. Among these 
tetrapeptides, several of them exhibit excellent selectivity for thrombin inhibition over trypsin 
inhibition. These include cyanobenzyl, nitrobenzyl, propyl imidazole, cyanobenzyl, C-4-
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piperidinylmethyl, and C-4-pyridinyl-methyl groups at the P1 positions. These P1 replacements 
are less basic or neutral, and generally have simpler or smaller groups than Argol or other 
guanidine containing units. The SAR data shown here is useful in finding thrombin inhibitors 
that are easy to synthesize and have superior selectivity toward thrombin. Further structure 
modifications can potentially lead to the discovery of potent and selective thrombin inhibitors 
that are also orally available. 
 
2.5. Experimental Procedure 
 
Synthesis of (R)-2-acetoxy-3-(4-(benzyloxy) phenyl) propanoic acid 22: 
Isoamyl nitrite (1.50 g, 12.88 mmol) was added slowly to a mixture of (R)-2-amino-3-(4-
(benzyloxy) phenyl) propanoic acid (1.0 g, 3.68 mmol) and NaOAc (1.05 g, 12.88 mmol) in 
glacial acetic acid. The reaction mixture was stirred for 24 hrs at room temperature. The mixture 
was concentrated to remove acetic acid. Residue was acidified using HCl and dissolved in 
EtOAc. The organic phase was extracted and washed with water and brine and dried over 
Na2SO4. The crude product was purified by flash chromatography on silica gel using a solvent 
system of AcOH: EtOAc: Hexane (1:9:1). The product was obtained as white powder, yield 
75%, [α]D = +7.2 (c = 0.70, CHCl3); ee = 98%, reported
26
 [α]D = +7.4 (c = 0.70, CHCl3); ee > 
98%,  
1
H NMR (CDCl3, 400 MHz) δ 2.10 (s, 3H), 3.07 (dd, 1H, J = 14.2, 8.7 Hz), 3.17 (dd, 1H, 
J = 14.2, 3.6 Hz), 5.04 (s, 2H), 5.22-519 (m, 1H), 6.93 (d, 2H, J = 8.0 Hz), 7.17 (d, 2H, J = 8.4 
Hz), 7.44-7.30 (m, 5H), 8.53 (s, 1H); 
13
C NMR (100 MHz, CDCl3) δ 21.9, 22.7, 24.7, 36.6, 41.6, 
50.2, 52.3, 69.9, 74.3, 114.7, 127.5, 128.0, 128.6, 130.7, 136.9, 157.8, 169.3, 173.1. 
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Synthesis of (S)-ethyl pyrrolidine-2-carboxylatester 23: 
Thionyl chloride (1.02 g, 8.6 mmoles) was added dropwise to a mixture of L-proline (1.0 g, 8.6 
mmoles) in ethanol (15 mL) as a solvent under cooling. Stirr the reaction mixture at RT for 30 
minutes and then reflux it for 3 hrs.  The mixture was concentrated on vacuum and then it was 
crystallized using ether to get compound 23 as a white solid. Yield 99%, 
1
H NMR (CDCl3, 400 
MHz) δ 1.25 (t, 3H, J = 7.1 Hz), 1.57 (m, 2H), 1.9 (m, 2H), 2.81 (m, 2H), 3.91 (m, 1H). 
 
Synthesis of (S)-ethyl 1-((R)-2-(tert-butoxycarbonylamino)-4-methylpentanoyl)pyrrolidine-
2-carboxylate 24:  
Boc-D-Leucine (375 mg, 2.60 mmol) was dissolved in dichloromethane, EDCI (747mg, 3.9 
mmol), HOBt (527 mg, 3.9 mmol) and DIPEA (1.006 ml, 7.8 mmol) were added to the reaction 
mixture. To this mixture, the ester-proline (500 mg, 2.17 mmol) in dichloromethane was added 
drop wise. The reaction was left stirring for 4 hrs at room temperature. After this, it was diluted 
with 100 mL dichloromethane and 25 mL water. The dichloromethane layer was separated and 
washed with 1N HCl, water, then saturated sodium bicarbonate and finally with brine. The 
compound was dried over on sodium sulfate and was concentrated using vaccum. The crude 
product was purified by flash chromatography on silica gel. The product was obtained as a light 
yellow solid. Yield 87%, 
1
H NMR (CDCl3, 400 MHz) δ 0.84 (m, 6H), 1.26 (t, 3H, J = 7.3 Hz ), 
1.42 (s, 9H), 1.59 (m, 2H), 1.94 (m, 2H), 2.75 (m, 2H), 3.84 (m, 1H), 4.12 (q, 2H, J = 6.9 Hz), 
4.45 (m, 1H), 5.20 (d, 1H, J = 6.95 Hz). 
 
Synthesis of (S)-ethyl 1-((R)-2-amino-4-methylpentanoyl)pyrrolidine-2-carboxylate 25: 
Compound 24 (500 mg, 1.40 mmoles ) was dissolved in dichloromethane and then TFA (0.2 ml) 
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solution in dichloromethane (0.1 ml) was added to the reaction mixture. The reaction mixture 
was stirred for 2 hours. For work up dichloromethane was removed under reduced pressure and 
was crystallized using ether. Yield 99%, 
1
H NMR (CDCl3, 400 MHz) δ 0.84 (m, 6H), 1.27 (t, 
3H, J = 7.3 Hz ), 1.58 (m, 2H), 1.97 (m, 2H), 2.75 (m, 2H), 3.84 (m, 1H), 4.12 (q, 2H, J = 6.9 
Hz), 4.45 (m, 1H). 
 
1. Preparation of tripeptide 26:  
 
 Synthesis of (R)-2-Acetoxy-3-(4 (benzyloxy) phenyl) propanoic acid 26: 
22 (300 mg, 1.16 mmol) was dissolved in dichloromethane, EDCI (244 mg, 1.27 mmol), HOBt 
(171 mg, 1.27mmol) and DIPEA (0.64 mL, 4.99 mmol) were added to the reaction mixture. To 
this mixture, the dipeptide 16 (356 mg, 1.39 mmol) in dichloromethane was added drop wise. 
The reaction was left stirring for 5 hrs at room temperature. After this, it was diluted with 100mL 
dichloromethane and 50 mL water. The dichloromethane layer was separated and washed with 
1N HCl, water, then saturated sodium bicarbonate and finally with brine. The compound was 
dried over on sodium sulfate and was concentrated under reduced pressure. The crude product 
was purified by flash chromatography on silica gel. The product was obtained as a white powder. 
Yield 80%, 
1
H NMR (CDCl3, 400 MHz) δ 0.85 (m, 6H), 1.1 (m, 1H) 1.21 (t, 2H, J = 9.5 Hz), 
1.25 (t, 3H, J = 7.3 Hz), 2.01 (m, 2H), 2.04 (s, 3H), 2.10 (m, 2H), 2.85 (dd, 1H, J = 14.2, 6.9 
Hz), 3.05 (dd, 1H, J = 14.2, 3.6Hz), 3.47 (t, 2H, J =  7.6Hz), 4.12 (q, 2H, J = 7.32), 4.35 (m, 1H), 
4.29 (m, 1H), 4.74 (m, 1H), 4.98 (s, 2H),  6.93 (d, 2H, J = 8.0 Hz), 7.17 (d, 2H, J = 8.4 Hz), 
7.44-7.30 (m, 5H), 8.53 (s, 1H). 
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Synthesis of (S)-1-((R)-2-((R)-2-acetoxy-3-(4-(benzyloxy) phenyl) propanamido)-4-
methylpentanoyl) pyrrolidine-2-carboxylic acid 27:  
To a stirred solution of compound 26 (200 mg, 0.361 mmol) in THF (5 mL) was added 0.2 N 
LiOH (5 mL) at 0° C. The reaction mixture was warmed at room temperature and stirred for 6 
hours before the reaction mixture was acidified to pH 2-3, and extracted with ethyl acetate (100 
mL) and then washed with brine. After removing the solvent on a rotavap, the product was 
obtained as a white powder. Yield 89%, 
1
H NMR (CDCl3, 400 MHz) δ 0.85 (m, 6H), 1.1 (m, 
1H), 1.25 (t, 3H, J = 7.3 Hz), 2.01 (m, 2H), 2.10 (m, 2H), 2.85 (dd, 1H, J = 14.2, 6.9 Hz), 3.05 
(dd, 1H, J = 14.2, 3.6 Hz), 3.47 (t, 2H, J =  7.6 Hz), 4.35 (m, 1H), 4.29 (m, 1H), 4.74 (m, 1H), 
4.98 (s, 2H),  6.93 (d, 2H, J = 8.0 Hz), 7.17 (d, 2H, J = 8.4 Hz), 7.44-7.30 (m, 5H), 8.53 (s, 1H).  
 
General procedure for the synthesis of tetrapeptides 30:  
Tripeptide (1 eq) was dissolved in dichloromethane and then EDCI (1.5 eq), HOBt (1.1 eq) and 
DIPEA (3 eq) were added to the reaction mixture. Various amines (1.2 eq) were dissolved in 
dichloromethane and then added drop wise to the reaction mixture. After stirring at room 
temperature for 5-7 hrs, the reaction mixture was diluted with dichloromethane and water. The 
dichloromethane layer was separated and washed with 1N HCl, water, saturated sodium 
bicarbonate and finally with brine. The compound was dried over sodium sulfate and was 
concentrated on a rotavap. The crude product was purified by flash chromatography on silica gel.   
 
General procedure for debenzylation to 31 by catalytic hydrogenation:   
10% Pd/C (20% by weight) was added to a solution of benzyl protected tetrapeptide (1 eq) in 
MeOH and the mixture was stirred under atmospheric hydrogen pressure (hydrogen balloon) for 
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20 h. The catalyst was removed by filtration through a short pad of celite, this was washed with 
MeOH. The filtrate and washing methanol were combined and concentrated to give the desired 
product.  
 
General Procedure for Boc-deprotection to the target tetrapeptides 32: 
Trifluoroacetic acid (2 eq) was added to a solution of Boc protected tetrapeptide in small amount 
of dichloromethane. The reaction mixture was stirred at 0 C for 2 hrs. Dichloromethane was 
removed under reduced pressure and the residue was treated with ether to produce the product as 
a precipitate. The precipitate was filtered and dried under reduced pressure using a vacuum 
pump.  
 
2. Preparation of tetrapeptide  
 
Preparation of Tetrapeptide 34 
 
The intermediates for the preparation of compound 34: 
 
 
34a:  
BnO
OH
N
H
O
N
O
O
NH
NHBocHN
NBoc  
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Yield 77%, 
1
H NMR (CDCl3, 400 MHz) δ 0.87 (m, 6H), 1.45 (s, 18H), 1.65 (m, 1H), 1.81 (m, 
2H), 2.01 (q, 2H, J = 7.6 Hz), 2.25 (m, 2H),  2.81 (dd, 1H, J = 14.2, 6.9 Hz), 3.02 (dd, 1H, J = 
14.2, 3.6 Hz), 3.11 (m, 2H), 3.25 (m, 2H), 3.42 (m, 2H), 4.44 (m, 1H, ) 4.49 (m, 1H), 4.51 (m, 
1H), 5.01 (s, 2H),  6.88 (d, 2H, J = 8.4 Hz), 7.16 (d, 2H, J = 8.7 Hz), 7.37 (m, 5H), 8.34 (s, 1H), 
11.42 (s, 1H). 
 
34b:  
HO
OH
N
H
O
N
O
O
NH
NHBocHN
NBoc  
 
Yield 85%, 
1
H NMR (CDCl3, 400 MHz) δ 0.87 (m, 6H), 1.45 (s, 18H), 1.65 (m, 1H), 1.81 (m, 
2H), 2.01 (q, 2H, J = 7.6 Hz), 2.25 (m, 2H),  2.81 (dd, 1H, J = 14.2, 6.9 Hz), 3.02 (dd, 1H, J = 
14.2, 3.6 Hz), 3.11 (m, 2H), 3.25 (m, 2H), 3.42 (m, 2H), 4.44 (m, 1H, ) 4.49 (m, 1H), 4.51 (m, 
1H), 5.01 (s, 2H),  6.72 (d, 2H, J = 8.0 Hz), 7.07 (d, 2H, J = 8.0 Hz), 7.48 (s, 1H), 11.25 (s, 1H). 
 
Compound 34: 
Gummy white material. Yield 99%, 
1
H NMR (CDCl3, 400 MHz) δ 0.87 (m, 6H), 1.45 (s, 18H), 
1.65 (m, 1H), 1.81 (m, 2H), 2.01 (q, 2H, J = 7.6 Hz), 2.25 (m, 2H),  2.81 (dd, 1H, J = 14.2, 6.9 
Hz), 3.02 (dd, 1H, J = 14.2, 3.6 Hz), 3.11 (m, 2H), 3.25 (m, 2H), 3.42 (m, 2H), 4.44 (m, 1H, ) 
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4.49 (m, 1H), 4.51 (m, 1H), 5.01 (s, 2H),  6.72 (d, 2H, J = 8.0 Hz), 7.07 (d, 2H, J = 8.0 Hz), 9.0 
(s, 1H), 11.25 (s, 1H); HRMS calcd for C24H38N6O5+H 491.2982, found 491.2977. 
 
Preparation of  teterapeptide 35 
The intermediates for the preparation of compound 35: 
35a: 
BnO
OH
N
H
O
N
O
O
NH
HN
NHBocBocN  
 
Yield 72 %, 
1
H NMR (CDCl3, 400 MHz) δ 0.85 (m, 6H), 1.1 (m, 1H), 1.45 (s, 18H), 1.97 (m, 
4H), 2.17 (m, 2H), 2.19 (m, 2H), 2.85 (dd, 1H, J = 14.2, 6.9 Hz), 3.05 (dd, 1H, J = 14.2, 3.6Hz), 
3.20 (m, 4H,), 4.35 (m, 1H), 4.29 (m, 1H), 4.74 (m, 1H), 5.01 (s, 2H),  6.88 (d, 2H, J = 8.7 Hz), 
7.16 (d, 2H, J = 8.4 Hz), 7.35 (m, 5H), 8.28 (s, 1H), 11.42 (s, 1H). 
 
 
35b: 
HO
OH
N
H
O
N
O
O
NH
HN
NHBocBocN  
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Yield 83%, 
1
H NMR (CDCl3, 400 MHz) δ 0.85 (m, 6H), 1.1 (m, 1H), 1.45 (s, 18H), 1.97 (m, 
4H), 2.17 (m, 2H), 2.19 (m, 2H), 2.85 (dd, 1H, J = 14.2, 6.9 Hz), 3.05 (dd, 1H, J = 14.2, 3.6 Hz), 
3.20 (m, 4H,), 4.35 (m, 1H), 4.29 (m, 1H), 4.74 (m, 1H), 5.01 (s, 2H),  6.88 (d, 2H, J = 8.7 Hz), 
7.18 (d, 2H, J = 8.4 Hz), 9.51 (s, 1H), 11.21 (s, 1H). 
 
Compound 35: 
Light yellow powder. Yield 91%, 
1
H NMR (CDCl3, 400 MHz) δ 0.85 (m, 6H), 1.1 (m, 1H),1.97 
(m, 4H), 2.17 (m, 2H), 2.19 (m, 2H), 2.85 (dd, 1H, J = 14.2, 6.9 Hz), 3.05 (dd, 1H, J = 14.2, 3.6 
Hz), 3.20 (m, 4H,), 4.35 (m, 1H), 4.29 (m, 1H), 4.74 (m, 1H), 5.01 (s, 2H),  6.88 (d, 2H, J = 8.7 
Hz), 7.18 (d, 2H, J = 8.4 Hz), 9.51 (s, 1H), 11.21 (s, 1H); HRMS calcd for C25H40N6O5+H 
505.3138, found 505.3140.  
 
Preparation of teterapeptide 36 
The intermediates for the preparation of compound 36:  
36a: 
BnO
OH
N
H
O
N
O
O
HN
HN
NHBocBocN  
 
Yield 78%, 
1
H NMR (CDCl3, 400 MHz) δ 0.86 (m, 6H), 1.30 (2H, m), 1.41 (s, 18H), 1.51 (m, 
4H), 2.20 (m, 4H), 2.21 (m, 2H),  2.82 (dd, 1H, J = 14.2, 6.9 Hz), 3.01 (dd, 1H, J = 14.2, 3.6 
Hz), 3.20 (m, 4H), 3.35 (2H, m), 4.02 (m, 2H), 4.33 (m, 1H, ) 4.41 (m, 1H), 4.52 (m, 1H), 5.01 
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(s, 2H),  6.88 (d, 2H, J = 8.7 Hz), 7.16 (d, 2H, J = 8.4 Hz), 7.35 (m, 5H), 8.28 (s, 1H), 11.48 (s, 
1H). 
 
36b: 
HO
OH
N
H
O
N
O
O
HN
HN
NHBocBocN  
 
Yield 84%, 
1
H NMR (CDCl3, 400 MHz) δ 0.87 (m, 6H), 1.30 (2H, m), 1.41 (s, 18H), 1.51 (m, 
4H), 2.20 (m, 4H), 2.21 (m, 2H),  2.81 (dd, 1H, J = 14.2, 6.9 Hz), 3.02 (dd, 1H, J = 14.2, 3.6 
Hz), 3.20 (m, 4H), 3.35 (2H, m), 4.02 (m, 2H), 4.33 (m, 1H, ) 4.41 (m, 1H), 4.52 (m, 1H), 5.01 
(s, 2H),  6.73 (d, 2H, J = 8.0 Hz), 7.04 (d, 2H, J = 8.0 Hz), 9.52 (s, 1H), 11.13 (s, 1H). 
 
Compound 36: 
White powder. Yield = 98%, 
1
H NMR (CD3OD, 400 MHz) δ 0.87 (m, 6H), 1.30 (2H, m), 1.51 
(m, 4H), 2.20 (m, 4H), 2.21 (m, 2H),  2.81 (dd, 1H, J = 14.2, 6.9 Hz), 3.02 (dd, 1H, J = 14.2, 3.6 
Hz), 3.20 (m, 4H), 3.35 (2H, m), 4.02 (m, 2H), 4.33 (m, 1H, ) 4.41 (m, 1H), 4.52 (m, 1H), 5.01 
(s, 2H),  6.67 (d, 2H, J = 8.4 Hz), 7.06 (d, 2H, J = 8.4 Hz), 7.77 (s, 1H), 7.78 (s, 1H); HRMS 
calcd for C26H42N6O5+H 519.3925, found 519.3928. 
 
Preparation of teterapeptide 37 
The intermediates for the preparation of compound 37: 
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37a:  
HN
N
OH
BnO
O
O
O NH
H
N NHNO2
OMe HN
O
 
 
Yield 82%, 
1
H NMR (CDCl3, 400 MHz) δ 0.85 (m, 6H), 1.12 (m, 1H), 1.25 (t, 3H, J = 7.3 Hz), 
1.90 (m, 2H), 2.01 (m, 2H), 2.10 (m, 2H), 2.51 (m, 2H), 2.85 (dd, 1H, J = 14.2, 6.9 Hz), 3.05 
(dd, 1H, J = 14.2, 3.6 Hz), 3.47 (t, 2H, J =  7.6 Hz), 3.72 (s, 3H), 4.45 (m, 1H), 4.68 (m, 1H), 
4.74 (m, 1H), 5.01 (s, 2H),  6.93 (d, 2H, J = 8.0 Hz), 7.17 (d, 2H, J = 8.4 Hz), 7.44-7.30 (m, 5H), 
8.43 (s, 1H). 
 
37b:  
HN
N
OH
BnO
O
O
O NH
H
N NHNO2
HO
NH  
 
Yield 79%, 
1
H NMR (CDCl3, 400 MHz) δ 0.85 (m, 6H), 1.12 (m, 1H), 1.25 (t, 3H, J = 7.3Hz), 
1.90 (m, 2H), 2.01 (m, 2H), 2.10 (m, 2H), 2.51 (m, 2H), 2.85 (dd, 1H, J = 14.2, 6.9 Hz), 3.05 
(dd, 1H, J = 14.2, 3.6 Hz), 3.25 (m, 2H), 3.47 (t, 2H, J =  7.6 Hz), 4.45 (m, 1H), 4.68 (m, 1H), 
 - 87 - 
 
4.74 (m, 1H), 5.01 (s, 2H),  7.12 (d, 2H, J = 8.2 Hz), 7.17 (d, 2H, J = 8.3 Hz), 7.44-7.30 (m, 5H), 
8.53 (s, 1H). 
 
Compound 37:  
White solid. Yield 82%, 
1
H NMR (CDCl3, 400 MHz) δ 0.85 (m, 6H), 1.12 (m, 1H), 1.25 (t, 3H, J 
= 7.3 Hz), 1.90 (m, 2H), 2.01 (m, 2H), 2.10 (m, 2H), 2.51 (m, 2H), 2.85 (dd, 1H, J = 14.2, 6.9 
Hz), 3.05 (dd, 1H, J = 14.2, 3.6 Hz), 3.25 (m, 2H), 3.47 (t, 2H, J =  7.6 Hz), 4.45 (m, 1H), 4.68 
(m, 1H), 4.74 (m, 1H), 5.01 (s, 2H),  7.12 (d, 2H, J = 8.2 Hz), 7.17 (d, 2H, J = 8.3 Hz). HRMS 
Calcd for C26H42N6O6+H is 535.3244, found 534.3234. 
 
Preparation of teterapeptide 38 
 
The intermediates for the preparation of compound 38: 
 
38a:  
BnO
OH
N
H
O
N
O
OHN
HN
NHBoc
NBoc
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Yield 68%, 
1
H NMR (CDCl3, 400 MHz) δ 0.85 (m, 6H), 1.1 (m, 1H), 1.42 (s, 18H), 2.01 (m, 
2H), 2.10 (m, 2H), 2.85 (dd, 1H, J = 14.2, 6.9 Hz), 3.05 (dd, 1H, J = 14.2, 3.6 Hz), 3.47 (t, 2H, J 
=  7.6 Hz), 4.35 (m, 1H), 4.29 (m, 1H), 4.84 (m, 1H), 4.98 (s, 2H),  6.85 (d, 2H, J = 8.4 Hz), 7.15 
(d, 2H, J = 8.4 Hz), 7.44-7.30 (m, 5H), 7.46 (d, 2H, J = 9.1 Hz) 7.65 (d, 2H, J = 9.1 Hz), 11.60 
(s, 1H), 10.22 (s, 1H). 
38b:  
HO
OH
N
H
O
N
O
OHN
HN
NHBoc
NBoc
 
 
Yield 89 %, 
1
H NMR (CDCl3, 400 MHz) δ 0.85 (m, 6H), 1.1 (m, 1H), 1.42 (s, 18H), 2.01 (m, 
2H), 2.10 (m, 2H), 2.85 (dd, 1H, J = 14.2, 6.9 Hz), 3.05 (dd, 1H, J = 14.2, 3.6 Hz), 3.47 (t, 2H, J 
=  7.6 Hz), 4.35 (m, 1H), 4.29 (m, 1H), 4.84 (m, 1H), 4.98 (s, 2H),  6.85 (d, 2H, J = 8.4 Hz), 7.15 
(d, 2H, J = 8.4 Hz), 7.46 (d, 2H, J = 9.1 Hz) 7.65 (d, 2H, J = 9.1 Hz), 10.22 (s, 1H), 11.88 (s, 
1H). 
 
Compound 38:  
Yellow powder. Yield 99%, 
1
H NMR (CDCl3, 400 MHz) δ 0.85 (m, 6H), 1.1 (m, 1H), 1.25 (t, 
3H, J = 7.3 Hz), 2.01 (m, 2H), 2.10 (m, 2H), 2.85 (dd, 1H, J = 14.2, 6.9 Hz), 3.05 (dd, 1H, J = 
14.2, 3.6 Hz), 3.47 (t, 2H, J =  7.6 Hz), 4.35 (m, 1H), 4.29 (m, 1H), 4.84 (m, 1H), 4.98 (s, 2H),  
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6.85 (d, 2H, J = 8.4 Hz), 7.15 (d, 2H, J = 8.4 Hz), 7.46 (d, 2H, J = 9.2 Hz), 7.65 (d, 2H, J = 9.1 
Hz), 10.22 (s, 1H), 11. (s, 1H); HRMS calcd for C27H36N6O5+H 525.2825, found 525.2833.  
 
Preparation of teterapeptide 39 
The intermediates for the preparation of compound 39: 
39a:   
HO
OH
N
H
O
N
O
OHO  
 
Yield 95%, 
1
H NMR (CDCl3, 400 MHz) δ 0.85 (m, 6H), 1.1 (m, 1H), 1.25 (t, 3H, J = 7.3 Hz), 
2.01 (m, 2H), 2.10 (m, 2H), 2.85 (dd, 1H, J = 14.2, 6.9 Hz), 3.05 (dd, 1H, J = 14.2, 3.6 Hz), 3.47 
(t, 2H, J =  7.6 Hz), 4.02 (s, 2H), 4.35 (m, 1H), 4.29 (m, 1H), 4.74 (m, 1H), 6.93 (d, 2H, J = 8.0 
Hz), 7.17 (d, 2H, J = 8.4 Hz). 
 
39b:  
HO
OH
N
H
O
N
O
OHN
N
HBocHN
BocN
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Yield 75%, 
1
H NMR (CDCl3, 400 MHz) δ 0.85 (m, 6H), 1.1 (m, 1H), 1.42 (s, 18H), 2.01 (m, 
2H), 2.10 (m, 2H), 2.85 (dd, 1H, J = 14.2, 6.9 Hz), 3.05 (dd, 1H, J = 14.2, 3.6 Hz), 3.47 (t, 2H, J 
=  7.6 Hz), 4.35 (m, 1H), 4.29 (m, 1H), 4.84 (m, 1H), 4.98 (s, 2H),  6.85 (d, 2H, J = 8.4 Hz), 7.15 
(d, 2H, J = 8.4 Hz), 7.46 (d, 2H, J = 9.1 Hz) 7.65 (d, 2H, J = 9.1 Hz), 11.60 (s, 1H), 10.22 (s, 
1H). 
 
Compound 39:  
Light yellow gummy solid. Yield 95%,  
1
H NMR (CDCl3, 400 MHz) δ 0.85 (m, 6H), 1.1 (m, 
1H), 1.25 (t, 3H, J = 7.3 Hz), 2.01 (m, 2H), 2.10 (m, 2H), 2.85 (dd, 1H, J = 14.2, 6.9 Hz), 3.05 
(dd, 1H, J = 14.2, 3.6 Hz), 3.47 (t, 2H, J =  7.6 Hz), 4.35 (m, 1H), 4.29 (m, 1H), 4.84 (m, 1H), 
4.98 (s, 2H),  6.85 (d, 2H, J = 8.4 Hz), 7.15 (d, 2H, J = 8.4 Hz), 7.46 (d, 2H, J = 8.7 Hz) 7.65 (d, 
2H, J = 8.9 Hz), 10.22 (s, 1H), 11.00 (s, 1H); MS calcd for C28H38N6O5 538.29, found 538.40.  
 
Preparation of teterapeptide 40 
The intermediates for the preparation of compound 40 
40a:  
BnO
OH
N
H
O
N
O
NO
HN
NBoc
NHBoc  
 
Yield 58%, 
1
H NMR (CDCl3, 400 MHz) δ 0.87 (m, 6H), 1.45 (s, 18H), 1.65 (m, 8H), 1.81 (m, 
2H), 2.01 (m, 2H),  2.81 (dd, 1H, J = 14.2, 6.9 Hz), 3.02 (dd, 1H, J = 14.2, 3.6 Hz), 3.31 (m, 
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8H), 4.03 (m, 2H), 4.26 (m, 1H, ) 4.45 (m, 1H), 4.51 (m, 1H), 5.03 (s, 2H),  6.91 (d, 2H, J = 8.7 
Hz), 7.17 (d, 2H, J = 8.7 Hz), 7.35 (m, 5H).  
 
40b:  
HO
OH
N
H
O N
O NO
HN
NBoc
NHBoc  
Yield 87%, 
1
H NMR (CDCl3, 400 MHz) δ 0.87 (m, 6H), 1.45 (s, 18H), 1.65 (m, 8H), 1.81 (m, 
2H), 2.01 (m, 2H),  2.81 (dd, 1H, J = 14.2, 6.9 Hz), 3.02 (dd, 1H, J = 14.2, 3.6 Hz), 3.31 (m, 
8H), 4.03 (m, 2H), 4.26 (m, 1H, ) 4.45 (m, 1H), 4.51 (m, 1H), 5.03 (s, 2H),  6.91 (d, 2H, J = 8.7 
Hz), 7.17 (d, 2H, J = 8.7 Hz), 8.42 (s, 1H), 11.41 (s, 1H). 
 
Compound 40:  
Colorless gummy material. Yield 95%, 
1
H NMR (CDCl3, 400 MHz) δ 0.87 (m, 6H), 1.45 (s, 
18H), 1.65 (m, 8H), 2.01 (m, 2H),  2.81 (dd, 1H, J = 14.2, 6.9 Hz), 3.02 (dd, 1H, J = 14.2, 3.6 
Hz), 3.31 (m, 8H), 4.03 (m, 2H), 4.26 (m, 1H, ) 4.45 (m, 1H), 4.51 (m, 1H), 5.03 (s, 2H),  6.91 
(d, 2H, J = 8.5 Hz), 6.96 (d, 2H, J = 8.6 Hz); MS calcd for C27H42N6O5+H 530.66, found 531.60. 
 
Preparation of teterapeptide 41 
The intermediates for the preparation of compound 41: 
41a:  
 - 92 - 
 
BnO
N
H
O
N
O
HN
O
OH
N Boc  
 
Yield 74% ,
1
H NMR (CDCl3, 400 MHz) δ 0.87 (m, 6H), 1.45 (s, 9H), 1.65 (m, 8H), 1.81 (m, 
2H), 2.01 (m, 2H),  2.81 (dd, 1H, J = 14.2, 6.9 Hz), 3.02 (dd, 1H, J = 14.2, 3.6 Hz), 3.31 (m, 
8H), 4.03 (m, 2H), 4.26 (m, 1H, ) 4.45 (m, 1H), 4.51 (m, 1H), 5.03 (s, 2H),  6.91 (d, 2H, J = 8.7 
Hz), 7.17 (d, 2H, J = 8.7 Hz), 7.35 (m, 5H). 
 
41b:  
BnO
N
H
O
N
O
HN
O
OH
NH
 
 
Yield 99%, 
1
H NMR (CDCl3, 400 MHz) δ 0.87 (m, 6H), 1.65 (m, 8H), 1.81 (m, 2H), 2.01 (m, 
2H),  2.81 (dd, 1H, J = 14.2, 6.9 Hz), 3.02 (dd, 1H, J = 14.2, 3.6 Hz), 3.31 (m, 8H), 4.03 (m, 
2H), 4.26 (m, 1H, ) 4.45 (m, 1H), 4.51 (m, 1H), 5.03 (s, 2H),  6.91 (d, 2H, J = 8.7 Hz), 7.17 (d, 
2H, J = 8.4 Hz), 7.37 (m, 5H). 
 
41c:  
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BnO
N
H
O
N
O
HN
O
OH
NH
 
 
Yield 75%, 
1
H NMR (CD3OD, 400 MHz) δ 0.87 (m, 6H), 1.45 (s, 18H), 1.65 (m, 8H), 1.81 (m, 
2H), 2.01 (m, 2H),  2.81 (dd, 1H, J = 14.2, 6.9 Hz), 3.02 (dd, 1H, J = 14.2, 3.6 Hz), 3.31 (m, 
8H), 4.03 (m, 2H), 4.26 (m, 1H, ) 4.45 (m, 1H), 4.51 (m, 1H), 5.03 (s, 2H),  6.91 (d, 2H, J = 8.7 
Hz), 7.17 (d, 2H, J = 8.6 Hz), 7.37 (m, 5H), 10.21 (s, 1H). 
 
41d: 
HO
N
H
O
N
O
HN
O
OH
N
NBoc
NHBoc
 
 
Yield 88%, 
1
H NMR (CD3OD, 400 MHz) δ 0.87 (m, 6H), 1.45 (s, 18H), 1.65 (m, 8H), 1.81 (m, 
2H), 2.01 (m, 2H),  2.81 (dd, 1H, J = 14.2, 6.9 Hz), 3.02 (dd, 1H, J = 14.2, 3.6 Hz), 3.31 (m, 
8H), 4.03 (m, 2H), 4.26 (m, 1H, ) 4.45 (m, 1H), 4.51 (m, 1H), 5.03 (s, 2H),  6.91 (d, 2H, J = 8.7 
Hz), 7.17 (d, 2H, J = 8.6 Hz). 
 
Compound 41:  
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Light brown gummy material. Yield 98%, 
1
H NMR (CD3OD, 400 MHz) δ 0.87 (m, 6H), 1.65 
(m, 8H), 1.81 (m, 2H), 2.01 (m, 2H),  2.81 (dd, 1H, J = 14.2, 6.9 Hz), 3.02 (dd, 1H, J = 14.2, 3.6 
Hz), 3.31 (m, 8H), 4.03 (m, 2H), 4.26 (m, 1H, ) 4.45 (m, 1H), 4.51 (m, 1H), 5.03 (s, 2H),  6.91 
(d, 2H, J = 8.7 Hz), 7.17 (d, 2H, J = 8.6 Hz). HRMS calcd for C27H42N6O5+H 531.3295, found 
531.3182. 
 
Preparation of teterapeptide 42 
The intermediates for the preparation of compound 42: 
42b:  
HO
N
H
O
N
O
HN
O
OH
N
NBoc
NHBoc
 
 
Yield 87%, 
1
H NMR (CDCl3, 400 MHz) δ 0.87 (m, 6H), 1.45 (s, 9H), 1.65 (m, 8H), 1.81 (m, 
2H), 2.01 (m, 2H),  2.81 (dd, 1H, J = 14.2, 6.9 Hz), 3.02 (dd, 1H, J = 14.2, 3.6 Hz), 3.31 (m, 
8H), 4.03 (m, 2H), 4.26 (m, 1H, ) 4.45 (m, 1H), 4.51 (m, 1H), 5.03 (s, 2H),  6.91 (d, 2H, J = 8.7 
Hz), 7.17 (d, 2H, J = 8.7 Hz). 
 
Compound 42: 
Colorless gummy material. Yield 95%, 
1
H NMR (CD3OD, 400 MHz) δ 0.87 (m, 6H), 1.65 (m, 
8H), 1.81 (m, 2H), 2.01 (m, 2H),  2.81 (dd, 1H, J = 14.2, 6.9Hz), 3.02 (dd, 1H, J = 14.2, 3.6Hz), 
3.31 (m, 8H), 4.03 (m, 2H), 4.26 (m, 1H, ) 4.45 (m, 1H), 4.51 (m, 1H), 5.03 (s, 2H),  6.91 (d, 2H, 
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J = 8.7 Hz), 7.17 (d, 2H, J = 8.7 Hz); HRMS calcd for C24H38N6O5+H 500.2873, found 
500.2856. 
 
Preparation of teterapeptide 43 
43a:   
HO
N
H
O
N
O
HN
O
OH
N
NBoc
NHBoc
 
 
Yield 85%, 
1
H NMR (CDCl3, 400 MHz) δ 0.87 (m, 6H), 1.21 (s, 2H), 1.25 (t, 3H, J = 7.3Hz), 
2.01 (m, 2H), 2.10 (m, 2H), 2.58 (m, 2H),  2.81 (dd, 1H, J = 14.2, 6.9 Hz), 3.02 (dd, 1H, J = 
14.2, 3.6 Hz), 3.47 (t, 2H, J =  7.6 Hz), 4.02 (t, 2H, J = 7.2 Hz) 4.35 (m, 1H), 4.29 (m, 1H), 4.42 
(m, 2H) 4.58 (m, 1H), 5.03 (s, 2H),  6.93 (d, 2H, J = 8.0 Hz), 6.94 (s, 1H) 7.17 (d, 2H, J = 8.4 
Hz), 7.38 (m, 5H), 7.82 (s, 1H).  
 
Compound 43:  
White solid. Yield 92%, 
1
H NMR (CDCl3, 400 MHz) δ 0.87 (m, 6H), 1.21 (s, 2H), 1.25 (t, 3H, J 
= 7.3Hz), 2.01 (m, 2H), 2.10 (m, 2H), 2.58 (m, 2H),  2.81 (dd, 1H, J = 14.2, 6.9 Hz), 3.02 (dd, 
1H, J = 14.2, 3.6 Hz), 3.47 (t, 2H, J =  7.6 Hz), 4.02 (t, 2H, J = 7.2 Hz) 4.35 (m, 1H), 4.29 (m, 
1H), 4.42 (m, 2H) 4.58 (m, 1H), 5.03 (s, 2H),  6.93 (d, 2H, J = 8.0 Hz), 6.94 (s, 1H) 7.17 (d, 2H, 
J = 8.4 Hz), 7.82 (s, 1H); HRMS calcd for C26H37N5O5+H 500.2873, found 500.2856. 
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Preparation of teterapeptide 44 
The intermediates for the preparation of compound 44: 
Compound 44: 
White solid, yield 85%, NMR: 
1
H NMR (CDCl3, 400 MHz) δ 0.85 (m, 6H), 1.1 (m, 1H), 1.25 (t, 
3H, J = 7.3 Hz), 2.01 (m, 2H), 2.10 (m, 2H), 2.85 (dd, 1H, J = 14.2, 6.9 Hz), 3.05 (dd, 1H, J = 
14.2, 3.6 Hz), 3.47 (t, 2H, J =  7.6 Hz), 4.35 (m, 1H), 4.29 (m, 1H), 4.74 (m, 1H), 4.98 (s, 2H),  
6.93 (d, 2H, J = 8.1 Hz), 7.17 (d, 2H, J = 8.4 Hz), 7.33 (d, 2H, J = 8.4 Hz), 7.47 (d, 2H, J = 8.3 
Hz); HRMS calcd for C28H34N4O5+H 507.2607, found 507.2609. 
 
Preparation of teterapeptide 45 
Compound 45:  
White solid. Yield 75%, 
1
H NMR (CDCl3, 400 MHz) δ 0.85 (m, 6H), 1.1 (m, 1H), 1.25 (t, 3H, J 
= 7.3 Hz), 2.01 (m, 2H), 2.10 (m, 2H), 2.85 (dd, 1H, J = 14.2, 6.9 Hz), 3.05 (dd, 1H, J = 14.2, 
3.6 Hz), 3.47 (t, 2H, J =  7.6 Hz), 4.35 (m, 1H), 4.29 (m, 1H), 4.74 (m, 1H), 4.79 (s, 2H),  6.93 
(d, 2H, J = 8.1 Hz), 7.17 (d, 2H, J = 8.4 Hz), 7.33 (d, 2H, J = 8.1 Hz), 7.52 (d, 2H, J = 8.1 Hz); 
HRMS calcd for C27H34N4O7+H 527.2506, found 527.2493. 
 
Preparation of teterapeptide 46 
Compound 46:  
Light yellow sticky semisolid. Yield 57%, 
1
H NMR (CDCl3, 400 MHz) δ 0.85 (m, 6H), 1.1 (m, 
1H), 1.25 (t, 3H, J = 7.3 Hz), 2.01 (m, 2H), 2.10 (m, 2H), 2.85 (dd, 1H, J = 14.2, 6.9 Hz), 3.05 
(dd, 1H, J = 14.2, 3.6 Hz), 3.47 (t, 2H, J =  7.6 Hz), 4.02 (s, 2H), 4.35 (m, 1H), 4.29 (m, 1H), 
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4.74 (m, 1H), 6.93 (d, 2H, J = 8.0 Hz), 7.17 (d, 2H, J = 8.4 Hz), 7.8 (d, 2H, J = 7.2 Hz), 8.15 (d, 
2H, J = 7.3Hz); HRMS Calcd for C27H34N4O7+H is 482.2506, found 482.2519. 
  
Preparation of teterapeptide 47 
The intermediates for the preparation of compound 47: 
47a:  
HO
N
H
O
N
O
HN
O
OH
N
NBoc
NHBoc
 
 
Yield 85%, 
1
H NMR (CDCl3, 400 MHz) δ 0.85 (m, 6H), 1.1 (m, 1H), 1.25 (t, 3H, J = 7.3Hz), 
2.01 (m, 2H), 2.07 (s, 3H), 2.10 (s, 3H), 2.10 (m, 2H), 2.85 (dd, 1H, J = 14.2, 6.9 Hz), 2.89 (s, 
3H), 2.91 (s, 3H), 3.05 (dd, 1H, J = 14.2, 3.6 Hz), 3.47 (t, 2H, J =  7.6 Hz), 4.02 (s, 2H), 4.35 (m, 
1H), 4.29 (m, 1H), 4.74 (m, 1H), 6.93 (d, 2H, J = 8.0 Hz), 7.17 (d, 2H, J = 8.4 Hz), 8.00 (s, 1H). 
 
47b: 
HO
N
H
O
N
O
HN
O
OH
N
NBoc
NHBoc
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Yield 78%, 
1
H NMR (CDCl3, 400 MHz) δ 0.85 (m, 6H), 1.1 (m, 1H), 1.25 (t, 3H, J = 7.3 Hz), 
2.01 (m, 2H), 2.07 (s, 3H), 2.10 (s, 3H), 2.10 (m, 2H), 2.85 (dd, 1H, J = 14.2, 6.9 Hz), 3.05 (dd, 
1H, J = 14.2, 3.6 Hz), 3.47 (t, 2H, J =  7.6 Hz), 4.02 (s, 2H), 4.35 (m, 1H), 4.29 (m, 1H), 4.74 
(m, 1H), 5.05 (s, 2H), 6.93 (d, 2H, J = 8.0 Hz), 7.17 (d, 2H, J = 8.4 Hz), 7.30 (m, 3H). 
 
Compound 47:  
White powder, yield 95%, 
1
H NMR (CDCl3, 400 MHz) δ 0.85 (m, 6H), 1.1 (m, 1H), 1.25 (t, 3H, 
J = 7.3 Hz), 2.01 (m, 2H), 2.10 (m, 2H), 2.85 (dd, 1H, J = 14.2, 6.9 Hz), 3.05 (dd, 1H, J = 14.2, 
3.6 Hz), 3.47 (t, 2H, J =  7.6 Hz), 4.02 (s, 2H), 4.35 (m, 1H), 4.29 (m, 1H), 4.74 (m, 1H), 5.05 (s, 
2H), 6.93 (d, 2H, J = 8.0 Hz), 7.17 (d, 2H, J = 8.4 Hz), 7.30 (m, 3H). HRMS calcd for 
C27H33Cl2N3O5+H 550.2087, found 550.2087.  
 
3. General procedures for enzyme inhibition assays 
 
Thrombin from bovine plasma, trypsin from bovine pancreas, trypsin inhibitor from chicken egg 
white, and trypsin substrate N-benzoyl-DL-arginine-4-nitroanilide hydrochloride were purchased 
from Sigma; chromogenic thrombin substrate, H-D-HHTAla-Arg-pNA.2AcOH 
(SPECTROZYME), was obtained from American Diagnostica Inc. Other common chemicals 
and reagents were purchased from Aldrich or Lancaster. The known thrombin inhibitor, PPACK, 
was purchased from Calbiochem (EMD bioscience). Standard enzyme assay procedures and 
chromogenic substrates were used for both enzymes. UV absorbance of the cleaved p-
nitroaniline was monitored at 405 nm on a UV spectrophotometer. Typical inhibitor 
concentrations are 1.0, 0.50, 0.25, 0.13, 0.063, 0.031 mg/mL, and 0 (buffer was used instead of 
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inhibitor). Further serial dilutions were performed for compounds that showed above 90% 
inhibition at the lowest concentration tested. In general, test compounds were dissolved in 
distilled water or a small amount of DMSO and then diluted with distilled water. Thrombin 
buffer is composed of 10 mM Tris–HCl (pH = 8), 150 mM of NaCl, 10 mM of HEPES, 0.10% of 
PEG6000 in distilled water. Enzyme assays were performed in 96-well microtiter plates using a 
microtiter plate reader (Biotek Powerwave XS Spectrophotometer). A mixture of 50 mL of 
inhibitor solution, 20 mL of bovine thrombin solution (0.25 NIH units/mL), and 30 mL thrombin 
buffer solution was incubated at 37 ⁰C for 10 min, then 50 mL of substrate Spectrozyme (0.032 
mg/mL) was added to each cell, this final mixture was then incubated for 30 min at 37 °C with 
slow shaking. The total volume in the cell was 150 mL. The UV absorbance at 405 nm before 
adding substrate was recorded as the blank. The absorbance at 405 nm was measured 
immediately after the incubation. The IC50 value was obtained from the curve of inhibitor 
concentration versus absorbance, the final data was obtained as an average of triplicate 
experiments. 
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Chapter 3 
 
 Synthesis of aeruginosin 298-A analogs: modification at P2 using O-
Choi (bicyclic unnatural amino acids) derived from sugars 
 
3.1 Abstract 
 
Aeruginosins are a family of marine natural products containing mostly non-proteogenic amino 
acids. These compounds contain a common 2-carboxy-6-hydroxy-octaindole (Choi) rigid 
bicyclic structure. Many aeruginosins are inhibitors for enzymes involved in the blood 
coagulation cascade, such as thrombin and Factor VIIa. In order to understand the structure 
activity relationship (SAR) of the aeruginosins and to discover novel anticoagulants with 
potentially improved inhibitory and pharmacokinetic properties, we have synthesized a series of 
novel analogs of aeruginosin 298-A, in which the Choi will be replaced with oxygenated Choi 
analogs, and the Argol is replaced with various other functionalities. These new O-Choi have 
been derived from sugar and are unnatural amino acids which have been replaced with the Choi 
(P2) moiety of aeruginosin. The preparation of oxygenated Choi analogs starting from glucose 
using a new method will be presented. 
 
O
N
HHO
O
OH
*
O
N
HHO
O
OHH3CO
*
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3.2. Introduction 
 
Thrombin (factor IIa) is a key trypsin like serine protease of the blood coagulation and is also a 
potent activator of platelet aggregation.
1-4
 Thrombin cause thrombosis and if not treated, it can 
lead to heart stroke, pulmonary diseases and many life threatening deaths. Hence design and 
synthesis of thrombin inhibitor can be very important in treating or preventing thrombosis. In 
recent years many thrombin inhibitors have been design and synthesized based on the crystal 
structure of thrombin.
5 
 
Despite much research effort, it is still very challenging to find an orally active anticoagulant 
which is safe and effective agent for treating or preventing thrombosis disorders. The major 
anticoagulants heparin and warfarin were introduced about 50 years ago. Currently recombinant 
hirudin and argatroban are approved for the treatment of thrombosis associated with heparin 
induced thrombocytopenia (HIT). Hirudin (66 amino acids) and its analogue hirulog (20 amino 
acids) are polypeptides isolated from medicinal leeches.9 Argatroban is a synthetic small 
molecule thrombin inhibitor which was recently approved for use as an anticoagulant for treating 
prophylaxis, HIT, and associated thrombotic complications.10 Like heparin, both hirudin and 
argatroban are administered parenterally. Ximelagatran is an orally active thrombin inhibitor and 
drug.11 In recent years, a new class of marine nature products, the aeruginosins, were isolated 
from cyanobacterial blooms.
6-15
 They are small linear peptides containing unnatural amino acids 
and they are found to be serine protease inhibitors. The approximately 16 compounds in this 
family share a common new bicyclic amino acid core structure 2-carboxy-6-
hydroxyoctahydroindole (Choi). 
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The X-ray crystal structures of thrombin being inhibited by several aeruginosins have been 
obtained through the inhibitor and thrombin-hirugen complexes.
5
 The binding mode of 
aeruginosin 298-A resembles closely that of D-Phe-Pro-Arg chloromethyl ketone and other 
serine protease inhibitors. Aeruginosin 298-A binds to the active site of thrombin in a 
monovalent way forming an antiparallel strand with thrombin.
15
 The five-membered ring of the 
Choi residue occupies the hydrophobic binding site, while its six-membered ring projects out and 
loosely interacts with Try 60 and Tyr 60 from thrombin. The active site where the Choi group 
interacts has many degrees of freedom. The crystal structures of oscillarin and dysinosin-A 
thrombin complexes revealed similar binding patterns as aeruginosin 298-A. Dysinosin-A forms 
a hydrogen bonding network with thrombin complex, but the 5,6-dihydroxyoctahydroindole 
group appears not to have hydrogen bonding interactions with the P2 binding pocket even though 
there are polar amino acid residues in the pocket 25 The crystal structure of oscillarin with 
thrombin complex is shown in Figure 3.2. The amide NH from the octahydroindole carboxamide 
forms a hydrogen bond with Ser 256, however no interactions were observed with the 6-
hydroxyl group of the Choi moiety. The terminal phenyl group has no interaction with the 
enzyme.22 In all the crystal structures of aeruginosin-thrombin complexes so far, Choi moieties 
of the aeruginosins which occupy the S2 binding site generally have a good degree of freedom. 
Thrombin generally can tolerate imprecise binding from different molecules. The rigid bicyclic 
amino acid structure is very important in defining the conformation of the molecule and it is 
essential in their antithrombin activity. The 6-hydroxyl group projects out and the Choi core is 
not interacting strongly with residues at the active site. Thus modifications on the core structure 
in this area should not impact negatively on binding to the protein while some changes will 
increase contact and enhance binding. Such changes include introducing an oxygen at the C-4. 
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As pharmacokinetics are very unpredictable, these changes will provide other possibilities that 
might provide scope for improving the pharmacokinetic profile of this compound class if 
required. The availability of different stereoisomers is also important in elucidating structure-
activity relationships. Studies to rationalize electronic and steric influence of different inhibitors 
have not given good correlations so far. Modification from the natural analogues can allow us to 
understand the stereoelectronic factors that determine the activity of these inhibitors. In recent 
years, a new class of marine natural products, the aeruginosin came into the picture. More than 
20 compounds have been isolated in the Aeruginosin series. They are a class of serine protease 
inhibitors isolated from cyanobacterial blooms. They are a linear peptide containing a new 
bicyclic amino acid core structure known as 2-carboxy-6-hydroxyotahydroinhole (Choi).  . These 
proposed Choi analogues are novel structures and will have great potential in discovering better 
thrombosis inhibitors. The 14 initially reported members mostly contain the configuration of 
2S,3aS,6R,7aS in their azabicyclic core. The structure below represents one of the aeruginosin 
series compound named 298-A. It shows a value of inhibition against thrombin (IC50 = 0.3 M) 
and trypsin (IC50 = 1.0 M)  
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Figure 3.1. Structure of Aeruginosin 298-A.  
 
The structures of aeruginosin 298-A is shown in Figure 3.1. Most of them exhibited high potency 
against thrombin making them attractive small-molecules targets in the search for new 
anticoagulents. These molecules are divided into three parts- P1, P2 and P3 subunits which 
correspond to the hydroxylphenyllactic acid (Hpla), Leucine, (P1), 2-carboxy-6-
hydroxyotahydroinhole (Choi) (P2), and argininal (Argal) at P3.  
 
The unusual structure and interesting biological activities of this class of molecules have 
attracted several research groups to carry out their total syntheses.
15-19
 Several methods are also 
available for synthesizing the Choi core structure and its analogs.
20-23  
Besides the synthesis of 
the aeruginosins, there is also a great interest in preparing analogs of the aeruginosin natural 
products and understanding the structure–activity relationship (SAR) pattern for these serine 
protease inhibitors. While several aeruginosin 298-A analogs have been synthesized, most of the 
modifications or variations of structures are on the units other than the Choi.
24-25
 These include 
the preparation of a combinatorial library and the study of stereochemical influences of the 
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amino acid residues at P3, P4 or P1 to the trypsin inhibition activity
24
 and several other analogs 
of aeruginosins with different amino acid residues.
25 
 
Our group has worked previously on the modification of p2 unit and has synthesized new 
bicyclic amino acids which can be derived from sugars.
21, 26-27
 Different bicyclic unnatural amino 
acids can be derived from different sugars. However it‟s always been a challenge to synthesize 
them.  
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Figure 3.2.  Different possible derived structure from different sugar 
 
Synthesis of bicyclic amino acids form glucose has been achieved previously.
21
 The general 
strategy to synthesize these structure has been shown in the Figure 3.2.  
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Starting from D-glucose, after several steps we can obtain the protected version of ring 
oxygenated Choi analogs 14 and 15.  Compound 8 can be prepared in 2-3 steps. It is then 
dibenzylated using sodium hydride and benzyl bromide, followed by deprotection of the acetal 
using acidic conditions and then mesylation to give the dimesylate 10, this is then converted to 
the bromomesylate 11, a key intermediate in the synthesis. The important step in this synthesis is 
the alkylation step to add a two carbon unit to the molecule to give compound 12, which is then 
converted to the cyclized products smoothly. This method is applicable for other sugar starting 
material as well, this allows us to synthesize a series of choi analogs with different 
stereochemistry or substituents.  
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Scheme 3.1. Synthetic approach towards o-Choi synthesis 
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To do further structure activity relationship we wanted to see how stereochemistry would play a 
role in the activities of thrombin. We designed o-choi with a mannose configuration and 
designed our strategy in the same way as we did for the glucose. The D- mannose 2 was 
acetylated and anomeric group was substituted using bromo in one pot reaction to get compound 
16. The bromo group was reduced to obtain tetra acetate 17 and then the acetyl groups were 
hydrolysed and then it was protected using benzylidine acetal to get a mixture of two products 19 
and 20. In case of mannose 2, 3 hydroxyl and 4, 6 hydroxyl on sugar are cis to each other and its 
difficult to protect 4,6-OH with benzylidine acetal. The reaction worked fine but all four 
hydroxyl groups were protected. And then we tried to reduce the 5 membered acetal group, we 
get a mixture of 2 products, which is difficult to purify.  
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Scheme 3.2. Synthetic approach for O-Choi starting from D-mannose 
 
The above scheme in not a good way to synthesize, as its very difficult to do the benzylidine 
protection at 4,6-position.  
 
Our group recently published a paper where it is reported that using mitsunobu reaction the 
stereochemistry of 2-OBn can be transformed into mannose configuration.
28
 However we wanted 
to comeup with a new idea where we could explore new chemistry and can comeup with high 
yield reactions. 
 
Keeping that in mind we synthesized various aeruginosin analogs where we replaced Choi 
moiety at P2 by a new kind of bicyclic unnatural amino acid which was derived from sugar and 
the P1 and P3 moieties were also replaced by other functionalities. We modified our strategy and 
started our synthesis starting from d-glucose.  
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Scheme 3.3. Synthetic approach towards O-Choi (mannose configuration) 
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First 1-deoxy-4,6-benzylidine-2,3-hydroxy compound was synthesized starting from D-mannose. 
The D-glucose was aceylated and in one pot anomeric –OAc group was replaced by bromo. The 
bromo group at anomeric position was then reduced using N-dibutyl tin hydride to get tetra 
acetate sugar compound. All acetyl groups were hydrolyzed using sodium methoxide in 
methanol and the compound was dried using azeotorope toluene. Further using Benzylidine 
dimethyl acetal and a catalytic amount of PTSA 2,3-dihydroxy-4,6-benzylidine deoxy glucose 
was afforded. 
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Scheme 3.4. Synthetic approach towards O-Choi (mannose configuration contd.) 
 
Further, the tosylation reaction was performed at 2-hydroxy using different conditions. 
Tosylation performed using pyridine and p-toluene sulfonyl chloride in different equivalents we 
always ended up with a mixture of 2-tosyl, 3-tosyl and 2,3-ditosyl product. Replacing pyridine 
by dibutyl tin oxide, the 2-tosyl product was formed predominately which was isolated using 
recrystallization on a small scale to large scale. And by this reaction its easy to scale up for 26. 
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Further epoxidation ring formation reaction was performed in methanol using 4 equivalents of 
sodium methoxide to give clean product 27. The epoxide ring was opened using lithium 
aluminum hydride in THF as a solvent to obtain 2-hydoxy compound with a mannose 
configuration 28.  The hydroxy group at C-2 was benzylated using sodium hydride and benzyl 
bromide in DMF to obtain 29.The 4,6-benzylidine group was deprotected using 65% acetic acid 
at 65 °C. The 4,6-dihydroxyl were mesylated using methane sulfonyl chloride and triethyl amine 
in dichloro methane to compound 30.  The primary mesylate was replaced by bromo using 
sodium bromide in DMSO to obtain 31.  
 
HCl.H2N
OEt
OEt
O
O
(Boc)2O
TEA, DCM
BocHN
OEt
OEt
O
O
90%32 33  
Scheme 3.5. Boc-protection of diethyl malonate 
 
For the cyclization purpose, the diethyl amino malonate-HCl 32 was protected using boc-
anhydride and triethyl amine in dichloromethane to obtain compound 33. The bromo compound 
was treated with mono boc-diethyl malonate ester using sodium hydride and TBAI and refluxed 
in toluene for 24 hours. 
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Figure 3.3. Synthetic approach towards O-Choi (mannose configuration) 
 
Both the displacement and cyclized reaction were done in one pot to get the cyclized material 35. 
It was further hydrolyzed using sodium hydroxide and decarboxylation was done in refluxing 
toluene to get diastereomers of bicyclic amino acids. 
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Scheme 3.6. Synthetic approach for the tertapeptide using O-Choi (mannose configuration) 
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The boc group was cleaved using acidic conditions and then it was coupled to Boc-D-Leucine 
using BOP-Cl as a coupling reagent to give 39. The other coupling reagents like EDCI, HATU 
and PyBOP were also used. However, we could not get the desired product or with very less 
yield. After column purification, Boc-protection of the dipeptide was cleaved using TFA and was 
further coupled to protected D-HPLA derived from D-tyrosine using EDCI, HOBt to get 
compound 42.  The tripeptide ester was hydrolyzed using LiOH to free acid 43 and then coupled 
with nitro arginine-methyl ester using EDCI, HOBt to give tertapeptide 44. The ester group of 
arginine was reduced to primary alcohol using lithium Borohydride to get 45 and finally nitro 
arginine and benzyl groups were reduced using Pd-C / H2 to give aeruginosin-298 analog 46.  
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Scheme 3.7. Synthetic approach for the tertapeptide using O-Choi (mannose configuration 
contd.) 
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After synthesizing the analog with p2 moiety, we were also interested in changing the p3 moiety. 
In place of D-HPLA-D-Leu, we replace the dipeptide with p-toluene sulfonyl chloride.  The free 
amino group of bicyclic compound 48 was treated with p-toluene sulfonyl chloride to get 
sulfonamide 45 in quantitative yield. and then the ester of dipeptide was hydrolyzed using 1N 
NaOH solution to get free acid 50 and then it was treated with nitro-arginine methyl ester using 
coupling reagent like EDCI, HOBt to give tripeptide 51. The ester group of the tripeptide was 
reduced using lithium borohydride to give an alcohol 52. And then finally the reduction of nitro 
group of arginine and debenzyaltion was performed using Pd-C / H2 to give aeruginosin analog 
53.  In the same way the compound 54 was also synthesized.  
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Scheme 3.8. Synthetic approach for the aeruginosin analogs 
 
To do further structure modification and to make synthesis more short we make another analog 
starting from D-glucose where we did not remove the anomeric position –OH group. The idea 
behind this to have one more hydroxyl available at sugar ring which can be further used in 
synthesis of various analogs of aeruginosin as well as for other peptidomemtics. 
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Scheme 3.9. Synthetic approach for the Choi analogs 
 
4,6- position of Methoxy-D-glucose was protected using benzylidine acetal and then selective 
tosylation was performed at 2-OH position using dibutyl tin oxide and tosyl chloride. Further 
epoxide ring formation was carried out using sodium methoxide in methanol. Epoxide ring was 
opened using LAH and then it was benzylated using benzyl bromide and sodium hydride as a 
base. Further benzylididne group was removed using acidic conditions and then both hydroxyl 
groups were mesylated and then primary mesytyl group was converted to bromo group where 
coupling reaction was performed using diethyl mono-boc malonate to get the cyclized product.   
 
3.3. Conclusion 
 
We have developed an efficient synthesis for aeruginosin 298-A analogs in which the P2 Choi 
unit is modified by replacing a methylene group in the six-membered ring with an oxygen and 
different configurations. The ring oxygenated Choi (mannose configuration) variants were 
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synthesized from D-glucose in an very efficient way. During this process a new highly yielding 
procedure to convert D-glucose to D-mannose has been established. The crucial step for the 
formation of the bicyclic Choi includes the alkylation and cyclization steps in a one-pot. These 
O-Choi were coupled with arginine, HPLA and D-leucine resulted in the tetrapeptides in good 
yields, which were then converted to the target compounds. We have also modified the P3 
position where we used p-toluene sulfonyl chloride.   Biological studies for these compounds are 
ongoing.  
 
3.4. Experimental section 
 
General methods 
 
Reagents, solvents, and starting materials were purchased from Aldrich, VWR, or Lancaster 
unless otherwise specified. Anhydrous solvents were purchased from Aldrich insure-seal bottles 
and used directly without further treatment. 
1
H and 
13
C NMR spectra were acquired on a Varian 
400 MHz and 500 MHz machine. Melting point was measured using a Fisher-Johns melting 
point apparatus. Typically thin layer chromatography (60 A pore, UV254, phosphomolybdic acid 
or Ninhydrin as the staining agent) was used to monitor reactions. Silica gel (230–400 meshes) 
was used for flash chromatography.  
 
Acetobromo-α-D-glucopyranose 23.  
The compound was synthesized according to literature procedure. To a magnetically stirred 
solution of D-glucose 7 (10.0 g) in 50 ml acetic anhydride was added 10 ml 33% HBr-HOAc 
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solution. The reaction mixture was stirred at room temperature for 5 hours. Another 50 ml 33% 
HBr- HOAc solution was then introduced, and after stirring at room temperature for another 6 
hours, the clear solution is diluted with 250 ml DCM and poured into 250 ml of ice-water. The 
phase was separated and the aqueous layer was extracted with DCM (150 ml x3). The organic 
phases were combined and neutralized with cold saturated NaHCO3 solution carefully. Then the 
DCM phase was washed with water and brine and dried over Na2SO4. After evaporation and 
recrystallization (ether-hexane), 20.4 g (89% yield) of white crystals was obtained as pure 
product. Mp 87-89 
oC, [α]D +196.0 (c 1.9, CHCl3); 
 1
H NMR (400 MHz, CDCl3) δ 6.56 (d, 2H, J 
= 4.0 Hz), 6.50 (t, 1H, J = 9.7 Hz), 5.10 (t, 1H, J = 9.7 Hz), 4.79 (dd, 1H, J = 9.99, 4.0 Hz), 4.29-
4.23 (m, 2H), 2.37 (dd, 1H, J = 12.1, 0.9 Hz,), 2.05 (s, 3H), 2.04 (s, 3H), 2.00 (s, 3H), 1.98 (s, 
3H); 
13
C NMR (100 MHz, CDCl3) δ 170.4, 169.74, 169.67, 169.4, 86.5, 72.0, 70.5, 70.1, 67.1, 
60.8, 20.6, 20.53, 20.4, 20.4. 
 
2,3,4,6-tetra-O-acetyl-1,5-anhydro-D-glucitol 24.  
Bu3SnH (14.4 g, 49.6 mmol) was added to a magnetically stirred solution of acetobromo-α-D-
glucopyranose 1 (20.4 g, 49.6 mmol) in 150 ml benzene. A few crystals of AIBN were then 
added to the solution. The reaction mixture was immersed immediately in a pre-heated oil-bath 
and stirred at 80 
o
C for one hour. After cooled down to room temperature, the reaction mixture 
was diluted with 150 ml ether and followed by adding a solution of 8.6g KF dissolved in 30 ml 
water. The mixture was rapidly stirred for 30 min. The insoluble Bu3SnF was collected and 
washed thoroughly with ether. The water was separated from the combined filtrate and the 
organic layer were washed with water and brine and dried over Na2SO4. After evaporation and 
recrystallization (ether-hexane), 14.9g of pure product was obtained in the form of colorless 
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crystals. The mother liquid was purified by flash chromatography and another 1.1g of pure 
product was recovered. The total weight of pure product was 16.0g (97% yields). Mp 71-73 
o
C, 
[α]D +42.6 (c 1.4, CHCl3); 
1
H NMR (400 MHz, CDCl3) δ 5.04 (t, 1H, J = 9.5 Hz), 4.87-4.81 (m, 
2H), 4.04 (dd, 1H, J = 4.9, 12.4 Hz), 3.99-3.94 (m, 2H), 3.47-3.44 (m, 1H), 3.15 (t, 1H, J = 10.9 
Hz), 1.92 (s, 3H), 1.86 (s, 6H), 1.85 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 170.2, 169.9, 169.4, 
169.2, 76.1, 73.4, 68.6, 68.1, 66.5, 61.9, 20.34, 20.27. 
 
1, 5-anhydro-4, 6-O-benzylidene-D-glucitol 8.  
Compound 23 (16.0 g, 48.1 mmol) was dissolved in 100 ml absolute ethanol. A solution of 
NaOEt in ethanol (21 wt% in ethanol, 0.37 ml, 10 mol%) was added to the flask. The reaction 
mixture was then stirred at room temperature under the protection of anhydrous CaCl2 till all 
starting material was consumed (monitored by TLC). The solvent was then completely 
evaporated followed by co-evaporation with toluene twice, after which, the product was dried 
again under high vacuum for 2 hours to afford the anhydrous 1,5-anhydro-D-glucitol 25. The 
dried compound 25 was then dissolved in 100 ml DMF, followed by the addition of 
benzaldehyde dimethyl acetyl (9.0 ml, 60 mmol) and p-TsOH (1.14 g, 6.0 mmol) at room 
temperature. The reaction mixture was stirred at 60
o
C for 7-10 hours, and then it was 
concentrated on a rotary evaporator to remove the methanol formed. The reaction was monitored 
by 
1
H NMR spectrum. Repeat the heating and evaporation till crude NMR shows all starting 
material consumed. DMF was then removed under reduced ressureusing an oil pump, and the 
residue was diluted with EtOAc, washed with aqueous saturated NaHCO3. The water phase was 
extracted with EtOAc three times, and the combined organic phase was washed with water and 
brine and dried over Na2SO4. After evaporation and recrystallization (EtOAc-hexane), 6.4g of 
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pure product was obtained in the form of colorless crystals. The mother liquor was purified again 
by flash chromatography and another 2.7g of pure product was recovered. The total yield for 8 
was 9.1g (75% yield); mp 163-165
oC, [α]D -20.5 (c 0.5, CHCl3); 
1
H NMR (400 MHz, CDCl3) δ 
7.48-7.46 (m, 2H), 7.37-7.35 (m, 3H), 5.51 (s, 1H), 4.31 (dd, 1H, J = 10.4, 4.9 Hz), 4.04 (dd, 1H, 
J = 11.3, 5.5 Hz), 3.81- 3.76 (m, 1H), 3.73-3.65 (m, 2H), 3.45 (t, 1H, J = 9.2 Hz), 3.41-3.32 (m, 
2H); 
13
C NMR (100 MHz, CDCl3) δ 137.0, 129.3, 128.4, 126.3, 101.8, 81.0, 75.4, 71.0, 70.3, 
69.9, 68.7 
 
Synthesis of 1,5-anhydro-2-O-tosyl-4,6-O-benzylidene-D-glucitol 26: 
To a round bottom flask compound 1,5-anhydro-4,6-O-benzylidene-D-glucitol 3 (1 g, 3.96 
mmol) was dissolved in 10 ml of toluene. Dibutyl tin oxide (1.08 g, 4.35 mmol) was added to the 
reaction mixture. The reaction mixture was heated to reflux conditions for 3-4 hrs and then 
toluene was evaporated using rotavaporator.  P-toluene sulfonyl chloride (0.83 g, 4.35 mmol) 
and toluene (15 ml) was added to the reaction mixture and it was heated at 60 °C for another 3-4 
hrs. The reaction was monitored using NMR. For work up the toluene was removed using 
rotavaporator and reaction mixture was quenched using 20 ml of saturated sodium bicarbonate 
solution. The reaction mixture was also diluted using ethyl acetate (50 ml). Then it was filtered 
using celite bed and then extracted using EtOAc: water. The water layer was again extracted 
using (2 x 50 ml) of EtOAc. The organic layer was combined and then it was washed with brine 
and dried over sodium sulphate. The organic layer was concentrated on rotavaporator. The 
compound was purified using EtOAc: Hexane (1:4) to get (1.57 g, 97.5%) compound as a white 
solid, mp 174.2-175.0 °C []D
25 
= -33.0 (CHCl3, c = 1.2). 
1
H NMR (400 MHz, CDCl3) δ  7.84 (d, 
2H, J = 8.4 Hz), 7.46–7.44 (m, 2H), 7.36-7.34 (m, 5H), 5.47 (s, 1H), 4.47-4.41 (m, 1H), 4.30 
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(dd, 1H, J = 10.6, 5.1 Hz), 4.11 (q, 1H, J = 11.3, 5.8 Hz), 3.85 (t, 1H, J = 9.1 Hz), 3.64 (t, 1H, J = 
10.3 Hz), 3.39-3.34 (m, 2H), 3.36-3.33 (m, 1H), 2.45 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 
145.3, 136.7, 132.8, 129.8, 129.2, 128.3, 128.0, 126.1, 101.8, 80.6, 78.1, 72.3, 70.9, 68.4, 67.7, 
21.7; HRMS calcd for C20H22O7S+H,  407.1165, found 407.1162  
 
Experimetal procedure for 27 by epoxide ring formation: Compound 1,5-anhydro-2-O-tosyl-
4,6-O-benzylidene-D-glucitol 2 (0.5 g, 1.23 mmol) was dissolved in dry methanol (5 ml) and 
then it was heated at 45 ⁰C for 15 min. Sodium methoxide (0.39 g, 7.38 mmol) was added to it 
and then the reaction mixture was heated to reflux for 45 minutes. The reaction was monitored 
by NMR. For work up the methanol was removed using rotavaporator and then reaction mixture 
was diluted using EtOAc and water. The organic layer was extracted and water layer was again 
extracted using ethyl acetate (2 times). The organic layer was combined and a brine wash was 
given. The compound was dried on sodium sulphate and it was concentrated on rotavaporator. 
The compound was purified using column chromatography using EtOAc: Hexane (1:6) to get 
(0.26 g, 90%) compound as a white solid. Mp 122.4-123.2 °C, []D
25 
= -15.8 (CHCl3, c = 1.5). 
1
H NMR (400 MHz, CDCl3) δ 7.51-7.49 (m, 2H), 7.40–7.37 (m, 3H), 5.58 (s, 1H), 4.30-4.28 (m, 
1H), 4.25 (d, 1H, J = 13.9 Hz), 3.97 (d, 1H, J = 13.5 Hz), 3.73-3.63 (m, 2H), 3.51 (d, 1H, J = 
13.5 Hz), 3.25 (d, 1H, J = 4.0 Hz), 3.20-3.14 (m, 1H); 
13
C NMR (100 MHz, CDCl3) δ 137.0, 
129.2, 128.3, 126.1, 102.3, 75.5, 69.4, 69.4, 65.3 HRMS calcd for C13H14O4+Na 257.0790, found 
257.0791. 
 
Experimental procedure for 28 by epoxide ring opening: 
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To a stirred solution of 27 (2.0 g, 8.53 mmoles) in THF (20 ml) at 0 °C the LAH (0.65 g, 17.07 
mmoles) was added slowly. The reaction mixture was stirred at room temperature for 30 min. 
The reaction was monitored by TLC. For work up first the unreacted LAH was quenched using 
saturated sodium sulphate solution and then the RM was filtered using celite. The reaction 
mixture was diluted with EtOAc and was extracted using water. The organic layer was extracted 
and the water layer was again extracted using ethyl acetate. The organic layer was combined and 
was washed using brine. The organic layer was dried on sodium sulphate and was concentrated 
using rotavaporator. The compound was purified on column using EtOAc: Hexane (1:4) to get 
compound 6 as white solid in (1.99 g, 99%) yield. Mp 87.4-88.0 °C, []D
25 
= -28.7 (CHCl3, c = 
2.0) 
1
H NMR (400 MHz, CDCl3) δ 7.52-7.46 (m, 2H), 7.38–7.34 (m, 3H), 5.58 (s, 1H), 4.30-
4.28 (m, 1H), 4.06 (s, 1H),4.0- 3.96 (m, 1H),3.90 (d, 1H, J = 12.5 Hz), 3.77 (t, 1H, J = 10.2 Hz), 
3.65 (d, 1H, J = 12.5 Hz), 3.40-3.34 (m, 1H), 2.26 (d, 1H, J = 12.8 Hz), 1.84-1.77 (m, 1H)  
13
C 
NMR (100 MHz, CDCl3) δ 137.7, 129.3, 128.6, 126.4, 102.3, 74.6, 74.5, 72.8, 69.3, 67.3, 35.9 
HRMS calcd for C13H16O4+Na,  259.0946, found 259.0948. 
 
Experimental procedure for 29 by benzylation reaction:  Compound 28 (1.9 g, 8.04 mmoles) 
was dissolved in DMF (10 ml). NaH (0.23 g, 9.65 mmoles) was added to the reaction mixture at 
0 °C. Reaction mixture was stirred for 45 min at 0 °C. Benzyl bromide (1.65 ml, 9.65 mmoles) 
was added and then the reaction mixture was stirred at room temperature for 2 hrs. The reaction 
was monitored by TLC. For work up first reaction mixture was quenched using saturated 
ammonium chloride and then it was extracted using ether and water. The organic phase was 
extracted and water layer was again extracted using ether (2 times). The organic layer was 
combined and was washed with brine.  The organic phase was dried on sodium sulphate and was 
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concentrated on rotavapor. Compoud 29 was purified on column chromatography using EtOAc: 
Hexane (1:7) to give an oily material (2.3 g, 87%). []D
25 
= -28.5 (CHCl3, c = 1.0). 
1
H NMR 
(400 MHz, CDCl3) δ 7.50-7.47 (m, 2H), 7.39-7.29 (m, 8H), 5.61 (s, 1H), 4.62 (2, 2H), 4.31-4.27 
(m, 1H), 3.81 (t, 1H, J = 10.3 Hz), 3.74 (s, 1H), 3.56 (d, 1H, J = 12.5 Hz), 3.43-3.36 (m, 1H), 
2.44 (d, 1H, J = 13.1 Hz), 1.76 (t, 1H, J = 12.1 Hz)  
13
C NMR (100 MHz, CDCl3) δ 138.2, 137.9, 
129.3, 128.7, 128.6, 128.0, 127.9, 126.4, 102.1, 74.7, 73.3, 70.7, 69.9, 69.3, 33.0 HRMS calcd 
for C20H22O4+H, 327.1596; found, 327.1601. 
 
Experimental Procedure for 30 by mesylation reaction: Compound 29 (1.4 g, 5.87 mmoles) 
was dissolved in 20 ml of dry dichloromethane. The reaction mixture was cooled at 0 °C. 
Triethyl amine (1.9 ml, 2.5 mmoles) was added to the reaction mixture. After 10 min methyl 
sulfonyl chloride (1.68 ml, 2.5 mmoles) was added to the reaction mixture. The reaction mixture 
was stirred for overnight at room temperature. For workup the reaction mixture was diluted using 
DCM and was extracted using water. The water phase was again extracted using DCM (2 x 50 
ml). The organic phase was combined and dried over sodium sulphate. The crude was purified 
over column chromatography using EtOAc: Hexane (9:1) to give pure compound as a gummy 
material (2.20 g, 95%). []D
25 
= + 17.5 (CHCl3, c = 1.5) 
1
H NMR (400 MHz, CDCl3) δ 7.36-7.32 
(m, 4H), 7.30-7.26 (m, 1H), 4.91-4.85 (m, 1H), 4.55 (s, 2H), 4.49 (dd, 1H, J = 11.7 Hz, 1.83 Hz),  
4.37-4.33 (m, 1H), 4.07 (d, 1H, J = 12.4 Hz), 3.69 (s, 1H), 3.59-3.55 (m, 1H),  3.407(d, 1H, J = 
11.4 Hz), 3.04 (s, 3H), 3.03 (s, 3H), 2.76-2.70 (m, 1H), 1.87-1.80 (m, 1H)  
13
C NMR (100 MHz, 
CDCl3) δ 137.6, 128.4, 127.7, 127.6, 76.6, 71.9, 71.7, 70.2, 68.9, 68.2, 38.3, 37.6, 34.4 HRMS 
calcd for C15H22O8S2+H, 395.0834; found, 395.0832. 
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Experemental procedure for 31 by substitution of primary Mesylate by bromo:  
Dimesylate compound 30 (1.3 g, 3.29 mmoles) was dissolved in 10 ml of DMSO. Sodium 
bromide (2.034 g, 19.77 mmoles) was added to the reaction mixture. Then TBAB (0.12 g, 0.823 
mmoles) was added and the reaction mixture was heated at 60 °C for overnight. Reaction was 
monitored by TLC and NMR. The reaction was diluted with ethyl acetate and was washed with 
water. The water layer was again washed with ethyl acetate and the combined organic layer was 
washed with brine and was dried over sodium sulphate. After concentrating at rotavaporator the 
compound was purified over column chromatography EtOAc: Hexane (8:1) to give a gummy 
material of (1.12 g, 89%). []D
25 
= + 14.5 (CHCl3, c = 1.2). 
1
H NMR (400 MHz, CDCl3) δ 7.35-
7.32 (m, 4H), 7.29-7.27 (m, 1H), 4.90-4.89 (m, 1H), 4.62-4.51 (m, 2H), 4.15-4.08 (m, 1H), 3.71-
3.66 (m, 2H), 3.53-3.48 (m, 3H), 3.06 (s, 3H), 2.72-2.64 (m, 1H), 1.82-1.79 (m, 1H)  
13
C NMR 
(100 MHz, CDCl3) δ 138.1, 128.7, 128.0, 127.9, 78.3, 75.1, 72.3, 70.6, 69.1, 38.9, 34.9, 32.1 
HRMS calcd for C14H19BrO5S+Na, 401.0034; found, 401.0036. 
 
Synthesis of Bicyclic compound 35:  
Monoboc diethyl malonate compound 33 (0.2 g, 0.726 mmoles) was dissolved in dry toluene (10 
ml) under nitrogen was treated using NaH (20.93 mg, 0.872 mmoles). Reaction mixture was 
stirred at RT for 30 minutes before 31 was added to it. The reaction mixture was stirred for 1 
hour at room temp and then TBAI was added and the reaction mixture was refluxed for 17 hours. 
For work up the RM was quenched by dil. HCl and diluted with Ethyl acetate. The organic layer 
was separated and the aqueous layer. The organic layer was washed with brine and was dried 
over sodium sulphate. The compound was purified using column chromatography using EtOAc: 
Hexane (6:1) to give an oily compound (0.171 g, 68%). []D
25 
= + 27.4 (CHCl3, c = 2.4) 
1
H 
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NMR (400 MHz, CDCl3) δ 7.36-7.32 (m, 4H), 7.30-7.26 (m, 1H), 4.91-4.85 (m, 1H), 4.55 (s, 
2H), 4.49 (dd, 1H, J = 11.7 Hz, 1.83 Hz),  4.37-4.33 (m, 1H), 4.07 (d, 1H, J = 12.4 Hz), 3.69 (s, 
1H), 3.59-3.55 (m, 1H),  3.40 (d, 1H, J = 11.4 Hz), 3.04 (s, 3H), 3.03 (s, 3H), 2.76-2.70 (m, 1H), 
1.87-1.80 (m, 1H)  
13
C NMR (100 MHz, CDCl3) δ 137.6, 128.4, 127.7, 127.6, 76.6, 71.9, 71.7, 
70.2, 68.9, 68.2, 38.3, 37.6, 34.4 HRMS calcd for C30H45N2O9+H, 478.2441; found, 478.2240. 
 
Synthesis of O-Choi 36:  
Compound 35 was dissolved in THF: MeOH (1:1). Cool it to 0 degree and then add 1N LiOH to 
it and stir for 4-5 hrs. Reaction mixture was extracted using ether and then ether layer was 
washed with water. The water layer was acidified and then it was extracted using EtOAc (4 
times) using 50 ml of ethyl acetate. The ethyl acetate was washed with brine and concentrated on 
vacuum. Then it was dissolved in toluene and was heat to reflux for 18 hours for 
decarboxylation. Completion of reaction gives 3 products which can be further esterified using 
ethyl Iodide to give only two products which can be further purified using column 
chromatography.  []D
25 
= + 17.6 (CHCl3, c = 1.0) 
1
H NMR (400 MHz, CDCl3) δ 7.39–7.21 (m, 
5H), 4.58–4.38 (m, 2H), 4.19–4.07 (m, 2H), 4.05–3.98 (m, 1H), 3.97–3.70 (m, 3H), 3.22 (dd, 
1H, J = 9.3, 9.0 Hz),1.76–1.93 (m, 1H), 1.61 (s, 9 H), 1.44 (s, 5 H), 1.17 (t, 3H, J = 4.0 Hz); 13C 
NMR (100 MHz, CDCl3) d 172.0, 171.8, 154.2, 138.3, 128.1, 127.4, 80.1, 79.8, 76.0, 75.3, 70.6, 
70.2, 69.5, 69.4, 68.7, 59.0, 57.5, 35.2, 30.5, 29.4, 13.9 HRMS calcd for C22H31NO6+Na, 
428.2049; found, 428.2052. 
 
Procedure for synthesis of dipeptide 39: 
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BOP-Cl (0.16 g, 0.62 mmoles) and DIPEA (.16 g, 1.25 mmoles) were added to a stirred solution 
of Boc-D-Leucine (.1 g, .417 mmoles) in 10 ml of DCM: CH3CN (1:1) at 0 °C. After stirring for 
15 minutes amine (.14 g, .45 mmoles) were added. The reaction mixture was stirred for 15 hours 
at room temperature. The reaction was diluted using 100 ml of ethyl acetate and then washed 
using NaHCO3, water and then by 1N HCl and then finally using brine. The organic layer was 
dried over sodium sulphate and it was purified using column chromatography to get dipeptide as 
a oily material. []D
25 
= +14.5 (CHCl3, c = 0.8) 
1
H NMR (400 MHz, CDCl3, mixture of 
conformers) : 7.36-7.28 (m, 5H), 4.59-4.57 (m, 2H), 4.45-4.39 (m, 1H), 4.36-4.28 (m, 2H), 4.23-
4.15 (m, 2H), 3.80-3.74 (m, 2H), 3.60-3.55 (m, 1H), 3.48-3.43 (m, 1H), 2.29 (t, 2H, J = 8.0 Hz), 
1.90-1.77 (m, 2H), 1.40 (s, 9H), 1.26 (t, 3H, J = 7.3 Hz), 1.02-0.96 (m, 6H) 
13
C NMR (100 MHz, 
CDCl3): 172.3, 171.1, 155.5, 137.8, 128.3, 127.7, 127.5, 127.4, 79.6, 73.1, 70.7, 70.6, 64.2, 61.1, 
56.4, 53.8, 49.6, 43.3, 42.0, 32.4, 28.1, 24.5, 23.3, 21.7, 13.9 HRMS calcd for C28H42N2O7+H, 
519.3070; found, 519.3067. 
 
Procedure for synthesis of tripeptide 42: 
Boc protected dipeptide was stirred in DCM at 0 °C and then TFA was added to the reaction 
mixture. Reaction was monitored using TLC. The reaction mixture concentrated on 
rotavaporator and can be dried on high vacuum. EDCI (66.9 mg, 0.34 moles), HOBt (42.9 mg, 
.318 mmoles) and DIPEA (123 mg, .954 mmoles) were added subsequently to a stirred solution 
of (R)-β-[4-(benzyloxy) phenyl lactic acid (100 mg, .318 mmoles) and dipeptide (159.7 mg, .381 
mmoles) were added in 10 ml of DCM at 0 °C. The reaction mixture was stirred for overnight at 
room temperature.  The reaction mixture was diluted using 100 ml of ethyl acetate and then it 
was washed using saturated NaHCO3, water, 1N HCl, and brine subsequently. The organic phase 
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was dried on sodium sulphate and it was purified using column chromatography to give pure 
tripeptide. []D
25 
= +7.5 (CHCl3, c = 0.75) 
1
H NMR (400 MHz, CDCl3, mixture of conformers) : 
δ 7.44-7.28 (m, 10H), 6.91 (d, 2H, J = 8.8 Hz), 6.91 (d, 2H, J = 8.4 Hz), 6.79 (d, 1H, J = 10.9 
Hz), 5.0 (s, 2H),  4.55 (q, 2H, J = 9.2, 20.8 Hz),  4.44 (t, 1H, J = 9.2 Hz), 4.36-4.29 (m, 1H), 
4.28-4.22 (m, 2H), 4.20-4.18 (m, 1H), 4.12 (q, 2H, J = 6.9, 14.0 Hz), 3.83-3.78 (m, 2H), 3.63-
3.43 (m, 3H), 3.16-3.08 (m, 1H), 2.84-2.76 (m, 1H), 2.52-2.46 (m, 1H), 2.34-2.25 (m, 2H), 2.04 
(s,3H), 1.56 (s, 9H), 1.29-1.23 (m, 4H),  1.02-0.96 (m, 6H) 
13
C NMR (100 MHz, CDCl3): 172.8, 
171.9, 171.5, 171.1, 157.8, 137.8, 136.9, 130.5, 130.4, 128.8, 128.5, 128.5, 128.3, 127.9, 127.8, 
127.5, 127.4, 114.9, 73.15, 72.6, 70.9, 70.7, 69.9, 64.3, 62.3, 61.3, 57.8, 56.5, 54.0, 51.2, 48.2, 
43.3, 41.7, 41.1, 40.4, 39.9, 33.3, 32.5, 28.7, 28.1, 24.7, 23.4, 22.8, 21.9, 21.7, 14.0  
HRMS calcd for C41H50N2O7+H, 715.8340; found, 715.8342. 
 
Experiment to synthesize tertapeptide 44:   
A solution of 42 (145 mg, 0.35 mmol) in THF (7.5 mL) was treated with 0.2 N LiOH (7.5 mL) at 
room temperature. The reaction mixture was stirred overnight and quenched with 1 N HCl. The 
mixture was extracted with EtOAc, washed with brine, and dried with Na2SO4. After evaporation 
of the solvent, the crude acid  was dried under vacuum for 2 h. To a solution of compound 23a 
(170 mg, 0.29 mmol) in DCM (8 mL) was added TFA (2 mL) at 0 °C. The reaction mixture was 
warmed up to room temperature and stirred for 2 h before the solvent was evaporated under 
reduced pressure. The TFA salt 24 was dried under vacuum for 2 h.  HATU (135 mg, 0.35 
mmol) and DIEA (0.15 mL, 0.87 mmol) were added subsequently to a stirred solution of acid 27 
and TFA salt 24 in DMF (2.5 mL) at 0 ⁰C. After stirred for 24 h at room temperature, the 
reaction was quenched with saturated NaHCO3, extracted with EtOAc (20 mL x 5), washed with 
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brine, dried over Na2SO4, and concentrated. The residue was purified by column 
chromatography (2% MeOH in chloroform) to get pure tetrapeptide (192 mg, 77%), []D
25 
= -
18.5 (CHCl3, c = 0.8) 
1
H NMR (400 MHz, CDCl3, mixture of conformers) 8.54 (d, 1H, J = 8.4 
Hz), 7.45–7.09 (m, 12H), 6.89 (d, 2H, J = 8.2 Hz), 5.0 (s, 2H), 4.63–4.35 (m, 6H), 4.30–4.13 (m, 
1H), 3.98 (br, 1H), 3.90-3.88 (m, 1H), 4.03–3.82 (m, 2H), 3.69 (s, 3H), 3.57–3.30 (m, 2H), 3.13–
3.02 (m, 2H), 2.90-2.82 (m, 1H), 2.40–2.12 (m, 2H), 1.82-1.75 (m, 1H), 1.61-1.23 (m, 6H), .93-
.83 (m, 6H); 
13
C NMR (100 MHz, CDCl3) δ 175.6, 174.4, 173.9, 172.9, 172.2, 172.0, 171.8, 
159.3, 159.2, 157.9, 157.6, 137.6, 137.4, 137.0, 136.9, 130.7, 130.6, 129.2, 128.5, 128.4, 128.1, 
127.9, 127.8, 127.6, 127.5, 114.9, 114.6, 76.0, 75.1, 72.8, 72.6, 71.3, 70.3, 69.9, 69.8, 68.7, 65.2, 
61.8, 58.2, 55.1, 52.3, 52.1, 51.6, 51.1, 49.9, 48.2, 42.2, 40.2, 39.5, 37.0, 31.5, 28.7, 25.4, 25.3, 
24.5, 24.3, 23.5, 21.3, 21; HRMS calcd for C44H57N7O11 + H, 860.4194; found, 860.4199. 
 
Synthesis of compound 45 by reduction using LiBH4: 
Freshly prepared 0.2 N LiBH4 solution in THF (1.0 mL, 0.20 mmol) was added via syringe to a 
N2 protected solution of tetrapeptide 44 (120 mg, 0.13 mmol) in dry THF (5 mL) at 0 °C. The 
resulting solution was stirred at 0 °C for 30 min, another 1.0 mL 0.2 N LiBH4 solution was 
added, and continued stirring at 0 °C for 30 min. The reaction was quenched with water followed 
by saturated ammonium chloride.  The resulting mixture was extracted with MeOH: CHCl3 
(1:10). The extracted solution was dried over Na2SO4, concentrated, and the crude product was 
purified by chromatography (5% MeOH in CHCl3) to give pure material (84.4 mg, 74% yield).  
1
H NMR (400 MHz, CDCl3, mixture of conformers) δ 8.63 (br, 1H), 8.07 (d, 1H, J = 9.1 Hz), 
7.74 (br, 2H), 7.39–7.25 (m, 10H), 7.18 (br, 1H), 7.15 (d, 2H, J = 6.4 Hz), 6.89 (d, 2H, J = 8.2 
Hz), 4.99 (m, 2H), 4.74–4.51 (m, 2H), 4.51–4.41 (m, 1H), 4.41–4.25 (m, 3H), 4.25–4.14 (m, 
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1H), 4.14–4.00 (m, 2H), 3.99–3.79 (m, 1H), 3.77–3.59 (m, 2H), 3.58–3.38 (m, 2H), 3.36–2.99 
(m, 3H), 2.83 (br, 2H), 2.71–2.46 (m, 1H), 2.42–1.97 (m, 3H), 1.82–1.11 (m, 7H), 1.00–1.73 
(complex, 6H, J = 5.5, 5.0 Hz);  
13
C NMR (100 MHz, CDCl3) δ 173.1, 159.4, 157.9, 136.9, 
136.8, 130.6, 128.7, 128.6, 128.3, 127.9, 127.5, 115.0, 76.1, 72.9, 70.6, 69.9, 69.8, 68.9, 64.9, 
61.7, 58.2, 51.9, 50.4, 40.8, 39.9, 37.4, 29.7, 27.9, 25.7, 24.5, 24.2, 23.4, 21.0; HRMS calcd for 
C43H57N7O10 + H, 832.4245; found, 832.4252. 
 
Synthesis of final aeruginosin analog 46: 
Compound tertapeptide 45 (30 mg, 0.036 mmol) dissolved in 5.0 mL methanol containing 0.2 
mL TFA was treated with Pd/C (10.0 mg). The suspension was sequentially evacuated and 
purged with H2, stirred under  atmosphere of H2 (1 atm) for 24 h. The reaction mixture was 
filtered through a pad of Celite, which was washed with several portion of methanol. The 
combined solution was concentrated and dried under vacuum to afford aeruginosin 298-A analog  
as colorless amorphous solid (22 mg, 95%), [α]D + 37.6 (c 0.3, MeOH). 1H NMR (300 MHz, 
CD3OD, mixture of conformers) d 8.03 (d, 0.6H, J = 8.5 Hz), 7.96–7.79 (br, 1H), 7.06 (d, 2H, J 
= 8.0 Hz), 6.69 (d, 2H, J = 8.2 Hz), 4.73–4.57 (m, 1H), 4.57–4.39 (m, 1H), 4.39–4.11 (m, 3H), 
4.10–3.98 (m, 2H), 3.96 (s, 1H), 3.92–3.82 (m, 1H), 3.82–3.72 (m, 1H), 3.72–3.46 (m, 1H), 3.38 
(d, 2.4H, J = 5.2 Hz), 3.27–3.08 (m, 2H), 3.03 (t,1.6H, J = 9.6 Hz), 2.90–2.63 (m, 2H), 2.54 
(dd,1H, J = 8.5, 4.4 Hz), 2.43–2.05 (m, 2H),1.79–1.41 (m, 6H), 1.41–1.22 (m, 1H), 0.90 (d, 3H, 
J = 6.0 Hz), 0.85 (d, 3H, J = 6.3 Hz); 
13
C NMR (75 MHz, CD3OD, major conformer) d 174.9, 
173.8, 162.3, 157.5, 155.5, 132.2, 131.0, 130.64, 127.8, 115.7, 114.67, 75.9, 70.2, 63.7, 63.0, 
62.3, 61.8, 60.4, 51.2, 41.5, 37.2, 37.0, 29.7, 28.2, 27.8, 25.1, 24.7, 22.7,20.6; HRMS calcd for 
C29H46N6O8+H, 607.3455; found, 607.3452. 
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Synthesis of 56: 
To a round bottom flask compound 55 (10 g, 35.34 mmol) was dissolved in 50 ml of toluene. 
Dibutyl tin oxide (9.67g, 38.88 mmol) was added to the reaction mixture. The reaction mixture 
was heated to reflux conditions for 3-4 hrs and then toluene was evaporated using rotavaporator.  
P-toluene sulfonyl chloride (7.41g, 38.88 mmol) and toluene (50 ml) was added to the reaction 
mixture and it was heated at 60 °C for another 3-4 hrs. The reaction was monitored using NMR. 
For work up the toluene was removed using rotavaporator and reaction mixture was quenched 
using 100 ml of saturated sodium bicarbonate solution. The reaction mixture was also diluted 
using ethyl acetate (200 ml). Then it was filtered using celite bed and then extracted using 
EtOAc: water. The water layer was again extracted using (2 x 100 ml) of EtOAc. The organic 
layer was combined and then it was washed with brine and dried over sodium sulphate. The 
organic layer was concentrated on rotavaporator. The compound was purified using EtOAc: 
Hexane (1:4) to get (14.7 g, 95%) compound as a white solid. 
1
H NMR (400 MHz, CDCl3) δ  
7.84 (d, 2H, J = 8.4 Hz), 7.46–7.44 (m, 2H), 7.36-7.34 (m, 5H), 5.47 (s, 1H), 4.83 (d, 1H, J = 3.7 
Hz), 4.44-4.38 (m, 1H), 4.27-4.23 (m, 1H), 4.15-4.10 (m, 1H), 3.83-3.87 (m, 1H), 3.70 (t, 1H, J 
= 10.2 Hz), 3.45 (t, 1H, J = 9.5 Hz), 3.39-3.34 (m, 2H), 3.33 (s, 3H), 2.45 (s, 3H), 1.25 (t, 1H, J 
= 6.9 Hz) ; 
13
C NMR (100 MHz, CDCl3) δ 145.1, 136.9, 133.1, 129.7, 129.1, 128.2, 128.0, 
126.2, 101.8, 98.1, 80.9, 79.4, 68.6, 68.2, 61.9, 55.6, 21.6. 
 
Synthesis of 57:  
Compound 56 (10.0 g, 22.91 mmol) was dissolved in dry methanol (50 ml) and then it was 
heated at 45 ⁰C for 15 min. Sodium methoxide (7.42 g, 137.46 mmol) was added to it and then 
the reaction mixture was heated to reflux for 45 minutes. The reaction was monitored by NMR. 
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For work up the methanol was removed using rotavaporator and then reaction mixture was 
diluted using EtOAc and water. The organic layer was extracted and water layer was again 
extracted using ethyl acetate (2 times). The organic layer was combined and a brine wash was 
given. The compound was dried on sodium sulphate and it was concentrated on rotavaporator. 
The compound was purified using column chromatography using EtOAc: Hexane (1:6) to get 
(5.57 g, 92%) compound as a white solid. 
1
H NMR (400 MHz, CDCl3) δ 7.51-7.48 (m, 2H), 
7.40–7.36 (m, 3H), 5.58 (s, 1H), 4.90 (s, 1H),  4.29-4.23 (m, 1H), 3.73-3.63 (m, 3H), 3.47 (s, 
3H), 3.17 (d, 1H, J = 3.7 Hz) ; 
13
C NMR (100 MHz, CDCl3) δ 137.0, 129.2, 128.3, 126.1, 102.3, 
96.8, 74.8, 69.8, 69.4, 61.6, 55.7, 53.8, 50.5. 
 
Experimental procedure for epoxide ring opening 58: 
To a stirred solution of 57 (2.0 g, 6.79 mmoles) in THF (20 ml) at 0 °C the LAH (0.52 g, 13.58 
mmoles) was added slowly. The reaction mixture was stirred at room temperature for 30 min. 
The reaction was monitored by TLC. For work up first the unreacted LAH was quenched using 
saturated sodium sulphate solution and then the RM was filtered using celite. The reaction 
mixture was diluted with EtOAc and was extracted using water. The organic layer was extracted 
and the water layer was again extracted using ethyl acetate. The organic layer was combined and 
was washed using brine. The organic layer was dried on sodium sulphate and was concentrated 
using rotavaporator. The compound was purified on column using EtOAc: Hexane (1:4) to get 
compound 6 as white solid in (1.91 g, 95%) yield 
1
H NMR (400 MHz, CDCl3) δ 7.49-7.47 (m, 
2H), 7.39–7.34 (m, 3H), 5.57 (s, 1H), 4.50 (s, 1H), 4.27-4.22 (m, 1H), 3.99- 3.91 (m, 2H), 3.87-
3.83 (m, 2H), 3.40 (s, 3H), 3.65 (d, 1H, J = 12.5 Hz), 3.40-3.34 (m, 1H), 2.61-2.59 (m, 2H), 
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2.07-2.92 (m, 2H);  
13
C NMR (100 MHz, CDCl3) δ 137.7, 129.0, 128.2, 126.1, 102.0, 100.6, 
73.8, 69.2, 68.2, 64.8, 54.7, 31.8,  74.5, 72.8, 69.3, 67.3, 35.9. 
 
Experimental procedure for 59 by benzylation reaction:  Compound 58 (5.0 g, 18.77 
mmoles) was dissolved in DMF (30 ml). NaH (0.7 g, 28.16 mmoles) was added to the reaction 
mixture at 0 °C. Reaction mixture was stirred for 45 min at 0 °C. Benzyl bromide (2.45 ml, 20.64 
mmoles) was added and then the reaction mixture was stirred at room temperature for 2 hrs. The 
reaction was monitored by TLC. For work up first rexn mixture was quenched using saturated 
ammonium chloride and then it was extracted using ether and water. The organic phase was 
extracted and water layer was again extracted using ether (2 times). The organic layer was 
combined and was washed with brine.  The organic phase was dried on sodium sulphate and was 
concentrated on rotavapor. Compoud was purified on column chromatography using EtOAc: 
Hexane (1:7) to give a oily material (6.02 g, 90%). 
1
H NMR (400 MHz, CDCl3) δ 7.57-7.50 (m, 
2H), 7.42-7.37 (m, 8H), 5.58 (s, 1H), 4.72-4.62 (m, 2H), 4.31-4.27 (m, 1H), 4.09-4.02 (m, 1H), 
3.89-3.84 (m, 2H), 3.74-3.70 (m, 1H), 3.51-3.48 (m, 1H), 3.42 (s, 3H), 2.31-2.25 (m, 1H), 2.07-
1.97 (m, 1H); 
13
C NMR (100 MHz, CDCl3) δ 137.7, 137.5, 129.1, 128.9, 128.3, 128.2, 128.0, 
127.7, 127.6, 126.0, 101.9, 98.7, 74.9, 74.0, 71.1, 69.2, 69.1, 64.9, 54.6, 29.1. 
 
Experimental Procedure for 60 by mesylation reaction: Compound 59 (3.0 g, 11.18 mmoles) 
was dissolved in 30 ml of dry dichloromethane. The reaction mixture was cooled at 0 °C. 
Triethyl amine (4.83 ml, 33.54 mmoles) was added to the reaction mixture. After 10 min methyl 
sulfonyl chloride (3.84 ml, 33.54 mmoles) was added to the reaction mixture. The reaction 
mixture was stirred for overnight at room temperature. For workup the reaction mixture was 
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diluted using DCM and was extracted using water. The water phase was again extracted using 
DCM (2 x 100 ml). The organic phase was combined and dried over sodium sulphate. The crude 
was purified over column chromatography using EtOAc: Hexane (9:1) to give pure compound as 
a gummy material (3.81 g, 95%). 
1
H NMR (400 MHz, CDCl3) δ 7.37-7.31 (m, 5H), 4.91-4.85 
(m, 1H), 4.64-4.55 (m, 4H), 4.40-4.36 (m, 1H), 3.96-3.92 (m, 1H), 3.61 (s, 1H), 3.38 (s, 3H), 
3.04 (s, 6H), 2.55-2.49 (m, 1H), 2.1-2.04 (m, 1H); 
13C NMR (100 MHz, CDCl3) δ 137.4, 128.5, 
127.9, 127.7, 98.2, 74.0, 71.4, 71.1, 68.2, 55.2, 38.5, 37.7, 30.4  
 
Experemental procedure for 61 by substitution of primary Mesylate by bromo: 
Dimesylate compound 60 (2.0 g, 4.71 mmoles) was dissolved in 10 ml of DMSO. Sodium 
bromide (2.90 g, 28.26 mmoles) was added to the reaction mixture. Then TBAB (0.18 g, 1.18 
mmoles) was added and the reaction mixture was heated at 60 °C for overnight. Reaction was 
monitored by TLC and NMR. The reaction was diluted with ethyl acetate and was washed with 
water. The water layer was again washed with ethyl acetate and the combined organic layer was 
washed with brine and was dried over sodium sulphate. After concentrating at rotavaporator the 
compound was purified over column chromatography EtOAc: Hexane (8:1) to give a gummy 
material of (1.61 g, 84%). 
1
H NMR (400 MHz, CDCl3) δ 7.38-7.28 (m, 5H), 4.86-4.79 (m, 1H), 
4.69 (s, 1H), 4.59 (s, 2H), 3.93-3.88 (m, 1H), 3.71-3.68 (m, 1H), 3.61-3.60 (m, 1H), 3.53-3.49 
(m, 1H), 3.43 (s, 3H), 3.04 (s, 3H), 2.48-2.43 (m, 1H), 2.10-2.03 (m, 1H) 
13
C NMR (100 MHz, 
CDCl3) δ 137.5, 128.5, 127.9, 127.7, 98.2, 74.5, 74.2, 71.1, 69.6, 55.1, 38.7, 32.0, 30.7  
 
Synthesis of Bicyclic compound 62:  
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Monoboc diethyl malonate compound 33 (0.2 g, 0.726 mmoles) was dissolved in dry toluene (10 
ml) under nitrogen was treated using NaH (20.93 mg, 0.872 mmoles). Reaction mixture was 
stirred at RT for 30 minutes before 61 (140 mg, .363 mmol) was added to it. The reaction 
mixture was stirred for 1 hour at room temp and then TBAI (25 mg) was added and the reaction 
mixture was refluxed for 17 hours. For work up the RM was quenched by dil. HCl and diluted 
with Ethyl acetate. The organic layer was separated and the aqueous layer. The organic layer was 
washed with brine and was dried over sodium sulphate. The compound was purified using 
column chromatography using EtOAc: Hexane (6:1) to give an oily compound (0.117 g, 72%).  
1
H NMR (400 MHz, CDCl3) δ 7.36-7.32 (m, 4H), 7.30-7.26 (m, 1H), 4.91-4.85 (m, 1H), 4.55 (s, 
2H), 4.49 (dd, 1H, J = 11.7 Hz, 1.83 Hz),  4.37-4.33 (m, 1H), 4.07 (d, 1H, J = 12.4 Hz), 3.69 (s, 
1H), 3.59-3.55 (m, 1H),  3.407(d, 1H, J = 11.4 Hz), 3.04 (s, 3H), 3.03 (s, 3H), 2.76-2.70 (m, 1H), 
1.87-1.80 (m, 1H)  
13
C NMR (100 MHz, CDCl3) δ 137.6, 128.4, 127.7, 127.6, 76.6, 71.9, 71.7, 
70.2, 68.9, 68.2, 38.3, 37.6, 34.4.  
 
Synthesis of O-Choi 36:  
Compound 62 (50 mg, 0.10 mmol) was dissolved in THF: MeOH (1:1) 5 ml. Cool it to 0 ⁰ C and 
then add 1N LiOH (5 mg, .20 mmol) to it and stir for 4-5 hrs. Reaction mixture was extracted 
using ether and then ether layer was washed with water. The water layer was acidified and then it 
was extracted using EtOAc (4 times) using 50 ml of ethyl acetate. The ethyl acetate was washed 
with brine and concentrated on vacuum. Then it was dissolved in toluene and was heat to reflux 
for 18 hours for decarboxylation. Completion of reaction gives 3 products which can be further 
esterified using ethyl Iodide to give only two products which can be further purified using 
column chromatography to give a mixture of compounds. Final compound was purified to get a 
 - 138 - 
 
oily compound.  
1
H NMR (400 MHz, CDCl3) δ 7.35-7.28 (m, 5H), 4.6 (s, 2H), 4.45-4.42 (m, 
1H), 4.26 (s, 1H), 3.69 (s, 1H), 3.44 (s, 1H), 3.38 (s, 3H), 2.29-2.24 (m, 2H), 1.95 (d, 2H, J = 
15.7 Hz), 1.42 (s, 9H), 1.24 (s, 2H); 
13
C NMR (100 MHz, CDCl3) δ 174.5, 136.2, 133.4, 128.5, 
128.3, 128.0, 97.6, 81.2, 71.5, 69.4, 61.2, 55.5, 55.2, 35.8, 29.6, 28.1, 21.4 
 
3.5. References 
 
1. Srivastava, S.; Goswami, L. N.; Dikshit, D. K. Med. Res. Rev. 2005, 25, 66-92. 
2.  Kontogiorgis, C. A.; Hadjipavlou-Litina, D. Curr. Med. Chem. 2003, 10, 525-577.  
3.  Lettino, M.; Toschi, V. Curr. Med. Chem. Cardiovasc. Hematol. Agents 2004, 2, 267-
275.  
4.  Steinmetzer, T.; Stu rzebecher, J. Curr. Med. Chem. 2004, 11, 2297-2321.  
5. Gustafsson, D.; Bylund, R.; Antonsson, T.; Nilsson, I.; Nystrom, J. E.; Eriksson, U.; 
Bredberg, U.; Teger-Nilsson, A. C. Nat. Rev. Drug Discov. 2004, 3, 649-659. 
6. Shin, H. J.; Matsuda, H.; Murakami, M.; Yamaguchi, K. J. Org. Chem. 1997, 62, 1810-
1813. 
7.  Matsuda, H.; Okino, T.; Murakami, M.; Yamaguchi, K. Tetrahedron 1996, 52, 14501-
14506. 
8.  Murakami, M.; Ishida, K.; Okino, T.; Okita, Y.; Matsuda, H.; Yamaguchi, K. 
Tetrahedron Lett. 1995, 36, 2785-2788. 
9.  Murakami, M.; Okita, Y.; Matsuda, H.; Okino, T.; Yamaguchi, K. Tetrahedron Lett. 
1994, 35, 3129-3132. 
 - 139 - 
 
10.  Ishida, K.; Okita, Y.; Matsuda, H.; Okino, T.; Murakami, M. Tetrahedron 1999, 55, 
10971-10988. 
11.  Kodani, S.; Ishida, K.; Murakami, M. J. Nat. Prod. 1998, 61, 1046-1048. 
12.  Ploutno, A.; Shoshan, M.; Carmeli, S. J. Nat. Prod. 2002, 65, 973-978. 
13.  Carroll, A. R.; Buchanan, M. S.; Edser, A.; Hyde, E.; Simpson, M.; Quinn, R. J. J. Nat. 
Prod. 2004, 67, 1291-1294. 
14.  Carroll, A. R.; Pierens, G. K.; Fechner, G.; de Almeida Leone, P.; Ngo, A.; Simpson, M.; 
Hyde, E.; Hooper, J. N. A.; Bostrom, S. L.; Musil, D.; Quinn, R. J. J. Am. Chem. 
Soc. 2002, 124, 13340-13341. 
15. Hanessian, S.; Del Valle, J. R.; Xue, Y.; Blomberg, N. J. Am. Chem. Soc. 2006, 128, 
10491-10495.  
16. Hanessian, S.; Del Valle, J. R.; Xue, Y.; Blomberg, N. J. Am. Chem. Soc. 2006, 128, 
10491-10495.  
17. Steiner, J. L. R.; Murakami, M.; Tulinsky, A. J. Am. Chem. Soc. 1998, 120, 597-598. 
18.  Wipf, P.; Methot, J. L. Org. Lett. 2000, 2, 4213-4216. 
19.  Valls, N.; Lopez-Canet, M.; Vallribera, M.; Bonjoch, J. J. Am. Chem. Soc. 2000, 122, 
11248-11249 
20. Ohshima, T.; Gnanadesikan, V.; Shibuguchi, T.; Fukuta, Y.; Nemoto, T.; Shibasaki, 
M. J. Am. Chem. Soc. 2003, 125, 11206-11207. 
21. Nie, X.; Wang, G. J. Org. Chem. 2005, 70, 8687-8692. 
22. Bonjoch, J.; Catena, J.; Isabal, E.; Lopez-Canet, M.; Valls, N. Tetrahedron: 
Asymmetry 1996, 7, 1899–1902. 
23. Toyoka, N.; Okumura, M.; Himiyama, T.; Nakazawa, A.; Nemoto, H. Synlett 2003, 
 - 140 - 
 
55-58. 
24. Doi, T.; Hoshina, Y.; Yamada, Y.; Takahashi, T. J. Comb. Chem. 2006, 8, 571-582 
25. Hanessian, S.; Ersmark, K.; Wang, X.; Valle, J. R. D.; Blomberg, N.; Xue, Y.; 
Fjellstrom, O. Bioorg. Med. Chem. Lett. 2007, 3480-3485. 
26. Nie, X.; Wang, G. Tetrahedron, 2008, 64, 5784-5793 
27. Ella-Menye, J.-R.; Nie, X; Wang, G. Carbohyd. Res. 2008, 343, 1743-1753. 
28. Wang, G.; Ella-Menye, J. R.; St. Martin, M.; Yang, H.; Williams, K.  Org.  Lett. 2008, 
10, 4203-4206. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 141 - 
 
Chapter 4: Self-assembly of D-glucosamine derivatives 
 
4.1. Abstract 
 
Carbohydrate-based low molecular weight gelators are an interesting class of molecules with 
many potential applications. Previously, we have found that certain esters and carbamates of 4,6-
O-benzylidene-α-D-methyl-glucopyranoside are low molecular weight gelators for a variety of 
solvents, including water. In order to obtain effective and robust sugar-based organogelators and 
understand the structure and gelation relationship, we extended our studies using 4,6-O-
benzylidene-α-D-methyl-2-deoxy-2-amino-glucopyranoside as well as 4,6-O-p-methoxy-
benzylidene-α-D-methyl-2-deoxy-2-amino-glucopyranoside the headgroup and a series of 
amides and ureas were prepared from the protected D-glucosamine and the corresponding 
isocyanates or acid chlorides, in good yields. The self-assembling properties of these compounds 
were studied in several solvents, including water and aqueous solutions. Comparing to the ester 
and carbamate derivatives previously prepared from D-glucose, the amides and urea derivatives 
afforded more robust gels at lower concentrations typically. Most of these compounds were 
found to be efficient low molecular weight hydrogelators (LMHGs) for aqueous solutions at 
concentrations lower than 0.5 wt %. The preparation and characterization of these compounds 
are reported here. 
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4.2. Intoduction: 
This chapter is adapted from paper: Goyal, N.; Cheuk, S.; Wang, G. Tetrahedron. 2010, 
66, 5962-5971. 
Low molecular weight organogelators and hydrogelators are an interesting new class of 
compounds that have drawn great attention over the past few decades.  LMWGs are small 
molecules that can self-assemble and form 3-dimensional network which allows the 
immobilization of solvents. 
1-6 
 Based on the solvent system they are divided into two categories. 
Low molecular weight hydro gelator (LMHGs) and low molecular weight organo gelator 
(LMOGs). The resulting gels are usually called supramolecular gels or physical gels to 
differentiate from polymer gels. Formation of a compound to form gel depends on many factors 
including π-π interaction, hydrophobic interaction and Van der Waal force attractions. 7-9 
 
The preparation of organogels or hydrogels using LMOGs is pretty straightforward. In general, a 
certain amount of a LMOG is placed in a vial containing the testing solvent. Then it is heated 
above the sol-gel temperature (Tgel) to dissolve the compound. Gels are formed when the 
solution is cooled below the Tgel.
10-11
 The resulting solidification or increase of the viscosity of 
the solvent(s) is caused by the formation of a fibrous network, which is created by the 
noncovalent inter and intramolecular forces. The minimum gelation concentration (MGC) is 
obtained through serial dilution and heating until a stable gel is no longer formed. 
 
LMWGs have gained considerable amount of interest due to their implications in supramolecular 
chemistry, and their potential applications as advanced soft materials in biomedical and materials 
research.  For instance, organogelators have been explored as optical electronic devices and have 
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found applications in semiconductors and photovoltaic cells.
 
They have also been explored as 
sequestering agent for oil and chemical spill cleanup.
 
 As for hydrogels, they are also being 
explored for biomedical applications, such as matrix for cell growth, enzyme assays, drug 
delivery, and tissue engineering.
 
 The supramolecular gels are reversible and can be engineered 
to be stimuli-responsive.
12-15
  
 
Because the main driving force for supramolecular hydrogel is hydrophobic interactions, the 
structure of hydrogelators mainly consists of contrasting polar and nonpolar regions, in which 
polar groups mainly include amino acids or sugars,
16-25 
while the nonpolar regions mainly 
include long alkyl chains or aromatic rings.
26-28
 Figure 3.1 shows the structures of several 
compounds (1-5) that can form gels in water. Compounds 3 and 4 are ambidextrous (they are 
able to gelate both water and organic solvents).
29   
 
Compound 5 has a unique bisoxalyl group with a phenyl side chain. It forms gels in organic 
solvents and its trans isomer can also form a gel in water. 
30 
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Figure 4.1. Structures of some hydrogelators.
28-30 
 
Many studies have been directed towards designing hydrogelators.  Most of them are discovered 
serendipitously and improved analogs are found by modifying the parent structure.  To design a 
hydrogel, there must be a balance between the polar and nonpolar groups. Furhop and coworkers 
synthesized a library of LMHGs by introducing the alkyl amine chain into several aldonic 
acids.
29 
Hamilton‟s group has shown that ureas with short alkyl chains act as hydrogelators, 
while those with larger chains act as organogelators.
21 
Urea derivatives are placed in a separate 
category, because they exhibit strong hydrogen bonding, even in water.
21
  Suzuki and coworkers 
synthesized many compounds with positively charged nitrogen atoms in the structure and tested 
for their gelation activity, many of them form gel in pure water.
24
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Carbohydrates are naturally abundant renewable resources, which are useful in the preparation of 
chiral intermediates and advanced materials.
31
 Carbohydrate-based low-molecular-weight 
gelators have been reported by several research groups.
32-50
 The dense chiral hydroxyl groups 
present in carbohydrates can be regioselectively functionalized to form interesting self- 
assembled supramolecular structures including LMWGs. The modification of carbohydrate 
derivatives to obtain effective low molecular weight hydrogelators and organogelators is of great 
interest to us.
35-40
 Previously, we had found that various derivatives of 4,6-O-benzylidene-
methyl-α-D-glucopyranose exhibited good gelation properties.47-49  
 
4.3. Results and Discussion 
 
In order to understand the structure requirements for the glucosamine derivatives to form stable 
and efficient hydro/organogels at lower gelation concentrations, we synthesized and 
characterized two new series of compounds, the amides 10 and ureas 11. The amides and ureas 
can be synthesized by derivatizing the amino group in compound 9, which is obtained in four 
steps from N-acetyl-glucosamine 6 as shown in Scheme 4.1.
51  
First, N-Acetyl-D-glucosamine 6 
was methylated in the presence of acidic resin, giving a mixture of anomers with the  anomer as 
the major product. The resulting intermediate 7 was converted to the actamide 8 using 
benzylidene dimethyl acetal. The major isomer was separated via recrystallization in ethanol, 
followed by hydrolysis using KOH afforded the head group 9.   
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Scheme 4.1. Synthesis of the amides and ureas from N -acetyl-D-glucosamine. 
 
Amide derivatives  
 
The amides 10 were prepared by the method shown in the last step of Scheme 4.1. The amino 
group from 9 was typically functionalized with an acid chloride in the presence of pyridine or 
triethylamine to give the amide in good yield. The structures of the amides synthesized and their 
gelation properties in several solvents are summarized in Table 4.1. These functional groups 
were chosen partially based on the structural information obtained from the ester derivatives. We 
expected that the additional hydrogen bonding unit would allow a wider range of the 
hydrophobic tail R groups to afford gels because of the potential for enhanced hydrogen bonding 
interactions. Therefore, a broader series of acyl groups were selected here. These include the 
straight chain analogs with 5-8 carbons 12-15, compounds with terminal acetylene functional 
groups 16-19, compounds with alkene groups 20 and 21, compounds with halogens 22 and 23, 
and aromatic derivatives 24 and 25. After their preparation, these compounds were screened for 
their gelation properties (Table 4.1).  From Table 4.1, most of the compounds were able to form 
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stable gels in 33% aqueous solutions of DMSO or ethanol at concentrations lower than 5.0 
mg/mL. Several compounds also formed gels in ethanol and fewer formed gels in hexane or 
water. These results are different than the ones obtained from the glucose ester derivatives, in 
which a majority of the alkynyl 2-esters were able to gelate both hexane and water. The presence 
of the amide bonds, especially the NH bond, is important in the formation of the self-assembled 
networks. Similar to the glucose ester derivatives, the alkyl chain plays an important role in 
gelation. We found that amides containing chains that were 6-8 carbons in length formed very 
stable gels at relatively low concentrations. Typically, the amides formed robust and translucent 
gels. For example, the hexylamide formed gels that were stable for several months in closed 
containers. The gels can be reformed repeatedly by reheating and sonication of the solution 
phases. The ability of these various amides to form stable gels in aqueous mixtures might arise 
from a hydrogen bonding interaction of the amide bonds with the solvents. Ethanol and DMSO 
can aid in self-assembly by solvating the hydrophobic regions of the LMOGs, disrupting the 
crystalline packing, and thus forming gels. In addition, the compounds and the solvents have a 
certain „matched‟ hydrophobicity and hydrophilicity, in that ethanol and DMSO can help to 
stabilize the gels by interacting with both regions in the amides. 
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Table 4.1. Library of amide derivatives of 9 and their corresponding minimum gelation 
concentrations (MGCs) in mg/mL. 
R =
13
24
14
O
O
HO
OCH3
NH
OPh
R
O
15
Cl
2012
21
25
Br
22
23
17
18
19
16
5
 
G*unstable gel; G, gel at room temperature; the numbers in the table are the minimum gelation concentrations in 
mg/mL; I, insoluble; C, crystallization; S, soluble at ~20 mg/mL, P, precipitation.  
Com
pd 
 
Structure Hexane Water EtOH 
Water:DMSO 
(2:1) 
Water:EtOH 
(2:1) 
THF Isoprop. DCM 
12 
 
I I G 5.0 G 4.0 4.0 S S S 
13 
 
C C S G 1.3 G 1.3 S S S 
14 
 
G 1.7 I S G 1.0 G 2.0 S S S 
15  G* 2.0 I S G 1.2 G 1.6 S S S 
16 
 
C I 
G 
10.0 
G 10.0 G 5.0 
S 
 
G 20 S 
17  
 
C I S G 5.0 G 2.2 S G10 S 
18  
 
 
C C S G 2.0 G 0.7 C C S 
19 
 
G 4.0 I S G 1.7 G 1.2 P C S 
20 
 
C I S C G 10 S S S 
21 
 
C I G 10 G 5 G 2.5 P S S 
22 Cl 
C I G 10 G 6.6 G 5.0 S S S 
23 
Br
 
I I G 20 G 5 G 20 S S S 
24 
 
I G 2 S G 5.0 G 3.3 C S S 
25 
 
 
 
C I S C G 10 C S S 
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For the aliphatic derivatives, the amides with saturated alkyl chains (12-15) are quite versatile 
and efficient LMOGs that are able to efficiently gelate a range of solvents, including hexane and 
aqueous mixtures of ethanol and DMSO, but not pure water. The compounds with 6-8 carbon 
chains (13-15) are the most efficient gelators. The alkynyl derivatives exhibit a similar trend, in 
that a longer chain is somewhat more favorable than a shorter chain; compounds 17-19 are good 
gelators for aqueous solutions of DMSO and EtOH. The hexynyl compound 16 proved to be the 
most  efficient, forming stable gels in ethanol/water at 0.7 mg/mL. For the alkenyl derivatives, 
the pentenyl derivative 21 is a versatile gelator, but the methacrylate derivative 20 is less 
efficient. The halogenated compounds 22 and 23 also showed positive results. For the two aryl 
derivatives, the phenyl amide 24 formed stable gels in water, and aqueous DMSO and ethanol, 
while the naphthyl amide 25 only formed gels in aqueous DMSO at higher concentrations. 
 
Urea derivatives  
 
Several urea derivatives were prepared by reacting compound 9 with a stoichiometric amount of 
the corresponding isocyanate in THF. For the compounds with terminal acetylenes, terminal 
alkynyl acids were converted to the corresponding isocyanates in situ by Curtis rearrangement 
using DPPA and triethylamine. The reactions generally proceeded with close to quantitative 
yields and the products can be purified on silica gel by flash chromatography using a polar 
solvent. The structures of the ureas synthesized and their gelation properties are shown in Table 
4.2. The selection of the R groups is based on the results from the carbamate and amide series 
and the availability of starting materials. These include compounds 26-28, with saturated 5-7 
carbon alkyl chains, and 29 and 30, which are 5-6 carbon terminal alkynyl derivatives. The 
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cyclohexyl urea 31, several compounds with terminal substituents 32-34, and aryl ureas 35-37 
were also prepared. The gelation test results are shown in Table 4.2. From the screening of the 
gelation results of these compounds, we can determine how the structure of the alkyl or aryl 
groups affects self assembling. 
 
For the sugar derivatives here, the urea analogs showed gelation tendencies similar to the amides, 
with the aliphatic derivatives with 5-7 carbons being most versatile gelators for aqueous 
mixtures. Compounds 26-29 formed gels in EtOH/water and DMSO/water at concentrations 
lower than 0.2 wt %. The presence of a terminal acetylene group does not seem to affect 
gelation, and the compounds with the same chain length as their saturated counterparts gave 
similar gelation results. Interestingly, the chloroethyl and methacryloyl ethyl ureas (32, 33) were 
also able to form gels in aqueous solutions, while the carbamate and ester analogs were not able 
to form gels in these solvents. The methacrylate 32 can form gels in water at 10 mg/mL. After 
hydrolysis of the methacrylate, the alcohol 34 can also form stable clear gels in water. Aromatic 
ureas are somewhat less effective for aqueous solutions compared to the aliphatic ureas; this may 
be due to the extra rigidity in the molecule. The aromatic urea derivatives 35-37 contain 
hydrogen bonding functions plus the aromatic rings necessary for π-π stacking. These aromatic 
interactions reinforce the molecular packing and result in stronger intermolecular forces. 
Therefore, they tend to be insoluble or crystallize in polar solvents. 
 
 
 
 
 - 151 - 
 
Table 4.2. Library of urea derivatives of 2 and corresponding MGCs (mg/mL). 
.
R =
27
36
28
O
O
HO
OCH3
NH
O
Ph
NH
O
29
Cl
33
O
34
26
OH
35
30
31
R
O
37
Br
32
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
G, stable gel at room temperature, the numbers are the minimum gelation concentrations in 
mg/mL; I, insoluble; C, crystallization; S, soluble at ~20 mg/mL, P, precipitate.  
 
 
We analyzed several gels in their gel states using optical microscopy, in an attempt to reveal the 
supramolecular assembly of the gels with the solvents still trapped inside. The dried xerogels 
were also studied by optical microscopy and scanning electron microscopy. These results are 
Cm
pd 
R =  Hex
ane 
Wat
er 
EtOH Water: 
DMSO 
(2:1) 
Water: 
EtOH 
(2:1) 
THF                                                        Isopr
op. 
DCM 
26 
  I I S G 1.2 G 1.3 
S S S 
27 
 
I I S G 1.0 G 1.5 
S S S 
28 
  
I P G 10 G 1.0 G 1.6 S G20 S 
29 
 
P I 
G 
6.6 
G 2.8 G 1.2 
S G20 S 
30 
  
C I S G 2.8 G 1.3  
P S S 
31 
 
I I G 10 G 3.3 G 1.3 
S S S 
32 Cl
 I I S G 10 G  10 
S S S 
33 O
O  
P 
G 
10 
S G 6.7 G  2.2 
S S S 
34 OH
 I 
G 
2.2 
G 20 G  10 G 4.0 
S G20 S 
35 
 
I I G 10 G 5 G 20 
S S S 
36 
Br
 
I I I G 2.5 G 2.0 
C S S 
37 
 
I I G 15 G 2.2 P 
S S S 
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shown in Figures 4.2-4.4. The optical micrographs of the wet gels formed by compound 19 are 
shown in Figures 4.2. The gel of 19 in ethanol/water showed bundled fibrous assemblies, as 
shown in Figures 4.2 a-c. At lower magnification (200x), we can see the long fibers floating in 
the gel solvent matrix. Figures 4.2c is a picture of the bundled fibers in Figure 4.2b at a higher 
magnification, and it is evident that the dark regions are composed of many tubular types of 
aggregates and smaller, softer feather like fibers spanning from the center. In DMSO/water 
solutions, we also observed tubular types of structures, as shown in Figure 4.2d-f. The fibers or 
tubules emerged from the gel media or were trapped in the gel media (Figure 4.2d and e). At 
higher magnification (500x), we can observe the embedded fibrous network at the surface of the 
gel droplet (Figure 4.2f). 
 
 
   
Figure 4.2. Optical micrographs of the gels formed by compound 19 in wet gel state. a-c are gels 
in EtOH/H2O (1:2) at 3 mg/mL; d-f are gels in DMSO/H2O (1:2) at 2 mg/mL. a,b,d and e are 
obtained at 200x magnification; c and f are at 500x magnification. 
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The gels formed by compound 21 also showed somewhat similar morphologies, as shown in 
Figure 4.3. In EtOH/H2O, we can clearly observe the fibrous assemblies at low magnification 
(Figure 4.3a), while at higher magnification, more detailed features of the fibrous networks can 
be observed (Figure 4.3b-d), including birefringent fibers and tubules. In DMSO/water, long 
fibers were also the predominant morphologies observed in the gel (Figure 4.3e-f). These were 
more difficult to see since the gel is three-dimensional. In many regions, we were only able to 
focus on one slice of the gels.  
 
 
Figure 4.3. Optical micrographs of the gels formed by compound 21 in wet gel state. a and d are 
gels in EtOH/H2O (1:2) at 2.5 mg/mL; e and f are gels in DMSO/H2O (1:2) at 3 mg/mL. 
These images were obtained under crossed polarizers in phase contrast mode. a and e are 200x, 
b,c,d and f are at 500x magnification. 
 
We also obtained the optical micrographs of the ureas in the gel phase, and these are shown in 
Figure 4.4. They formed somewhat different morphologies compared to those of the amides. 
Compound 30 formed a stable gel in ethanol/water (1:2). The gel surface was smooth and 
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contained some contiguous fibrous assemblies, though it was difficult to obtain better-quality 
pictures since, typically, they were not isolated fibers (Figure 4.4a). In DMSO/water (1:2), it 
formed a similar morphology, and a slice of the gel showed some intertwined fibrous networks 
(Figure 4.4b). The gel formed by compound 26 showed different morphologies as well. In 
EtOH/H2O, in thinner regions, we could observe the soft tubular networks (Figure 4.4c), while in 
the denser regions, when the solvent evaporated, we were able to observe densely packed fibrous 
structures (Figure 4.4d). In DMSO/H2O, we again were able to see some continuous intertwined 
fibrous assemblies at low magnification (Figure 4.4e) and the tubular fibrous networks were 
observed more clearly at higher magnifications (Figure 4.4f). Again, it was difficult to obtain the 
images of the gels since they are three-dimensional, so we obtained the micrographs of different 
cross-sections of the gels. These images showed that at different surfaces of the gels similar 
features of the fibrous assemblies can be observed. 
 
For the dried gels, it was easier to obtain their morphologies using OM or EM, and several of 
these are shown in Figure 4.5. The gels exhibit different morphologies, depending on their 
structures. The optical microscopy of the dried gels revealed that flexible fibers lead to more 
effective gelators, and that the derivatives with straight alkyl chains (as opposed to aromatic 
groups) tend to form these morphologies, especially in aqueous solvents. The gel formed by 18 
in ethanol/water showed long uniform fibrous features (Figure 4.5a). The gel of compound 13 in 
DMSO/water showed presence of very thin fibrous network structures (Figure 4.5d). 
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Figure 4.4. Optical micrographs of the gels formed by compounds 26 and 30 in gel phases. a, gel 
by 30 in EtOH/H2O (1:2) at 1.5 mg/mL; b, gel by 30 in DMSO/H2O (1:2) at 3.0 mg/mL; 
c and d, gel by 28 in EtOH/H2O (1:2) at 1.5 mg/mL; e and f, gel by 28 in DMSO/H2O (1:2) at 1.2 
mg/mL. Magnification for e is 200x, and for the rest is 500x. 
 
Both the OM and SEM of the gel formed by heptyl amide 14 in hexane showed the formation of 
entangled fibrous networks (Figure 4.5b-c). The urea derivative 34 also formed fibrous or tubular 
type of structures (Figure 4.5e-f). The SEM indicated that the tubular structures typically have 
diameters less than 1 µm. 
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Figure 4.5. Optical micrographs (a, b, d, e) and scanning electron micrographs (c, f) of several 
dried gels. A, gel of compound 18 in EtOH/H2O (1:2) at 0.7 mg/mL, b and c, gel of compound 
14 in hexane at 1.7 mg/mL; d, gel formed by compound 13 in DMSO/H2O (1:2) at 1.0 mg/mL, e 
and f, gel formed by compound 34 in water at 2.5 mg/mL. Magnifications for a, b, c, and e are 
1000x. 
 
From Tables 4.1 and 4.2, we can compare the gelation properties of amides and ureas containing 
similar alkyl chain derivatives. The compounds containing similar alkyl chain lengths are shown 
in Table 4.3, where the headgroup linkages are ester 38, carbamate 39, amide 14, or urea 26. The 
gelation ability of the compounds increases with the addition of an NH hydrogen bond donor. 
The solvents also affect the results, since hydrophobic forces are dominant in hydrogels, whereas 
hydrogen bonding is the primary force in organogels. In aqueous solutions of DMSO and 
ethanol, the presence of organic soluble components makes the hydrogen bonding somewhat 
more important and the hydrophobic interactions less important. The notable difference in the 
gelation ability between the ester and carbamate derivatives of compound 9 indicates that the -
NH is essential. This hydrogen bond donor is likely involved in the formation of a one-
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dimensional hydrogen bonding network. When the hydrogen bond donor NH group is closer to 
the sugar pyranoside ring as in compounds 15 and 19, the gelation capabilities are similar to that 
of the carbamates. From esters to carbamates, amides, and ureas, the number of hydrogen bond 
donors in the molecules increases. It seems that the increase in intermolecular interactions is 
necessary to extend the network. Typically, the amides and ureas formed more robust gels than 
the esters.  
 
Table 4.3. Comparing LMOGs with similar alkyl chain lengths. Positive gelation results are 
noted in mg/mL; P, precipitate; I, insoluble. 
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O
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NH
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14
O
O
HO
OCH3
NH
OPh
O
NH
26   
Compounds 38 39 14 26 
H2O I 20 I I 
H2O:DMSO 2:1 P 3.0 1.0 1.2 
H2O:EtOH 2:1 P 1.4 2.0 1.3 
 
4.4. Polymerizable diacetylenes 
 
Polydiacetylenes (PDAs) are important conjugate polymers that have drawn great attention over 
the past few decades. PDAs exhibit a unique blue to red color transition in the presence of heat, 
mechanical stress, pH change, and binding to biological agents. 
52-54
 Polydiacetylenes are 
interesting polymers exhibiting a typically blue to red color transitions in response to 
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environmental changes and binding to biomolecules, they also have non-linear optical properties 
and show other important optical effects. Extensive studies of polymerizable diacetylenes have 
been carried out in crystals,
 55,56
 thin films,
57,58
 and at air-water interfaces. The optical electronic 
properties and the unique color transitions of polydiacetylenes lend themselves to many 
applications in optical electronic devices, chemosensors, and biosensors.
59-64
  
 
To cross-link diacetylene groups, the monomer diacetylenes must be aligned at specific distances 
and orientations to their neighbors.  It is generally accepted that the color transition is due to the 
conformation change of  the PDA side chains (Scheme 4.2). 
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Scheme 4.2. The topochemical polymerization of diacetylene and the color transition mechanism 
 
The diacetylene-containing organogels may have interesting properties of color transition  
combined with gel-solution phase transition in response to external stimuli. These compounds 
can be useful in designing biosensors or chemosensors. Sugar containing amphiphilic molecules 
are cell membrane mimics and are expected to be biocompatible. As part of our goal to discover 
carbohydrate-based stimuli-responsive functional materials that are useful in enzyme  
purification, protein and DNA immobilization, drug and gene delivery carriers, and as 
scaffolding material for tissue engineering. 
 
We have previously studied a series of diacetylene containing glycolipids using D-glucose as the 
headgroup, a small library of glycolipids were synthesized and screened, we found that a 
majority of the 2-monoacylated derivatives were effective low molecular weight gelators for 
ethanol and ethanol aqueous mixtures.   
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Scheme 4.3. Synthesis of diacetylene containing lipids type A, type B, and type C.  
 
These diacetylene containing glycolipids with long chain fatty acyl tails are effective gelators for 
organic solvents, including ethanol, and ethanol/water mixtures, but not pure water. The gels 
formed by some of our diacetylene ester compounds can be polymerized, and depending on the 
structure, some of them showed the typical blue to red color transition upon heating.
47
 
 
Recently we also found that amide and urea analogs (10, 11) using the protected D-glucosamine 
2 as headgroup are excellent gelators for polar solvents and aqueous mixtures.
50
 The additional 
hydrogen bonding capacity in amides and ureas can potentially produce more stable gels than 
ester derivatives. Therefore, we synthesized a series of diacetylene derivatives using 
glucosamine headgroup. 
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4.5. Results and Discussion 
 
Previously, we have found that diacetylene containing glycolipids with long chain fatty acyl tails 
are effective gelators, however, these esters may be susceptible to hydrolysis under basic or 
strong acid conditions.
47
 Also, the gels produced typically required concentrations around 1wt%. 
Recently we also found that amide and urea analogs using the protected D-glucosamine as 
headgroup are excellent gelators for polar solvents and aqueous mixtures at concentrations well 
below 1wt%. The additional hydrogen bonding capacity in amides and ureas can potentially 
produce more stable gels than ester derivatives.  We are interested in producing effective gels 
that are responsive to environmental changes, this could be used as chemosensors or biosensors. 
In this study, we synthesized a series of diacetylene containing compounds using the D-
glucosamine headgroup, these are shown in Schemes 4.2-4.3. Here we prepared similar 
monoacyl chain derivatives which can be viewed as analogs to the type B ester gelators. The 
preparation of these compounds is straightforward with generally high yields. Besides these, we 
also synthesized a few bis-polar derivatives (Figure 4.6) with two polar headgroups at each end. 
The dimeric systems (48, 49, 54) are interesting compounds that may produce different self-
assembling morphology and properties than the monomeric systems (45-47, 50-53) and form 
important and interesting materials.   
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Figure 4.6. Structures of diacetylene containing amide derivatives synthesized. 
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Figure 4.7. Structures of diacetylene containing urea derivatives synthesized. 
 
These compounds were then screened for their gelation in a series of solvents, the result is shown 
in Table 4.4. Nearly all the compounds synthesized here are effective gelators for ethanol at 
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concentration less than 20 mg/mL, (2 wt%) except compound 45 which is soluble in ethanol. 
Most of the compounds are not soluble in either water or hexane or water/DMSO mixture. 
However, while many compounds were able to gelate water and ethanol mixture, most of them 
are efficient gelator for toluene. Several of them are also effectively solidify isopropanol. Among 
these compounds, the amide 47 is the most efficient gelator, forming gel in ethanol at 0.08 wt%, 
and 0.3 wt% in isopropanol. For the bispolar compound, they are as effective as or better than the 
monomeric derivatives.   
 
 Table 4.4. Library of diacetylene containing amides and ureas derivatives of D-glucosamine and 
their corresponding minimum gelation concentrations (MGCs) in mg/mL.  
Compound  Hexane toluene EtOH iPr-
OH 
H2O:EtOH   
(2:1) 
H2O:EtOH   
(3:1) 
 
Water H2O: 
DMSO 
(2:1) 
45  I 20 S S 1.0 20 I I 
46  I 10 20.0 20 1.6 C I C 
47  I 10                        0.8             3.0 C ND I                          I 
48   I I 10.0 10 2.5 I I I 
49   I 20 3.0 4.0 C ND I I 
50  I 5 5.0 10 2.5 10 I I 
51  I 10 5.0 5 2.5 C I I 
52  I 6.6 5.0 S I ND I I 
53  I 20 5.0 S I ND I I 
54   I 10 1.2 6.6 I ND I I 
U, unstable gel; G, gel at room temperature; I, insoluble; C, coaservate at 10 mg/mL; Cr, 
crystallization; S, soluble at ~20 mg/mL  
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4.6. Conclusions 
 
A series of acyl derivatives of the protected D-glucosamine were prepared and analyzed for their 
gelation properties. These include amides and ureas, which were synthesized via straightforward 
reactions with high selectivity. For both libraries, alkyl derivatives are the most efficient LMOGs 
and they form very robust gels in aqueous ethanol or aqueous DMSO solutions. These two 
classes of compounds contain extra hydrogen bond donors in comparison to the esters and 
carbamates with similar acyl functional groups. The amino group at the 2-postion easily allows 
for the preparation of these library compounds and the reactions can be scaled up for large scale 
application studies. These small molecules can be useful for entrapping large biomolecules such 
as enzymes and provide a good media for enzymatic reactions. The gels formed by several 
compounds were analyzed using optical microscopy and scanning electronic microscopy.  
Several excellent low molecular gelators were obtained in this study, and the correlation between 
the structure and gelation can be used for the design of other functional organo/hydrogelators. 
We have also used this glucosamine to synthesis the diacetylene based amides and ureas. The 
self-assembling properties of these compounds were studied in several solvents. We identified 
several excellent organogelators for ethanol and ethanol water mixture. The color transition 
properties of the polydiacetylene gels can be used to predict changes in environmental 
conditions, such as in the event of binding to a biological agent.   
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4.7. Experimental Procedures 
 
General Methods 
Gelation Testing. The compounds were tested in a 1 dram vial with a rubber lined screw cap 
from Kimble. A starting concentration of 20 mg/mL was used. The mixture was heated and 
sonicated until the sample was fully dissolved compounds are dissolved.  The solution was 
allowed to cool at r.t. for 20-30 minutes. If a gel is formed, then the vial is inverted and if no 
solvent flows while the gel is inverted, then it is called a stable gel. If the gel falls apart during 
inversion and by gentle shaking, then it is called an unstable gel. If a stable gel is formed, serial 
dilution is performed until the gels resulted are no longer stable. The concentration prior to the 
unstable gel was recorded as the minimum gelation concentration (MGC). 
 
Optical Microscopy.  The slides were prepared after a stable gel has formed. A small amount of 
the gel was placed on a clean glass slide and air dried over night. The xerogels were observed 
with an Olympus BX60M optical microscope using a DSP Color Hi-Res EXvision camera and 
an Olympus U-TV1X lens. The program used to acquire and store the photos was Corel Photo-
Paint 7. 
 
Scanning Electron Microscopy. Samples were prepared by drying the gel on an aluminum 
pellet in a desiccator under reduced pressure for several days. A thin layer of platinum was 
deposited on to the pellet by a Denton Vacuum (model Desk II) at a reduced pressure of ~30 
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mtorr and a current of 45 mA for 60 sec. The sample was analyzed using a JEOL JSM 5410 
scanning microscope with an EDAX Detecting Unit.  
 
Acknowledements: Thanks to Prof. Guijun Wang and Dr. Sherwin Cheuk for help with for OM 
and SEM images. 
 
General procedure for the synthesis of amides 
4,6-O-Benzylidene-2-amino-2-deoxy-methyl-α-D-glucopyranoside 4 and pyridine or DIEA (2 
eq) were mixed in anhydrous THF at 0°C. The corresponding acyl halide (1.1 eq) was added 
dropwise. After 4-6 hrs the reaction was diluted with DCM and washed with H2O and then dilute 
HCl (~0.1N). The organic layer was dried with anhydrous Na2SO4. The crude products are 
purified using flash chromatography with a gradient of solvent system hexane and acetone.   
 
General procedure for the synthesis of ureas 
The urea library was synthesized by mixing compound 4 and the corresponding isocyanate in 
stoichiometric quantities in anhydrous THF. The solution was stirred at r.t. for 6-8 hours and the 
crude products are formed. These are purified by chromatography if the 
1
H NMR spectrum 
indicates the product is not pure. Typically DCM/MeOH gradient solvent system is used for the 
chromatography separation if needed.    
 
Pentyl amide 12 
The compound was obtained as a white solid at a yield of 87.6%, m.p. 195.2-196.0 C. 1H NMR 
(400MHz, CDCl3), δ (ppm) 7.47-7.54 (m, 2H), 7.32-7.40 (m, 3H), 5.83 (d, 1H, J = 8.1 Hz), 5.57 
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(s, 1H), 4.72 (d, 1H, J = 4.0 Hz), 4.20-4.33 (m, 2H), 3.90 (dt, 1H, J = 3.3, 9.5 Hz), 3.78 (m, 2H), 
3.59 (m, 1H), 3.41 (s, 3H), 3.13 (d, 1H, J = 3.3 Hz, OH), 2.26 (t, 2H, J = 7.3 Hz), 1.64 (m, 2H), 
1.36 (sext, 2H, J = 7.3Hz), 0.92 (t, 3H, J = 7.3 Hz). 
13
C NMR (100 MHz, CDCl3) δ 174.7, 137.1, 
129.1, 128.2, 126.3, 101.8, 98.8, 82.0, 70.7, 68.8, 62.3, 55.3, 54.0, 36.3, 27.6, 22.2, 13.7.  HRMS 
Cacld for C19H28NO6  [M+H]
+
 366.1917, found 366.1920. 
 
Hexyl amide 13  
The hexyl amide was obtained as a white solid at a yield of 86%, m.p. 192.3-193.1°C.  
1
H NMR, 
(400 MHz, CDCl3) δ (ppm) 7.47-7.52 (m, 2H), 7.33-7.39 (m, 3H), 5.85 (d, 1H, J = 8.4 Hz), 5.57 
(s, 1H), 4.72 (d, 1H, J = 3.7 Hz), 4.19-4.32 (m, 2H), 3.91 (dd~t, 1H, J = 9.7 Hz), 3.74-3.83 (m, 
2H), 3.59 (m, 1H), 3.41 (s, 3H), 2.25 (t, 2H, J = 7.3), 1.65 (p, 2H, J = 7.3 Hz), 1.32 (m, 4H), 0.90 
(t, 3H, J = 7.2 Hz). 
13
C NMR, (100 MHz, CDCl3) δ (ppm) 174.9,137.0, 129.1, 128.2, 126.2, 
101.8, 98.9, 82.0, 69.7, 68.7, 62.4, 55.2, 53.8, 36.3, 31.2, 25.1, 22.2, 13.8. HRMS Calcd for 
C20H30NO6 [M+H]
+
 380.2073, found 380.2071. 
 
Heptyl amide 14  
The product was obtained as a white crystalline solid at a yield of 87%. m.p. 197.8-198.1°C. 
1
H 
NMR (400 MHz, CDCl3) δ (ppm) 7.44-7.51 (m, 2 H), 7.30-7.38 (m, 3 H) 6.08 (d, 1 H, J = 8.8 
Hz), 5.54 (s, 1 H), 4.69 (d, 1 H, J = 3.7 Hz), 4.25 (m, 1H), 4.15 (d, 1 H, J = 3.7, 9.9 Hz), 3.83 (t, 
1H, J = 9.7 Hz), 3.69-3.78 (m, 2 H), 3.55 (m, 1 H), 3.37 (s, 3 H), 2.13-2.26 (m, 3H), 1.60 (m, 
2H), 1.27 (s, 6 H), 0.85 (t, 3H, J = 6.6 Hz). 
13
C NMR (100 MHz, CDCl3) δ 174.8, 137.0, 129.1, 
128.2, 126.2, 101.9, 98.9, 82.1, 70.0, 68.8, 62.4, 55.3, 53.8, 36.5, 31.4, 28.7, 25.5, 22.4, 14.0. 
HRMS Calcd for C21H32NO6 [M+H]
+
 394.2230, found 394.2237. 
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Octyl amide 15  
The product was obtained as a white crystalline solid at a yield of 88%, m.p. 183.8-185.0 C.  1H 
NMR (400 MHz, CDCl3) δ (ppm) 7.46-7.52 (m, 2H), 7.33-7.39 (m, 3H), 5.85 (d, 1H, J = 8.8 
Hz), 5.57 (s, 1H), 4.72 (d, 1H, J = 4.0 Hz), 4.28 (m, 1H), 4.23 (m, 1H), 3.90 (t, 1H, J = 9.5 Hz), 
3.74-3.83 (m, 2H), 3.59 (m, 1H), 3.41 (s, 3H), 3.15 (sb, 1H), 2.25 (m, 2H), 1.64 (m, 2H), 1.19-
1.40 (m, 8H), 0.87 (t, 3H, J = 7.0 Hz). 
13
C NMR (100 MHz, CDCl3) δ (ppm) 174.7, 137.0, 129.2, 
128.2, 126.3, 101.9, 98.8, 82.1, 70.9, 68.8, 62.3, 55.3, 54.0, 36.6, 31.7, 29.1, 29.0, 25.6, 22.6, 
14.0. HRMS Calcd for C22H34NO6 [M+H]
+
 408.2386, found 408.2395. 
 
4-pentynyl amide 16 
The compound was obtained as a white solid at a yield of 79%, m.p. 180.0-180.7 C. 1H NMR 
(400MHz, CDCl3), δ (ppm) 7.46-7.53 (m, 2H), 7.32-7.40 (m, 3H), 6.04 (d, 1H, J = 8.4 Hz), 
5.57(s, 1H), 4.72 (d, 1H, J = 4.0 Hz), 4.22-4.33 (m, 2H), 3.91 (t, 1H, J = 9.5 Hz), 3.73-3.85 (m, 
2H), 3.59 (m, 1H), 3.41 (s, 3H), 2.99 (sb, 1H), 2.52-2.59 (m, 2H), 2.45-2.50 (m, 2H), 2.02 (m, 
1H). 
13
C NMR (100 MHz, CDCl3) δ 172.4, 136.9, 129.1, 128.1, 126.2, 101.8, 98.8, 82.6, 81.9, 
69.5, 69.2, 68.7, 62.4, 55.2, 53.9, 35.0, 14.7. HRMS Cacld for C19H24NO6  [M+H]
+
 362.1604, 
found 366.1604. 
 
5-Hexynyl amide 17.  
Flash chromatography using solvent CH2Cl2:MeOH 9.3: 0.7 to obtain the product in 70% yield 
as a white solid. M.p. 176.1-177.0 C. 1H NMR (400MHz, CDCl3), δ (ppm) 7.47-7.52 (m, 2H), 
7.33-7.40 (m, 3H), 5.92 (d, 1H, J = 8.8 Hz), 5.57(s, 1H), 4.72 (d, 1H, J = 3.7 Hz), 4.20-4.31 (m, 
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2H), 3.90 (dt, 1H, J = 3.3, 9.9 Hz), 3.73-3.83 (m, 2H), 3.59 (m, 1H), 3.41 (s, 3H), 3.06 (d, 1H, J 
= 3.3 Hz),  2.41 (t, 2H, J = 7.1 Hz), 2.28 (m, 2H), 1.99 (t, 1H, J = 2.6 Hz),  1.88 (m, 2H).  
13
C 
NMR (100 MHz, CDCl3) δ 172.7, 137.0, 129.2, 128.3, 126.3, 101.9, 98.8, 83.4, 82.0, 70.8, 69.3, 
68.8, 62.3, 55.3, 53.9, 34.9, 23.9, 17.6. HRMS Cacld for C20H26NO6  [M+H]
+
 376.1760, found 
376.1756.  
 
6-Heptynyl amide 18.  
The compound was isolated as a white solid at a yield of 70%, m.p. 174.4-175.1 C.  1H NMR 
(400MHz, CDCl3), δ (ppm) 7.47-7.53 (m, 2H), 7.33-7.40 (m, 3H), 5.85 (d, 1H, J = 8.4 Hz), 5.57 
(s, 1H), 4.72 (d, 1H, J = 3.7 Hz), 4.29 (m, 1H), 4.24 (ddd, 1H, J = 3.7, 4.0, 8.8 Hz), 3.90 (dt, 1H, 
J = 3.3, 9.5 Hz), 3.74-3.85 (m, 2H), 3.59 (m, 1H), 3.41 (s, 3H), 3.03 (d, 1H, J = 3.3 Hz),  2.29 (t, 
2H, J = 7.3 Hz), 2.22 (dt, 1H, J = 2.6, 7.0 Hz), 1.96 (t, 1H, J = 2.6 Hz), 1.79 (m, 2H), 1.58 (m, 
2H). 
13
C NMR (100 MHz, CDCl3) δ 174.0, 137.0, 129.1, 128.2, 126.3, 101.8, 98.8, 84.0, 82.0, 
70.6, 68.8, 68.6, 62.3, 55.3, 53.9, 35.9, 27.7, 24.6, 18.1. HRMS Cacld for C21H28NO6  [M+H]
+
 
390.1917, found 390.1917.   
 
10-Undecynyl amide 19   
 The product was obtained as a white solid at a yield of 84%. Mp 184.5-185.3°C. 
1
H NMR (400 
MHz, CDCl3) δ (ppm) 7.46-7.52 (m, 2H), 7.32-7.39 (m, 3H), 5.92 (d, 1H, J = 8.4 Hz), 5.54 (s, 
1H), 4.71 (d, 1H, J = 3.7 Hz), 4.26 (m, 1H), 4.20 (ddd, 1H, J = 3.7, 4.0, 8.8 Hz), 3.87 (t, 1H, J = 
9.6 Hz), 3.71-3.82 (m, 2H), 3.57 (t, 1H, J = 9.0 Hz), 3.38 (s, 3H), 2.22 (m, 2H), 2.16 (dt, 2H, J = 
2.6, 7.1 Hz), 1.93 (t, 1H, J = 2.6 Hz), 1.62 (m, 2H), 1.50 (pentet, 2H, J = 7.0), 1.37 (m, 2H), 1.29 
(m, 6H). 
13
C NMR (100 MHz, CDCl3) δ (ppm) 174.6, 137.1, 129.1, 128.2, 126.3, 101.8, 98.8, 
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84.6, 82.0, 70.5, 68.7, 68.1, 62.3, 55.2, 53.9, 36.5, 29.1, 29.0, 28.8, 28.5, 28.3, 25.5, 18.3. HRMS 
Calcd for C25H36NO6 [M+H]
+
 446.2543, found 446.2524.  
 
Methacrylamide 20 
The compound was obtained as a white solid at a yield of 85%. m.p. 187.2-187.9 C. 1H NMR 
(400MHz, CDCl3), δ (ppm) 7.45-7.55 (m, 2H), 7.30-7.42 (m, 3H), 6.21 (d, 1H, J = 8.4 Hz), 5.76 
(s, 1H), 5.56 (s, 1H), 5.39 (s, 1H), 4.76 (d, 1H, J = 3.7 Hz), 4.23-4.33 (m, 2H), 3.94 (t, 1H, J = 
9.5 Hz), 3.72-3.84 (m, 2H), 3.60 (t, 1H, J = 8.8 Hz), 3.40 (s, 3H), 3.29 (s, 1H), 1.99 (s, 3H). 
13
C 
NMR (100 MHz, CDCl3) δ 169.3, 139.2, 137.1, 129.1, 128.2, 126.3, 120.7, 101.8, 98.8, 82.0, 
70.6, 68.8, 62.3, 55.3, 54.1, 18.5.  HRMS Cacld for C18H24NO6 [M+H]
+
 350.1604, found 
355.1588.  
 
5-hexenyl amide 21 
The compound was obtained as a white solid at a yield of 76%, m.p.178.1-179.0 C. 1H NMR 
(400MHz, CDCl3), δ (ppm) 7.46-7.52 (m, 2H), 7.33-7.39 (m, 3H), 5.86 (d, 1H, J = 8.4 Hz), 5.77 
(m, 1H), 5.56 (s, 1H), 5.03 (d, 1H, J = 17.9 Hz), 4.99 (d, 1H, J = 10.6 Hz), 4.71 (d, 1H, J = 3.7 
Hz), 4.28-4.19 (m, 2H), 3.88 (t, 1H, J = 9.5 Hz), 3.77 (m, 2H), 3.58 (m, 1H), 3.40 (s, 3H), 3.19 
(sb, 1H), 2.25 (t, 2H, J = 7.5 Hz), 2.10 (q, 2H, J = 7.0 Hz), 1.76 (pentet, 2H, J = 7.5 Hz). 
13
C 
NMR (100 MHz, CDCl3) δ 174.3, 137.8, 137.1, 129.2, 128.2, 126.3, 115.5, 101.9, 98.8, 82.0, 
70.8, 68.8, 62.3, 55.3, 54.0, 35.7, 33.0, 24.5. HRMS Cacld for C20H28NO6  [M+H]
+
 378.1917, 
found 378.1899.  
 
4-Chlorobutyl amide 22   
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The compound was obtained as a white solid at a yield of 89%, m.p. 195.2-196.1. C.  1H NMR 
(400MHz, CDCl3), δ (ppm) 7.46-7.53 (m, 2H), 7.34-7.40 (m, 3H), 5.89 (d, 1H, J = 8.4 Hz), 5.57 
(s, 1H), 4.72 (d, 1H, J = 4.0 Hz), 4.21-4.34 (m, 2H), 3.91 (dt, 1H, J = 2.9, 9.9 Hz), 3.73-3.84 (m, 
2H), 3.55-3.68 (m, 3H), 3.42 (s, 3H), 2.91 (d, 1H, J = 2.9 Hz), 2.46 (t, 2H, J = 7.0 Hz), 2.14 (m, 
2H). 
13
C NMR (100 MHz, CDCl3) δ 173.1, 136.9, 129.0, 128.1, 126.1, 101.7, 98.8, 81.8, 69.3, 
68.7, 62.4, 55.2, 53.8, 44.2, 33.0, 27.9. HRMS Cacld for C18H25NO6Cl  [M+H]
+
 386.1370, found 
386.1355.  
 
5-Bromopenyl amide 23    
The compound was obtained as a white solid at a yield of 80.5%. m.p. 169.2-170.0 C.   1H 
NMR (400MHz, CDCl3), δ (ppm) 7.45-7.52 (m, 2H), 7.33-7.39 (m, 3H), 5.88 (d, 1H, J = 8.4 
Hz), 5.56 (s, 1H), 4.72 (d, 1H, J = 4.0 Hz), 4.28 (m, 1H), 4.22 (m, 1H), 3.89 (dd~t, 1H,  J  = 9.7 
Hz), 3.77 (m, 2H),  3.58  (m, 1H), 3.41 (t, 2H, J = 6.6 Hz), 3.40 (s, 3H), 2.38 (t, 2H, J = 7.1 Hz), 
1.90 (m, 2H), 1.81 (m, 2H).  
13
C NMR (100 MHz, CDCl3) δ 173.1, 136.9, 129.0, 128.1, 126.1, 
101.7, 98.8, 81.8, 69.2, 68.6, 62.4, 55.1, 53.8, 44.2, 32.9, 27.9. HRMS Cacld for C19H27BrNO6   
[M+H]
+  
444.1022, found 444.1014.   
 
Benzoyl amide 24  
The product was obtained as a white crystalline solid at a yield of 89%, m.p. 247.2-247.8 
1
H 
NMR (400MHz, CDCl3-MeOH), δ (ppm) 7.74 (d, 2H, J = 8.1 Hz), 7.40-7.47 (m, 3H), 7.33-7.38 
(m, 3H), 7.26-7.32 (m, 3H), 5.52 (s, 1H), 4.78 (d, 1H. J = 3.7 Hz), 4.27 (dd, 1H, J = 3.3, 10.3 
Hz), 4.22 (m, 1H), 3.91 (t, 1H, J = 9.5 Hz), 3.70-3.82 (m, 2H), 3.57 (t, 1H, J = 8.8 Hz), 3.33 (s, 
3H). 
13
C NMR (100 MHz, CDCl3-MeOH) δ (ppm) 168.7, 137.0, 133.6, 131.8, 129.0, 128.4, 
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128.1, 127.0, 126.1, 102.1, 99.1, 81.9, 69.1, 68.7, 62.5, 55.2, 54.4. HRMS Calcd for C21H24NO6 
[M+H]
+ 
386.1604, found 386.1595. 
 
Naphthyl amide 25  
The compound was obtained as a white solid at a yield of 84%, m.p. 206.8-207.4 C. 1H NMR 
(400MHz, CDCl3, CD3OD), δ (ppm) 8.34 (d, 1H, J = 8.1 Hz), 7.93 (d, 1H, J = 8.4 Hz), 7.88 (d, 
1H, J = 7.3 Hz), 7.67 (d, 1H, J = 7.0 Hz), 7.43-7.59 (m, 5H), 7.32-7.40 (m, 3H), 6.38 (d, 1H, J = 
8.8 Hz), 5.60 (s, 1H), 4.93 (d, 1H, J =3.7 Hz), 4.53 (m, 1H), 4.31 (m, 1H), 4.02 (m, 1H), 3.75-
3.88 (m, 2H), 3.63 (t, 1H, J = 9.2 Hz), 3.41 (s, 3H), 3.25 (d, 1H, J = 3.3 Hz). 
13
C NMR (100 
MHz, CDCl3, CD3OD) δ 170.7, (170.6 minor rotamer), 136.9, 133.6 (133.62, minor rotamer), 
133.4, 130.6, 129.8, 129.0, 128.1, 128.06, 127.0, 126.2, 126.1, 125.1, 124.9, 124.6, 101.7, 98.9, 
81.9, 69.1, 68.7, 62.5, 55.2, 54.4 (54.5, minor tautomer).   HRMS Cacld for C25H26NO6   [M+H]
+   
436.1760, found 436.1742.  
 
Pentyl urea 26  
The compound was obtained as a white solid at a yield of 96%, m.p. 186.2-187.0. 
1
H NMR (400 
MHz, d6-DMSO) δ (ppm) 7.41-7.49 (m, 2H), 7.34-7.41 (m, 3H), 6.06 (t, 1H, J = 5.5 Hz), 5.79 
(d, 1H, J = 8.8 Hz), 5.59 (s, 1H), 5.21 (d, 1H. J = 5.1 Hz), 4.61 (d, 1H, J = 3.7 Hz), 4.16 (dd, 1H, 
J = 4.8, 9.9 Hz ), 3.63-3.77 (m, 2H), 3.41-3.62 (m, 3H), 3.28 (s, 3H), 2.95 (q, 2H, J = 6.3 Hz), 
1.35 (pentet, 2H, J = 7.0 Hz), 1.24 (m, 4H), 0.85 ( t, 3H, J = 6.6 Hz). 
13
C NMR, (100 MHz, d6-
DMSO) δ (ppm) 158.1, 137.8, 129.0, 128.1, 126.5, 101.0, 99.6, 82.0, 68.6, 68.1, 62.6, 54.8, 54.7, 
39.2, 29.6, 28.7, 21.9, 14.0. HRMS Calcd for C20H31N2O6 [M+H]
+
 395.2182, found 395.2196. 
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Hexyl urea 27  
Isolated as a light yellow solid in quantitative yield, m.p. 183.8-185.0°C. 
1
H NMR (400 MHz, 
d6-DMSO) δ (ppm) 7.42-7.49 (m, 2H), 7.34-7.41 (m, 3H), 6.07 (t, 1H, J = 5.5 Hz), 5.80 (d, 1H, J 
= 8.4 Hz), 5.60 (s, 1H), 5.22 (sb, 1H), 4.62 (d, 1H, J = 3.7 Hz), 4.17 (dd, 1H, J = 4.8, 9.9 Hz), 
3.73 (t, 1H, J = 10.3 Hz), 3.69 (dd, 1H, J = 3.7, 8.8 Hz), 3.55-3.62 (m, 1H), 3.49 (m, 2H), 3.30 
(s, 3H), 2.98 (q, 2H, J = 6.2 Hz), 1.35 (m, 2H), 1.25 (sb, 6H), 0.86 (t, 3H, J = 6.8 Hz). 
13
C NMR 
(100 MHz, d6-DMSO) δ (ppm) 157.9, 137.7, 128.8, 127.9, 126.3, 100.8, 99.5, 81.9, 68.5, 68.0, 
62.4, 54.6, 54.55, 39.1, 31.0, 29.8, 26.0, 22.0, 13.8. HRMS Calcd for C21H33N2O6 [M+H]
+
 
409.2339, found 409.2355. 
 
Heptyl urea 28 
Isolated as an off white solid in quantitative yield, m.p. 201.3-202.2 C.  1H NMR (400 MHz, 
DMSO) δ (ppm) 7.40-7.46 (m, 2H), 7.32–7.39 (m, 3H), 6.04 (t, 1H, J = 5.5 Hz), 5.78 (d, 1H, J = 
8.4 Hz), 5.58 (s, 1H), 5.21 (d, 1H, J = 5.1 Hz), 4.60 (d, 1H, J  = 3.2 Hz), 4.15 (dd, 1H, J = 4.6, 
9.8 Hz), 3.63-3.74 (m, 2H), 3.57 (m, 1H), 3.42-3.51 (m, 2H), 3.28 (s, 3H), 2.96 (q, 2H, J = 6.2 
Hz), 1.33 (m, 2H), 1.23 (bs, 8H), 0.84 (t, 3H, J  = 6.4 Hz). 
13
C NMR (100 MHz, DMSO) δ 157.8, 
137.7, 128.8, 127.9, 126.3, 100.8, 99.4, 81.9, 68.4, 68.0, 62.4, 54.6, 54.5, 39.1, 31.2, 29.9, 28.4, 
26.3, 22.0, 13.9. HRMS Calcd for C22H35N2O6 [M+H]
+
 423.2495, found 423.2500. 
 
4-Pentynyl urea 29  
 The compound was obtained as a white solid at a yield of 90.5%, m.p. 210.0-211.0 C.  1H 
NMR (400MHz, DMSO), δ (ppm) 7.42-7.48 (m, 2H), 7.34-7.41 (m, 3H), 6.13 (t, 1H, J = 5.6 
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Hz), 5.78 (d, 1H, J = 8.8 Hz), 5.60 (s, 1H), 5.20 (d, 1H, J = 5.5 Hz), 4.62 (d, 1H, J = 3.7 Hz), 
4.17 (dd, 1H, J = 4.8, 9.9 Hz), 3.73 (m, 1H), 3.69 (m, 1H),  3.59 (dt, 1H, J = 4.8, 9.9 Hz), 3.44-
3.55 (m, 2H),  3.30 (s, 3H), 3.04 (pseudo q, 2H, J = 6.0 Hz), 2.78 (t, 1H, J = 2.6 Hz), 2.15 (dt, 
2H, J = 2.6, 7.0 Hz), 1.54 (pentet, 2H, J = 7.0 Hz), 
13C NMR (100 MHz, DMSO) δ 157.8, 137.7, 
128.8, 127.9, 126.3, 100.8, 99.4, 83.9, 82.0, 71.3, 68.5, 68.0, 62.4, 55.6, 54.5, 38.2, 28.8, 15.2 
HRMS Cacld for C20H27N2O6 [M+H]
+
 391.1869, found 391.1855.  
 
5-Hexynyl urea 30 
The compound was obtained as a white solid at a yield of 87%, m.p. 212.0-213.0 C.  1H NMR 
(400MHz, CDCl3), δ (ppm) 7.47-7.52 (m, 2H), 7.33-7.39 (m, 3H), 5.58 (s, 1H), 4.72 (d, 1H, J = 
3.7 Hz), 4.62-4.81 (m, 2H), 4.28 (m, 1H), 3.84-3.96 (m, 2H), 3.73-3.83 (m, 2H), 2.53-3.61 (m, 
1H), 3.40 (s, 3H), 3.21 (m, 2H), 2.22 (dt, 2H, J = 2.6, 6.9 Hz), 1.96 (t, 1H, J = 2.6 Hz), 1.51-1.68 
(m, 4H). 
13
C NMR (100 MHz, CDCl3-1drop of CD3OD) δ 159.2, 137.0, 129.0, 128.1, 126.2, 
101.8, 99.5, 84.1, 82.0, 70.5, 68.8, 68.5, 62.4, 55.2, 54.9, 39.5, 28.9, 25.5, 18.0. HRMS Cacld for 
C21H29N2O6   [M+H]
+
 405.2026, found 405.2034.  
 
Cyclohexyl urea 31   
Isolated as a light yellow solid in quantitative yield, m.p. 210°C (dec). 
1
H NMR (400 MHz, d6-
DMSO) δ (ppm) 7.42-7.47 (m, 2H), 7.35-7.40 (m, 3H), 6.04 (d, 1H, J = 8.1 Hz), 5.74 (d, 1H, J = 
8.4 Hz), 5.60 (s, 1H), 5.23 (d, 1H, J = 4.8 Hz), 4.61 (d, 1H, J = 3.3 Hz), 4.17 (dd, 1H, J = 4.8, 9.9 
Hz), 3.64-3.76 (m, 2H), 3.58 (m, 1H), 3.44-3.54 (m, 2H), 3.36 (m, 1H), 3.34 (s, 3H), 1.68-1.78 
(m, 2H), 1.57-1.67 (m, 2H), 1.46-1.55 (m, 1H), 1.19-1.32 (m, 2H), 1.00-1.18 (m, 3H). 
13
C NMR 
(100 MHz, d6-DMSO) δ (ppm) 157.1, 137.7, 128.8, 127.9, 126.3, 100.8, 99.4, 81.9, 68.5, 68.0, 
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62.4, 54.6, 54.5, 47.6, 33.2, 25.2, 24.3. HRMS Calcd for C21H31N2O6 [M+H]
+
 407.2182, found 
407.2191. 
 
2-Chloroethyl urea 32  
The compound was obtained as a white solid at a yield of 95%, m.p. 184.1°C 
1
H NMR, (400 
MHz, d6-DMSO) δ (ppm) 7.40-7.47 (m, 2H), 7.33-7.39 (m, 3H), 6.34 (t, 1H, J = 5.5 Hz), 6.07 
(d, 1H, J = 8.8 Hz), 5.58 (s, 1H), 5.20 (d, 1H, J = 5.5 Hz), 4.61 (d, 1H, J = 3.3 Hz), 4.15 (dd, 1H, 
J = 4.8, 9.9 Hz), 3.64-3.75 (m, 2H), 3.53-3.61 (m, 3H), 3.42-3.53 (m, 2H), 3.32 (m, 2H), 3.28 (s, 
3H). 
13
C NMR, (100 MHz, d6-DMSO) δ (ppm) 157.6, 137.7, 128.9, 128.0, 126.4, 100.8, 99.4, 
81.9, 68.3, 68.0, 62.5, 54.7, 54.6, 44.7, 41.4. HRMS calcd for C17H24N2O6Cl [M+H]
+
 387.1323, 
found 387.1335. 
 
2-Methyl-acrylic acid 2-ureido-ethyl ester 34   
The compound was obtained as a white solid in quantitative yield, m.p. 198.8-200.0°C. 
1
H NMR 
(400 MHz, d6-DMSO) δ (ppm) 7.42-7.48 (m, 2H), 7.34-7.40 (m, 3H), 6.24 (t, 1H, J = 5.7 Hz), 
6.08 (sb, 1H), 5.99 (d, 1H, J = 8.4 Hz), 5.70 (m, 1H), 5.60 (s, 1H), 5.20 (d, 1H, J = 5.5 Hz), 4.62 
(d, 1H, J = 3.7 Hz), 4.17 (dd, 1H, J = 4.8, 9.9 Hz), 4.06 (m, 2H), 3.66-3.77 (m, 2H), 3.65-3.63 
(m, 1H), 3.43-3.53 (m, 2H), 3.22-3.32 (m, 5H), 1.89 (s, 3H). 
13
C NMR (100 MHz, d6-DMSO) δ 
(ppm) 166.5, 157.7, 137.7, 135.8, 128.8, 127.9, 126.4, 125.9, 100.8, 99.4, 81.9, 68.3, 68.0, 64.2, 
62.5, 54.62, 54.57, 38.1, 17.9. HRMS Calcd for C21H29N2O8 [M+H]
+
 437.1924, found 437.1944. 
 
(2-Hydroxy-ethyl)-urea 35 
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Isolated as a white solid solid in quantitative yield, m.p. 232.3-233.0 C.  1H NMR (400 MHz, 
d6-DMSO) δ (ppm) 7.42-7.47 (m, 2H), 7.34-7.39 (m, 3H), 6.26 (t, 1H, J = 5.5 Hz), 6.13 (d, 1H, J 
= 8.1 Hz), 5.59 (s, 1H), 5.33 (sb, 1H), 4.78 (sb, 1H), 4.61 (d, 1H, J = 3.3 Hz), 4.16 (dd, 1H, J = 
4.8, 9.9 Hz), 3.72 (m, 1H), 3.66 (m, 1H), 3.58 (m, 1H), 3.44-3.55 (m, 2H), 3.32-3.40 (m, 2H, 
overlap), 3.29 (s, 3H), 3.05 (q, 2H, J = 5.5 Hz). 
13
C NMR (100 MHz, d6-DMSO) δ ppm 158.2, 
137.7, 128.8, 128.0, 126.4, 100.8, 99.5, 81.9, 68.3, 68.0, 62.5, 60.7, 54.7, 42.0. HRMS Calcd for 
C17H25N2O7 [M+H]
+
 369.1662, found 369.1677. 
 
Phenyl urea 36 
Isolated as a light yellow solid solid in quantitative yield, m.p. >300°C. 
1
H NMR, (400 MHz, d6-
DMSO) δ (ppm) 8.65 (s, 1H), 7.43-7.49 (m, 2H), 7.43-7.42 (m, 5H), 7.22 (m, 2H), 6.89 (m, 1H),  
6.15 (d, 1H, J = 8.8 Hz), 5.63 (s, 1H), 5.34 (sb, 1H), 4.71 (d, 1H, J = 3.3 Hz), 4.20 (dd, 1H, J = 
4.8, 9.9 Hz), 3.72-3.83 (m, 2H), 3.63 (m, 1H), 3.49-3.60 (m, 2H), 3.34 (s, 3H). 
13
C NMR (100 
MHz, d6-DMSO) δ (ppm) 154.8, 140.3, 137.7, 128.8, 128.6, 127.9, 126.3, 121.0, 117.3, 100.8, 
99.2, 81.7, 68.3, 68.0, 62.6, 54.7, 54.2. HRMS Calcd for C21H25N2O6 [M+H]
+
 401.1713, found 
401.1726. 
 
4-Bromophenyl urea 37   
The compound was obtained as a white solid at a yield of 92%, m.p. unstable after 265 C. 1H 
NMR, (400 MHz, d6-DMSO) δ (ppm) 8.77 (sb, 1H),  7.43-7.48 (m, 2H), 7.33-7.42 (m, 7H),  6.16 
(d, 1H, J = 8.4 Hz), 5.62 (s, 1H),  5.33 (d, 1H, J = 5.5Hz), 4.70 (d, 1H, J = 3.7Hz), 4.19 (dd, 1H, 
J = 4.8, 9.9 Hz), 3.72-3.82 (m, 2H), 3.49-3.66 (m, 3H), 3.33 (s, 3H). 
13
C NMR (100 MHz, d6-
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DMSO) δ (ppm) 154.6, 139.7, 137.7, 131.4, 128.8, 128.0, 126.4, 119.3, 112.3, 100.8, 99.2, 81.7, 
68.3, 68.0, 62.6, 54.7, 54.2. HRMS Calcd for C21H24N2O6Br [M+H]
+
 479.0818, found 479.0836. 
 
Napthyl urea 38  
 Isolated as a light yellow solid in quantitative yield, m.p. 253.8-255.0 °C. 
1
H NMR, (400 MHz, 
d6-DMSO) δ (ppm) 8.73 (s, 1H),  8.14 (d, 1H, J = 8.1 Hz), 8.09 (d, 1H, J = 7.7 Hz), 7.87 (d, 1H, 
J = 8.1 Hz),  7.49-7.56 (m, 3H), 7.44-7.49 (m, 2H), 7.39-7.43 (m, 1H), 7.34-7.39 (m, 3H),   6.81 
(d, 1H, J = 8.4 Hz), 5.63 (s, 1H), 5.42 (sb, 1H), 4.76 (d, 1H, J = 3.3 Hz), 4.20 (dd, 1H, J = 4.4, 
9.9 Hz), 3.88 (m, 1H), 3.77 (t, 1H, J = 10.1 Hz), 3.60-3.71 (m, 2H), 3.56 (m, 1H), 3.36 (s, 3H). 
13
C NMR, (100 MHz, d6-DMSO) δ 155.4, 137.7, 135.1, 133.7, 128.9, 128.4, 128.1, 126.4, 126.0, 
125.8, 125.4, 125.0, 121.9, 121.2, 115.7, 101.0, 99.4, 81.9, 68.5, 68.1, 62.7, 54.8, 54.5. HRMS 
Calcd for C25H27N2O6 [M+H]
+
 451.1869, found 451.1882. 
 
Amide 45 from 5,7-Hexadecadiynoic acid   
87% yield 
1
H NMR (400 MHz, CDCl3) δ 7.46-7.54 (m, 2H), 7.32-7.41 (m, 3H), 5.97 (d, 1H, J = 
8.4 Hz), 5.55 (s, 1H),  4.71 (d, 1H, J = 4.0 Hz), 4.26 (m, 1H), 4.2 (m, 1H),  3.88 (dt, 1H, J = 2.9, 
9.8 Hz),  3.71-3.83 (m, 2H), 3.57 (t, 1H, J = 9.0 Hz), 3.40 (s, 3H), 3.28 (d, 1H, J = 3.3 Hz), 2.34 
(m, 4H), 2.24 (t, 2H, J = 7.0 Hz), 1.84 (q, 2H, J = 7.0 Hz), 1.51 (q, 2H, J = 7.1 Hz), 1.18-1.43 
(m, 10H), 0.86 (t, 3H, J = 6.8 Hz). 
13
C NMR (100 MHz, CDCl3) δ 173.4, 137.1, 129.1, 128.2, 
126.3, 101.8, 98.8, 82.0, 78.1, 76.0, 70.5, 68.8, 66.3, 65.0, 62.3, 55.3, 53.9, 34.9, 31.7, 29.1, 29.0,  
28.8, 28.2, 23.8, 22.6, 19.1, 18.4, 14.1. HRMS calcd for C30H42NO6 [M+H]
+
 512.3102, found 
512.2999.  
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Amide 46 from 10,12-octadecadiynoic acid  
The product was obtained as a white crystal at a yield of 83%. 
1
H NMR (400 MHz, CDCl3) δ 
(ppm) 7.46-7.54 (m, 2H), 7.33-7.40 (m, 3H), 5.85 (d, 1H, J = 8.8 Hz), 5.56 (s, 1H), 4.72 (d, 1H, 
J = 3.7 Hz,), 4.28 (m, 1H), 4.23 (ddd ~dt,1H, J = 3.7, 8.8, 9.8 Hz), 3.90 (ddd ~dt,1H, J = 3.3, 9.8 
Hz), 3.73-3.83 (m, 2H), 3.58 (m, 1H), 3.40 (s, 3H), 3.15(d, 1H, J = 3.3 Hz), 2.19-2.29 (m, 6H), 
1.64 (m, 2H), 1.51 (m, 4H), 1.22-1.42 (m, 12H), 0.89 (t, 3H, J = 7.1 Hz). 
13
C NMR (CDCl3, 
100MHz) not pure contain acid δ 174.7, 137.1, 129.1, 128.2, 126.3, 101.9, 98.8, 82.1, 77.6, 77.4, 
70.8, 68.7, 68.1, 65.3, 62.3, 55.3, 54.0, 36.6, 31.0, 29.1, 29.0, 28.9, 28.7, 28.2, 28.0, 25.5, 22.1, 
19.1, 13.8. HR ESIMS calcd for C32H46NO6 [M+H]+ 540.3325, found 540.3308.  
 
Amide 47 from 10,12-Tricosadiynoic acid  
yield = 83.5%  
1
H NMR (400 MHz, CDCl3) δ 7.48-7.53 (m, 2H), 7.33-7.39 (m, 3H), 5.84 (d, 1H, 
J = 8.4 Hz), 5.57 (s, 1H),  4.72 (d, 1H, J = 3.7 Hz), 4.23 (ddd~dt, 1H, J = 3.6, 9.8, 9.9 Hz), 3.90 
(ddd~dt, 1H, J = 2.9, 9.5 Hz),  3.74-3.84 (m, 2H ), 3.59  (m, 1H), 3.41 (s, 3H), 3.12 (d, 1H, J = 
3.7 Hz),  2.20-2.29 (m, 6H), 1.64 (m, 2H), 1.50 (m, 4H), 1.20-1.42 (m, 22H), 0.88 (t, 3H, J = 6.8 
Hz); 
13
C NMR (100 MHz, CDCl3) δ 174.7, 137.1, 129.1, 128.2, 126.3, 101.9, 98.8, 82.1, 77.6, 
77.4,  70.9, 68.8, 65.3, 65.2, 62.3, 55.3, 54.0, 36.6, 31.8, 29.5, 29.4,  29.3, 29.1, 29.0, 28.9, 28.8, 
28.7, 28.3, 28.2, 25.5, 22.6, 19.2, 19.1, 14.1. HRMS [M+1]
+
  C37H56NO2  calcd 610.4108, found 
610.4108. 
 
Amide 48 from using 5,7-dodecadiyndioic acid  
yield = 83% 
1H NMR (400 MHz, DMSO) δ  7.91-7.82 (d, 1H, J = 8.4 Hz), 7.45-7.42 (m, 4H), 
7.36-7.34 (m, 6H), 5.59 (s, 2H), 5.13 (d, 2H, J = 3.7 Hz),  4.60 (d, 2H, J = 3.7 Hz), 4.17-4.09 
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(m, 2H), 3.85-3.80 (m, 2H),  3.74-3.55 (m, 6H), 3.46 (t, 2H, J = 9.1 Hz), 3.27 (s, 6H), 3.15 (d, 
1H, J = 5.4 Hz), 2.47 (m, 8H), 2.47 (m, 1H), 2.28 (t, 4H, J = 6.9Hz), 2.20 (t, 4H, J = 7.3 Hz), 
1.70-1.63 (m, 4H); 
13C NMR (100 MHz, DMSO) δ 172.6, 138.3, 129.5, 128.7, 127.0, 101.5, 
99.3, 82.5, 78.4, 68.0, 66.2, 63.1, 55.5, 54.7, 34.6, 24.7, 18.5 ; HRMS [M+1]
+
 C40H49N2O12   
calcd 749.3286, found 749.3278.  
 
Amide 49 from using 10,12-docosadiyndioic acid  
yield = 78% 
1
H NMR (400 MHz, CDCl3) δ 7.4-7.52 (m, 4H), 7.31-7.39 (m, 6H), 5.91 (d, 2H, J 
= 8.8 Hz), 5.55 (s, 2H),  4.72 (d, 2H, J = 3.7 Hz), 4.27 (m, 2H), 4.20 (m, 2H), 3.88 (m, 2H),  
3.71-3.82 (m, 4H), 3.57 (m, 2H), 3.39 (s, 6H), 3.32 (d, 2H, J = 2.9 Hz), 2.17-2.28 (m, 8H),  1.62 
(m, 4H), 1.50 (m, 4H), 1.20-1.41 (m, 16H). 
13
C NMR (100 MHz, CDCl3) δ 174.6, 137.1, 129.1, 
128.2, 126.3, 101.8, 98.8, 82.0, 77.4, 70.6, 68.8, 65.3, 62.3, 55.3, 54.0, 36.5, 29.1, 29.0, 28.8, 
28.6, 28.2, 25.5, 19.1 ; HRMS [M+1]
+
 C50H69N2O12 Calcd 889.4851, found 889.4857.  
  
Synthesis of urea (50) 
 Yield = 90% 
1
H NMR (400 MHz, CDCl3) δ 7.47-7.52 (m, 2H), 7.32-7.42 (m, 3H), 5.56 (s, 1H), 
5.12 (m , peusdo triplet, 1H),  4.91 (d, 1H, J = 8.1 Hz), 4.72 (d, 1H, J = 3.3 Hz), 4.28 (m, 1H),  
3.85-3.97 (m, 2H), 3.73-3.83 (m, 2H),  3.55-3.63 (m, 2H), 3.41 (s, 3H), 3.24-3.39 (m, 2H), 2.46 
(m, 2H), 2.23 (t, 2H, J = 7.0 Hz), 1.54 (hex, 2H, J = 7.3 Hz), 0.98 (q, 3H, J = 7.3 Hz).   
13
C NMR 
(100 MHz, CDCl3) δ 158.4, 137.1, 129.2, 128.3, 126.3, 101.9, 99.2, 82.0, 78.3, 74.6, 71.5, 68.8, 
66.8, 65.1, 62.2, 55.3, 39.1, 21.7, 21.1, 20.9, 13.5.  HRMS  Calcd for C24H31N2O6  M+H  HRMS: 
[M+H]
+ 
 C24H31N2O6 Calcd. 443.2179, found 443.2182 
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Synthesis of urea (51) 
Yield = 90% 
1
H NMR (400 MHz, CDCl3) δ 7.45-7.51 (m, 4H), 7.26-7.37 (m, 6H), 5.55 (s, 1H), 
5.26 (m , peusdo triplet, 1H),  5.03(d, 1H, J = 7.7 Hz), 4.72 (d, 1H, J = 3.3 Hz), 4.27 (m, 1H),  
3.86-3.97 (m, 2H), 3.70-3.83 (m, 2H), 3.55-3.62 (m, 1H), 3.40 (s, 3H), 3.28-3.45 (m, 2H), 2.56 
(td, 2H, J = 2.2, 6.3 Hz).
13
C NMR (100 MHz, CDCl3) δ 158.5, 137.1, 132.5, 129.2, 129.1, 128.4, 
128.3, 126.3, 121.6, 101.9, 99.2, 82.0, 81.96, 75.4, 74.0, 71.4, 68.8, 66.5, 62.2, 55.3, 39.0, 21.3.  
HRMS: [M+H]
+ 
C27H29N2O6 Calcd 477.2014, found 477.2026 
 
Synthesis of urea (52)  
yield = 90% 
1
H NMR (400 MHz, CDCl3) δ 7.44-7.50 (m, 2H), 7.30-7.37 (m, 3H), 5.54 (s, 1H), 
5.07-5.20 (m, 2H), 4.69 (d, 1H, J = 3.7 Hz), 4.28 (m, 1H),  3.81-4.00 (m, 2H), 3.71-3.81 (m, 
2H), 3.54-3.63 (m, 1H), 3.37 (s, 3H), 2.98-3.24 (m, 2H), 2.22 (t, 4H, J = 7.0 Hz), 2.06 (bs, 1H), 
1.18-1.56 (m, 24H), 0.87 (t, 3H, J = 7.0 Hz). 
13
C NMR (100 MHz, CDCl3) δ 159.0, 137.1, 129.1, 
128.2, 126.3, 101.9, 99.4, 82.0, 77.7, 77.2, 71.2, 68.8, 65.4, 65.1, 62.3, 55.2, 55.1, 40.4, 31.8, 
29.8, 29.5, 29.4, 29.2, 29.0, 28.9, 28.4, 28.3, 28.1, 26.3, 22.6, 19.1, 19.0, 14.1. HRMS, [M+H]
+
 
C35H53N2O6 Calcd 597.3904, found 597.3907 
 
Synthesis of urea (53)  
Yield = 87%
 1
H NMR (400 MHz, CDCl3) δ 7.47-7.54 (m, 2H), 7.32-7.40 (m, 3H), 5.56 (s, 1H), 
4.83 (d, 1H, J = 8.1 Hz), 4.73 (m, 1H),  4.71 (d, 1H, J = 3.7 Hz), 4.28 (m, 1H),  3.84-4.00 (m, 
2H), 3.72-3.83 (m, 2H), 3.55-3.63 (m, 1H), 3.40 (s, 3H), 3.15 (m, 2H), 2.24 (t, 4H, J = 7.0 Hz), 
1.15-1.57 (m, 28H), 0.88 (t, 3H, J = 7.0 Hz). 
13
C NMR (100 MHz, CDCl3) δ 158.8, 137.1, 129.2, 
128.3, 126.3, 101.9, 99.2, 82.0, 77.6, 77.4, 71.6, 68.8, 65.3, 65.2, 62.2, 55.3, 40.1, 31.8, 29.9, 
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29.5, 29.4, 29.3, 29.1, 28.9, 28.8, 28.7, 28.3, 28.2, 26.7, 22.6, 19.2, 19.1, 14.1.  HRMS, [M+H]
+
 
C37H56N2O6 Calcd 625.4217, found 625.4220.    
 
Synthesis of urea (54) 
Yield = 90% as white solid.  
1
H NMR (400 MHz, CDCl3) δ 7.39-7.48 (m, 4H), 7.34-7.39 (m, 
6H), 6.04 (t, 2H, J = 5.4 Hz), 5.76 (d, 2H, J = 8.4 Hz), 5.60 (s, 2H), 5.19 (d, 2H, J = 5.1 Hz), 
4.61 (d, 2H, J = 3.7 Hz), 4.16 (dd, 2H, J = 4.4, 9.9 Hz),  3.43-3.75 (m, 10H), 3.30 (s, 6H), 2.97 
(m, 4H), 2.27 (t, 4H, J = 6.8 Hz), 1.17-1.48 (m, 24H). 
13
C NMR (100 MHz, CDCl3) δ 157.9, 
137.7, 128.8, 128.0, 126.4, 100.8, 99.5, 81.9, 78.0,  68.5, 68.0, 65.3, 62.4, 54.7, 54.6, 40.2, 29.9, 
28.6, 28.4, 28.1, 27.7, 26.3, 18.2.  HRMS: Calcd. For C50H71N4O12 [M+H]
+ 
919.5068, found 
919.5067.  
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